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Abbreviations list 
Abbreviation Meaning 
7AAD 7-actinomycinD 
ABC ATP-Binding Cassette 
Abs Absorbance 
ADC Albumin, dextrose, catalase 
AES Allelic Exchange Substrate 
Amp Ampicillin 
ATP Adenosine triphosphate 
BAC Bacterial Artificial Chromosome 
BCG vaccine Bacille Calmette-Guerin vaccine 
Bdq Bedaquiline 
Bp Base pair 
BSA Bovine Serum Albumin 
BSL-2 Biosafety level 2 
BSL-3 Biosafety level 3 
C Cytosine 
cDNA Complementary DNA 
CFU Colony Forming Units 
CHCA alpha-Cyano-4-hydroxycinnamic acid 
Clo Clofazimine 
Cm Chloramphenicol 
CPZ Chlorpromazine 
CTAB Cetyltrimethylammonium bromide 
DAT Diacyltrehaloses 
DC Dendritic cell 
DFO Desferrioxamine 
DIP 2,2’-dipyridyl 
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DMEM Dulbecco’s modified Eagle medium 
DNA Deoxyribonucleic acid 
dsDNA Double stranded DNA 
DTT Dithiothreitol 
EDTA Ethylene-diamine-tetraacetic acid 
Emb Ethambutol 
EtBr Ethidium bromide 
Eth Ethionamide 
FAMEs Fatty Acid Methyl Esters 
FBS Fetal Bovine Serum 
FC Fold change 
FDR False Discovery Rate 
FQs Fluoroquinolones 
G Guanine 
GMM Glucose monomycolate 
HIV Human Immunodeficiency Virus 
Hyg Hygromycin 
IEF Isoelectric focusing 
IGRAs Interferon Gamma Release Assays 
Inh Isoniazid 
IPTG Isopropyl-β-thiogalactopyranoside 
Km Kanamycin 
LAM Lipoarabinomannan 
LB Luria Bertani 
LM Lipomannan 
Log-phase Logarithmic phase 
MAMEs Mycolic Acid Methyl Esters 
Man-LAM Mannose-capped Lipoarabinomannan 
MATE Multidrug And Toxic-compound Extrusion 
MDR Multidrug Resistant 
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MFS Major Facilitator Super-family 
MH-S Murine alveolar macrophages 
MIC Minimum Inhibitory Concentration 
MMDAG Monomeromycolyl diacylglycerol 
MmpL Mycobacterial Membrane Protein Large 
MmpS Mycobacterial Membrane Protein Small 
MOI Multiplicity of infection 
MPA Molybdophosphoric acid 
Mtb Mycobacterium tuberculosis 
OADC Oleic acid, albumin, dextrose, catalase 
OD Optical Density 
Ofx Ofloxacin 
PAMPs Pathogen-Associated Molecular Patterns 
PAT Polyacyltrehaloses 
PBS Phosphate-buffered saline 
PCR Polymerase Chain Reaction 
PDIM Phthiocerol dimycocerosate 
PE Proline-glutamic acid 
PFA Paraformaldehyde 
PGL Phenolic glycolipid 
PIMs Phosphatidylinositol mannosides 
PPE Proline-proline-glutamic acid 
PRRs Pattern Recognition Receptors 
Pza Pyrazinamide 
qRT-PCR Real-Time Quantitative PCR 
REMA Resazurin Microtiter Assay 
Rif Rifampicin 
RNA Ribonucleic acid 
RND Resistance Nodulation Division 
RNI Reactive Nitrogen Intermediates 
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RQ Relative quantification 
RT Room Temperature 
RT-PCR Real-Time PCR 
SCID Severe Combined Immune Deficient 
SD Standard deviation 
SDS Sodium Dodecyl Sulfate 
SDS-PAGE SDS polyacrylamide gel electrophoresis 
SL Sulpholipid 
Sm Streptomycin 
SMR Small Multidrug Resistance 
Spc Spectinomycin 
SSC Saline Sodium Citrate 
TAG Triacyl glycerol 
TAT Triacyltrehaloses 
TB Tuberculosis 
TBAH Tetrabutylammonium hydroxide 
TBE Tris-Borate-EDTA 
TCA Trichloroacetic acid 
TDM Trehalose dimycolate 
TDR Totally Drug Resistant 
TE Tris-EDTA 
Tet Tetracycline 
TFA Trifluoroacetic acid 
TLC Thin Layer Chromatography 
TMD Transmembrane domain 
TMM Trehalose monomycolate 
Tpp Tetraphenylphosphonium 
VP Verapamil 
WHO World Health Organization 
XDR Extensively Drug Resistant 
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Summary 
Mycobacterium tuberculosis has got several proteins of the MmpL family (Mycobacterial 
Membrane Protein Large) belonging to the RND (Resistance Nodulation Division) superfamily of 
transporters. The efflux system MmpL4/MmpS4 (Rv0450c y Rv0451c) may contribute to 
virulence and possibly to lipid transport, in addition to transport of siderophores and/or other 
compounds. The main objective of this thesis has been the characterization of this efflux system 
in M. bovis and M. tuberculosis. 
First, we constructed a mutant strain of M. tuberculosis deleted in rv0450c gene, a second 
strain deleting rv0450c and rv0451c genes, and derivatives of these mutants in which wild-type 
genes were complementing the deletions. Further, we produced a strain overexpressing 
rv0450c and rv0451c genes. All these strains have been used for investigating the role of this 
efflux system. 
Regarding in vitro tests, antibiotic susceptibility assays indicated that the efflux system 
MmpL4/MmpS4 of M. tuberculosis is not involved in intrinsic drug resistance, but we have got 
evidences of its ability to transport ethidium bromide. In addition, we have determined that 
deletion of the efflux system MmpL4/MmpS4 of M. tuberculosis does not affect the ability to 
grow in iron-deficient media, probably because bacteria still have the efflux system 
MmpL5/MmpS5, which may compensate the deletions. However, overexpression of the 
MmpL4/MmpS4 efflux system in M. tuberculosis caused a morphological change in its colonies, 
and a decrease in its in vitro growth rate, suggesting that structure and/or composition of the 
mycobacterial membrane has been affected notably. 
M. tuberculosis strains with altered levels of expression of the MmpL4 and MmpS4 efflux 
system, either by overexpression or by deletion, are affected in their capability for surviving 
inside macrophages, showing lower cytotoxicity than the parental strain H37Rv. These results 
indicate that efflux system MmpL4/MmpS4 is needed for virulence of M. tuberculosis, and that 
its level of expression is critical. 
The deletion of mmpL4 gene in M. tuberculosis alters expression of other genes encoding 
transport proteins of the same family, such as mmpL5/mmpS5 and mmpL10. Phenotypically, 
main lipids of M. tuberculosis were not affected significantly by the loss of mmpL4, the loss of 
both mmpL4 and mmpS4, or the overexpression of mmpL4 and mmpS4. Proteomic analysis of 
strains having altered levels of these genes or the complemented mutants showed that there 
were relevant changes in the levels of proteins related to fatty acid metabolism. 
In M. bovis, we observed that overexpression of the MmpL4/MmpS4 efflux system changed 
production of PDIM, an important lipid for mycobacterial virulence. 
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Resumen 
Mycobacterium tuberculosis posee varias proteínas de la familia MmpL (Mycobacterial 
Membrane Protein Large) que pertenecen a la superfamilia de transportadores RND 
(Resistance Nodulation Division). El sistema de eflujo MmpL4/MmpS4 (Rv0450c y Rv0451c) 
puede contribuir a su virulencia y posiblemente al transporte de lípidos, además de al 
transporte de sideróforos y/o de otros compuestos. El objetivo principal de esta tesis ha sido la 
caracterización de este sistema de eflujo en M. bovis y M. tuberculosis. 
En primer lugar, hemos construido una cepa mutante de M. tuberculosis en la que se ha 
delecionado el gen rv0450c, una cepa mutante en la que se han delecionado los genes 
rv0450c y rv0451c, y cepas derivadas de las anteriores, en la que los genes wild-type 
complementan la deleción. Además, se ha generado una cepa que sobreexpresa los genes 
rv0450c y rv0451c. Con estas cepas se han realizado diversos ensayos encaminados a 
identificar la función de este sistema de eflujo. 
En cuanto a los experimentos in vitro, los ensayos de susceptibilidad a antibióticos indican que 
el sistema de eflujo MmpL4/MmpS4 en M. tuberculosis no estaría implicado en la resistencia 
intrínseca a fármacos, pero sí se ha puesto en evidencia su capacidad para transportar 
bromuro de etidio. Además, hemos determinado que la delección del sistema de eflujo 
MmpL4/MmpS4 en M. tuberculosis no afecta la capacidad de la bacteria para crecer en medios 
deficientes en hierro, probablemente debido a que las bacterias todavía conservan el sistema 
de eflujo MmpL5/MmpS5 que compensa las delecciones realizadas. Sin embargo, la 
sobreexpresión del sistema de eflujo MmpL4/MmpS4 en M. tuberculosis provoca cambios en la 
morfología de las colonias y disminuye su velocidad de crecimiento, lo que sugiere que la 
estructura y/o composición de la membrana se ha visto alterada de forma importante. 
Las cepas de M. tuberculosis con alteraciones en la expresión del sistema de eflujo 
MmpL4/MmpS4, tanto por sobreexpresión como por delección, se vieron afectadas en su 
capacidad para sobrevivir en el interior de macrófagos, presentando una menor citotoxicidad 
que la cepa parental H37Rv. Estos resultados indican que el sistema de eflujo MmpL4/MmpS4 
es necesario para la virulencia de M. tuberculosis, y que su nivel de expresión es crítico. 
La delección del gen mmpL4 en M. tuberculosis ha provocado la alteración de los niveles de 
expresión de otros genes que codifican transportadores de la misma familia, entre ellos 
mmpL5/mmpS5 y mmpL10. A nivel fenotípico, no pudo observarse ninguna variación 
significativa en la producción de los principales lípidos de M. tuberculosis causados por la 
pérdida del gen mmpL4 o de ambos genes mmpL4 y mmpS4, ni tampoco por la sobreexpresión 
de los genes mmpL4 y mmpS4. Con el análisis proteómico de las cepas con alteraciones en la 
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expresión de estos genes, o de los mutantes complementados, se encontraron cambios 
relevantes en los niveles de proteínas relacionadas con el metabolismo de ácidos grasos. 
En M. bovis, se observó que la sobreexpresión del sistema de eflujo MmpL4/MmpS4 provocó 
alteraciones en la producción de PDIM, un lípido importante para la virulencia de las 
micobacterias. 
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1. Introduction 
1.1. Immersion in tuberculosis world 
1.1.1. Significance of tuberculosis 
Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis (TB) and has been 
present in the human population since antiquity. Initially, it was thought that Mycobacterium 
bovis strains jumped from infected cattle to humans during the domestication of animals in the 
Neolithic period, hence originating human TB [1]. However, it is now widely accepted that the 
ancients Mtb strains were originated from environmental mycobacteria 70,000 years ago in 
Africa [2, 3]. The introduction of agriculture, civilization and the increase in human population 
density led to the selection of virulent and transmissible Mtb strains. These modern Mtb strains 
spread throughout the world causing the TB epidemics that ravaged mankind for centuries [4]. 
Nowadays, 9 million people fell ill with TB and 1.5 million died in 2013 (including 360,000 deaths 
among HIV-positive people) according to the World Health Organization (WHO) [5]. At present, 
TB is the second leading cause of death from an infectious agent worldwide, after the Human 
Immunodeficiency Virus (HIV), in spite of the fact that we have powerful tools in order to face 
TB: vaccination, diagnostics and treatments. 
1.1.2. Vaccination 
BCG (Bacille Calmette-Guerin) was first developed in the 1920s and it is the only vaccine 
currently available for TB disease. BCG vaccine provides children with excellent protection 
against the disseminated forms of TB, especially against meningitis; however protection against 
pulmonary TB in adults is variable. Several hypotheses attempt to explain this variability: 
differences in protection between BCG substrains (which originated by subculturing the original 
vaccine strain in different laboratories or countries around the world), an inadequate dosage of 
BCG in some trials, interference with environmental mycobacteria, genetic differences in human 
populations, and geographic differences in clinical isolates of M. tuberculosis [6]. 
Due to its variable effectiveness, the inability to prevent primary infection and reactivation of 
latent TB, which is the principal source of disease transmission, great efforts are being made by 
governments, research institutions and private foundations for constructing and testing new 
promising vaccine candidates.  
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1.1.3. Diagnostics 
The most common methods for diagnosing TB worldwide are sputum smear microscopy and 
the Mantoux tuberculin skin test. These methods are simple, inexpensive and quick, but their 
main drawbacks are low specificity and sensitivity. It is necessary to carry out more tests such 
as chest radiography, Interferon Gamma Release Assays (IGRAs), and culturing, to confirm the 
infection with Mtb [7]. Diagnosing TB using culture involves the identification of Mtb by 
biochemical tests [8], and molecular identification methods. Moreover, cultures can also be 
used for drug susceptibility testing [8], which is important to get successful treatment in drug-
resistant TB patients. 
Early identification of people with symptomatic TB not only allows therapy to be administered 
before serious lung damage occurs, but also helps to prevent the spread of the bacteria to other 
susceptible people. For this purpose, there are several new diagnostic technologies under 
development [9]. 
1.1.4. Treatment and drug resistance 
Drug treatment is the only effective therapy for TB. Drugs are classified into three groups based 
on evidence of efficacy, potency and experience of use [10]. 
• First-line anti-TB drugs are the most effective and widely used drugs for the treatment of 
drug-susceptible TB (which is not drug resistant). 
• Second-line anti-TB drugs are reserved for resistant bacilli to first-line therapy. A drug 
may be classed as second-line instead of first-line for being less effective than the first-
line drugs (e.g. para-aminosalicylic acid), having toxic side-effects (e.g. cycloserine) or 
being effective, but unavailable in many developing countries (e.g. fluoroquinolones). 
• Third-line anti-TB drugs are characterized for not being very effective (e.g. 
clarithromycin) or because their efficacy has not been proven (e.g. clofazimine). 
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Table 1. Drugs used in the treatment of TB [10]. 
First-line drugs Second-line drugs Third-line drugs 
Isoniazid 
Aminoglycosides (Streptomycin, Kanamycin, 
Amikacin) 
Clofazimine 
Rifampicin Polypeptides (Capreomycin, Viomycin) Linezolid 
Pyrazinamide 
Fluoroquinolones (Ciprofloxacin, Levofloxacin, 
Moxifloxacin, Ofloxacin, Gatifloxacin) 
Amoxicillin plus 
clavulanate 
Ethambutol Para-aminosalicylic acid Imipenem plus cilastatin 
Rifapentine Cycloserine Clarithromycin 
Rifabutin Terizidone   
  Ethionamide   
  Prothionamide   
  Thioacetazone   
 Linezolid  
With appropriate antibiotic treatment, around 90% of HIV-negative patients with drug-
susceptible TB can be cured in 6 months using a combination of rifampicin (Rif), isoniazid (Inh), 
pyrazinamide (Pza) and ethambutol (Emb) for 2 months, followed by a four-month continuation 
phase of Rif and Inh [5]. The main reason for prescribing this combination of medicines in the 
treatment of TB is because the likelihood of the emergence of multiple drug resistance bacteria 
is virtually impossible [11], apart from the fact that the distinct anti-TB drugs have different 
modes of action: Inh are bactericidal against replicating bacteria; Emb is bacteriostatic at low 
doses, but is used in TB treatment at higher, bactericidal doses; Rif is bactericidal and has a 
sterilizing effect; and Pza is only weakly bactericidal, but is very effective against bacteria 
located in acidic environments, inside macrophages, or in areas of acute inflammation. 
Monotherapy, irregular drug supply, poor drug quality, inappropriate prescription, poor 
adherence to treatment and unsuitable supervision and support on the part of health personnel, 
can contribute to appearance, selection and multiplication of drug-resistant TB strains. This 
phenomenon is called acquired resistance [11]. The traditional mechanisms by which bacteria in 
general acquire drug resistance are: barrier mechanisms (decreased permeability/efflux), 
degrading/inactivating enzymes, modification of pathways involved in drug 
activation/metabolism, and drug target modification (mutations) or target amplification [12]. Mtb 
in particular is able to acquire drug resistance by spontaneous mutations in its chromosomal 
genes, but no horizontal transfer of resistance genes had been reported [13]. 
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Table 2. The commonly used TB drugs with the genes associated with their respective resistance and 
major mechanism of resistance [12]. 
 
1.1.5. New drugs to treat tuberculosis 
The advent of antibiotics for the treatment of TB represented a major breakthrough in the fight 
against the disease. However, since its very first use, antibiotic therapy has been associated 
with the emergence of resistance to drugs. Drug-resistant bacilli can be classified in three 
groups:  
• Multidrug-resistant (MDR) strains are resistant to Inh and Rif. In 2013, the highest levels 
of MDR-TB were found in Eastern Europe and central Asia, where in some countries 
more than 20% of new TB cases and more than 50% of those previously treated for TB 
have MDR-TB [5].  
• Extensively drug-resistant (XDR) strains are resistant to not only Inh and Rif, but also a 
quinolone and one of the second-line injectable drugs (kanamycin, amikacin or 
capreomycin). In 2006, the first XDR-TB outbreak was described in KwaZulu-Natal in 
South Africa. The mortality rate among HIV-positive patients, with limited or no access 
to highly active antiretroviral therapy was 98%, after a median survival period from 
diagnosis of only 16 days [14]. 
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• Totally drug-resistant (TDR) refers to strains that are resistant to all available TB drugs, 
although the number and level of resistance to each drug has not yet been precisely 
defined. To date, only a limited number of TDR-TB cases have been confirmed in Iran, 
India, South Africa and Italy [15]. 
Apart from multidrug resistance, there are other aspects that further underscore the urgency to 
discover new TB drugs, such as the long treatment duration, complex regimens that involve 
expensive and toxic drugs, and toxic effects when given with antiretroviral therapy. 
Consequently, a great effort is being done by academic laboratories, non-profit organizations 
and pharmaceutical companies to research in drug development. The result of this common 
work is reflected in the following figure, which represents the list of compounds that are 
currently in the pipeline of candidate drugs for the treatment of TB [16]. 
 
Figure 1. The development pipeline for new TB drugs [16]. 
It should be pointed out that although advances in drug discovery are significant, it is still 
necessary more anti-TB drugs that target new pathways or enzymes, new targets to avoid 
cross-resistance to existing medicines, and inhibitors that could enhance the activity of the 
current and new drugs. Given the current burden of TB, it would be a mistake to stop 
researching on new anti-TB drugs. 
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1.2. The tubercle bacillus 
1.2.1. General characteristics of Mycobacterium tuberculosis 
Mtb is an acid-fast, rod-shape and aerobe bacteria belonging to the family Mycobacteriaceae, 
included into the suborder Corynebacterineae, order Actinomycetales [17]. 
Mtb is not classified as either Gram-positive or Gram-negative since it gives the appearance of 
“ghost” cells when it is Gram stained [18]. Phenotypically it is catalase and nitrate reductase 
positive, non-motile and non-spore forming bacillus of 2-5 µm in length and 0.2-0.5 µm in width. 
Mtb is slow-growing mycobacteria with a generation time of ~15-20 hours. It takes 4 weeks to 
get visual colonies on solid medium. In smears made from in vitro-grown colonies, chains of 
cells often form distinctive serpentine cords, which is called cording, and it is related to virulent 
strains of the bacterium. 
1.2.2. Genome and genetic manipulation of Mycobacterium tuberculosis 
The complete genome sequence of the best-characterized strain of Mtb, H37Rv [19], was 
obtained in 1998 [20] and it is in continuous revision since then [21, 22]. The genome comprises 
4,411,532 base pairs, and has an unusually high G+C (guanine plus cytosine) content of 65.9%. 
The last re-annotation identifies 4,111 genes thought to encode 4,018 proteins and 80 stable 
RNAs [23]. The most striking feature of Mtb genome is the abundance of genes involved in lipid 
metabolism, both in lipid biosynthesis and lipolysis, which occupy about 7% of the coding 
capacity of the genome. Besides, the Pro-Glu motif containing (PE) and Pro-Pro-Glu motif 
containing (PPE) family of proteins represents 4% of the genome. They are highly expanded in 
pathogenic mycobacteria and have been linked to virulence [24, 25], but their function remains 
unknown. 
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Figure 2. Functional classification of Mycobacterium tuberculosis genes. Adapted from [21, 23]. 
Genetic manipulation of DNA remains one of the most powerful approaches for understanding 
the molecular basis of survival, virulence, and pathogenicity of a bacterium. It should be noticed 
that genetic manipulation of slow-growing mycobacteria such as Mtb is complicated by its 
pathogenesis, slow growth rate, inefficient DNA uptake and high level of illegitimate 
recombination. Eventually, the discovery of mycobacteriophages and plasmids, the 
development of mycobacterial vectors and transposons, transformation by electroporation, and 
successful methods to generate knockout mutant strains allowed the study gene function in 
mycobacteria. A variety of genetic methods have been developed such as those based on 
homologous recombination: counter-selection with sacB, specialized transduction, and 
recombineering. 
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• Counter-selection with sacB [26]: this two-step strategy consists of the integration of a 
suicide vector carrying an inactivated copy of the target gene through a single crossover 
under antibiotic pressure. The suicide vector contains a genetic marker (usually 
encoding resistance to an antibiotic) and sacB gene, which is lethal to mycobacteria in 
the presence of sucrose. The antibiotic resistant colonies are plated on sucrose to 
remove the vector sequence by a second crossover event. 
• Specialized transduction [27]: The target gene of interest is interrupted with a selectable 
marker and cloned into a cosmid vector in E. coli. This construct is cloned into a 
mycobacteriophage vector and packaged by transducing M. smegmatis. A high-titer 
stock can then be prepared to infect Mtb and obtain mutant strains. 
• Recombineering [28]: This strategy consists of the electroporation of a linear dsDNA 
allelic exchange substrate (AES), which contains two small portions of sequence 
identity to the target locus flanking an antibiotic resistance gene. Using Che9c gp60 and 
gp61 recombinases stimulate homologous recombination. 
1.2.3. Mycobacterial cell envelope 
The mycobacterial envelope is unique, both in molecular composition and in the architectural 
arrangement of its constituents. Its complex structure is composed of a typical phospholipid 
bilayer plasma membrane, an outer membrane called mycomembrane and an outermost layer 
known as the capsule. The plasma membrane is composed mainly of anionic phospholipids in a 
bilayer arrangement with proteins. The mycomembrane consists of an asymmetric lipid bilayer 
made of long chain (C60-C90) mycolic fatty acids in the inner leaflet, and free intercalating 
glycolipids and waxy components on the outer leaflet. Cryo-electron microscopy images support 
a folded or compact configuration of these mycolic chains, which reminiscent of Gram-negative 
bacterial cell walls [29-31], and also confirm that the measured thickness of the outer 
membrane is consistent with the size of mycobacterial porins, such as MspA from M. 
smegmatis, which may therefore form channels in this bilayer [29]. The outer and inner 
membrane form a periplasmic space, with the presence of a thin layer of peptidoglycan 
covalently linked to arabinogalactan and lipoarabinomannan, which in turn are bound to mycolic 
acids. Peptidoglycan, arabinogalactan and mycolic acids form the cell wall skeleton. The 
capsule is mainly composed of polysaccharides, proteins and small amounts of lipids, and it is 
considered to have a different molecular composition in pathogenic and non-pathogenic species 
[32]. The outermost layer is visible in conventional electron microscopy preparations only when 
cultures have been grown in free detergent medium. It is thought that mycobacterial growth 
under routine culturing conditions (with a detergent as Tween-80) promotes removing of this 
layer [33]. 
Free glycolipids are important components of the mycobacterial cell wall. Among them can be 
found trehalose dimycolate (TDM), often referred as cord factor, trehalose monomycolate 
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(TMM), glucose monomycolate (GMM), glycerol monomycolate, diacyltrehaloses (DAT), 
triacyltrehaloses (TAT), polyacyltrehaloses (PAT), the recently characterized family of 
mannosyl-b-1-phosphomycoketides, sulpholipids (SLs), phenolic glycolipids (PGLs) and 
phthiocerol dimycocerosate (PDIM). Other major glycolipids are lipomannan (LM), 
lipoarabinomannan (LAM) and phosphatidylinositol mannosides (PIMs). 
Ultrastructure of mycobacterial envelope is unclear yet; therefore, the spatial location of many 
lipid components is still mere speculation. A proposed model of the mycobacterial cell envelope 
is shown in the following figure. 
 
Figure 3. Schematic representation of the cell envelope of Mycobacterium tuberculosis. Adapted from [34]. 
The mycobacterial envelope is involved in important roles, such as defining the shape of the cell 
and providing mechanical and osmotic protection. Its unusual high hydrophobicity makes it an 
efficient barrier for chemotherapeutic agents. Other important function is the transport of 
molecules, including nutrients, ions and toxic metabolites. During infection, cell-wall compounds 
have been shown to trigger a set of biological effects including adjuvanticity, toxicity, immune 
down-modulation, and arrest of phagosome maturation [35]. 
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1.3. Pathogenesis and virulence 
1.3.1. Progress of the disease 
Early in infection, TB follows a relatively reproducible course. Mtb bacilli are inhaled from 
droplets aerosolized by individuals with active pulmonary TB into the alveoli of the lung. Once 
there, macrophages and dendritic cells (DCs) express numerous pattern recognition receptors 
(PRRs) that recognize antigenic molecules expressed on Mtb called pathogen-associated 
molecular patterns (PAMPs) to internalize the bacilli [36, 37]. This event induces a localized 
proinflammatory response that leads to recruitment of inflammatory cells [38]. Over time, the 
granuloma becomes a stratified lesion which includes blood-derived infected and uninfected 
macrophages, foamy macrophages, epithelioid cells (uniquely differentiated macrophages), and 
multinucleated giant cells (Langerhans cells), B and T lymphocytes, and fibroblasts [39]. In 
many lesions these cell populations are separated by a fibrous layer of extracellular matrix [40]. 
The main function of the granuloma is to localize and contain Mtb while concentrating the 
immune response to a limited area. Thanks to this strategy 90% of infected individuals defeat 
the disease or are successful in controlling TB (latent TB) [38]. People with latent TB are still 
infected but are non-infectious and asymptomatic. However, in 10% of the cases, when the 
host’s immune status changes as consequence of aging, malnutrition, stress, cancer, 
immunosuppressive drugs or co-infection with HIV among other factors, this situation leads to 
active disease in which the centre of the granuloma becomes necrotic, liquefies (caseous 
necrosis), and viable bacilli can be released and spread to the lung, other parts of the body and 
the atmosphere [39]. 
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Figure 4. The transmission cycle of Mycobacterium tuberculosis [41]. 
1.3.2. Life inside the phagosome 
In the lungs, Mtb bacilli are phagocytosed by alveolar macrophages, in which the bacteria are 
contained in phagosomes. Under normal circumstances, phagosomes are fused to lysosomes 
and other endosomes in a process called phagosome maturation [42]. The resultant 
compartment is among other attributes, iron limiting, carbon poor, hypoxic, nitrosative, and 
oxidative [43]. The mechanisms that Mtb have evolved to counteract the hostile environment of 
the macrophage, such as inhibiting phagosome-lysosome fusion or to escape into the cytosol 
are part of its virulence factors. The cytosol likely offers a more permissive environment, where 
the bacteria can replicate and induce the infected macrophages to undergo necrosis instead of 
apoptosis, a strategy that allows the bacteria to infect neighbouring cells, thereby enabling the 
perpetuation of the infection process [44]. 
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1.3.3. Virulence factors 
Mtb virulence determinants can be defined as factors that are important for the progression of 
the TB disease. 
In recent years, there have been considerable advances in the understanding of the molecular 
bases of pathogenicity, virulence and persistence of mycobacteria. The use of transposon 
mutant libraries in combination with different in vivo screening methods has allowed the 
identification of mycobacterial virulence genes, and factors, whose role in virulence is clear. For 
example, the nucleoside diphosphate kinase Ndk [45, 46] and the phosphatase SapM [47] both 
affect the maturation of the mycobacterial-containing phagosome; enzymes such as AhpC, 
SodC, KatG and TpX contribute to the detoxification of reactive oxygen intermediates (ROI) and 
reactive nitrogen intermediates (RNI) [48, 49]; and isocitrate lyase enzyme is essential for the 
metabolism of fatty acids [50]. 
Other genes have been identified as encoding potential virulence factors in Mtb. For instance, 
the inactivation of LipF resulted in attenuated mutant in mice [51, 52], possibly due to the 
metabolic shift suffered by Mtb during infection, from carbohydrates (in vitro) to fatty acids (in 
vivo). Deletion of at least three of the four phospholipases C genes results in an attenuated 
phenotype in the late phase of the infection in mice [53]. Mutants in two important two-
component regulatory systems, RegX3/SenX3 and PhoP/PhoR, were attenuated in mice [54]. 
Nevertheless, the deletion of kdpDE, tcrS, dosR and tcrXY led to a hypervirulent phenotype 
when tested in severe combined immune-deficient (SCID) mice [55]. 
A great variety of secreted and cell wall-associated proteins has been demonstrated to play a 
key role in bacterial survival and immune modulation in the host. For example, ESAT-6 is 
secreted in the early stages of Mtb infection and induces strong cell mediated and humoral 
immune responses [56]. The Ag85 complex (Ag85A, Ag85B, and Ag85C, also known as FbpA, 
FbpB and FbpC, respectively) is the major secreted protein constituent of mycobacterial cell 
culture, and contributes to the biosynthesis of TMM and TDM [49]. The fbpA mutant showed to 
be attenuated in growth in human and murine macrophages, unlike fbpB and fbpC mutants, but 
also vaccinogenic against TB [57]. Several pks genes along with fadD26, fadD28 and drrC, take 
part in biosynthesis or transport of PDIM, a major virulence factor of Mtb, in particular during the 
early step of infection when bacilli encounter their host macrophages. Mutant strains in these 
genes showed attenuated phenotypes in mice [49]. PIMs and mannose-capped 
lipoarabinomannan (Man-LAM) both interfere with phagosome maturation [58].  
Other proteins integrated into the membrane participate in the transport of virulence factors and 
drugs across the mycobacterial cell wall. In the following section, this and other roles of efflux 
proteins will be detailed. 
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1.4. Functional diversity of efflux pumps in Mycobacterium 
tuberculosis 
Efflux pumps are membrane proteins that transport actively a wide variety of compounds across 
bacterial envelope. They have been classified into five superfamilies: ATP-binding cassette 
(ABC), major facilitator super-family (MFS), resistance nodulation division (RND), small 
multidrug resistance (SMR) and multidrug and toxic-compound extrusion (MATE). While MFS, 
SMR, RND and MATE members are secondary transporters, typically energized by the proton 
motive force (H+ or Na+), members of the ABC superfamily use ATP as the energy source and 
are considered as primary transporters [59]. Whereas efflux pumps are mostly known because 
of the transport of drugs from the cytoplasm, other efflux pump substrates are sugars, lipids, 
proteins, synthetic compounds, toxic metabolites, host-defence molecules, virulence factors, 
etc. Such a heterogeneous substrate profile allows bacterial efflux pumps to play diverse roles 
in drug resistance, virulence, bacterial cell physiology, and detoxification [59], among others. 
1.4.1. Drug resistance 
In mycobacteria, intrinsic resistance to different drugs is conferred by mycobacterial efflux 
pumps as well as the low permeability of the mycobacterial envelope, enzymes like β-
lactamases [60], and transcriptional activators like whiB7 [61], among others. The following 
table summarizes our current knowledge on drug efflux pumps in Mtb that have been related to 
low-level resistance to drugs or whose expression increases in response to exposure to drugs. 
Most studies have been done by determining drug resistance levels after overexpressing genes 
encoding efflux pumps from multicopy plasmids or after deleting genes in the bacterial 
chromosome; others have been done by genomic and transcriptomic approaches in response to 
exposure to drugs. 
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Table 3. Efflux pumps related to drug resistance. 
Drug efflux pump 
Transporter 
family 
Drugs related References 
Rv1258c (Tap) MFS Rif, Ofx, aminoglycosides, Tet [62-65] 
RV1410c (P55) MFS Inh, Emb, Rif, Cfz [63, 66, 67] 
Rv2333c (Stp) MFS Spc, Tet [68] 
Rv1634 MFS FQs [69] 
Rv2459 (JefA) MFS Inh, Emb [70] 
Rv2846c (EfpA) MFS Inh, Eth [63, 71] 
Rv2936-Rv2937-Rv2938 
(DrrABC) 
ABC Emb, FQs, Sm [72] 
Rv2686c-Rv2687c-
Rv2688c 
ABC FQs [73] 
Rv1217c-Rv1218c ABC Inh, Rif [74] 
Rv3065 (Mmr) SMR Inh, EtBr, Tpp, CTAB [63, 75] 
Rv2942 (MmpL7) RND Inh [63, 76] 
Rv0676c-Rv0677c 
(MmpL5-MmpS5) 
RND Bdq, Cfz, azole [77-79] 
Ofx, ofloxacin; Tet, tetracycline; Clo, clofazimine; Spc, spectinomycin; FQs, fluoroquinolones; Eth, ethionamide; Sm, 
streptomycin; EtBr, ethidium bromide; Tpp, tetraphenylphosphonium; CTAB, cetyltrimethylammonium bromide; Bdq, 
bedaquiline. 
It is worth noting that in other bacterial pathogens efflux pumps are frequent mechanisms of 
acquired drug resistance, conferring high levels of resistance to the drugs transported by the 
efflux pumps. In contrast, in mycobacteria most efflux pumps contribute to intrinsic drug 
resistance by providing the bacterial cells with basal levels of resistance to the drugs 
transported by the efflux pumps. Recently, MmpL5-MmpS5 and Tap have been related to 
acquired drug resistance due to genomic mutations increasing their expression and conferring 
Bdq and Sm resistance, respectively [65, 77]. 
1.4.2. Drug tolerance 
Unlike intrinsic and acquired drug resistance, tolerance is a transitional situation, in which the 
bacteria change its physiological state to show phenotypic resistance or non-susceptibility to a 
drug, yet being genetically identical to drug-susceptible bacteria in the same population. 
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It is widely accepted that drug-tolerant bacilli have slowed growth and quiescent metabolism. In 
this non-replicating state, most of anti-TB drugs are unable to kill drug-tolerant mycobacteria, 
which make necessary to prolong treatment courses, and consequently increases the chances 
of emergence of genetic drug resistance. For example with Inh, greater than 99% of the initial 
sputum bacillary load is killed during the first two days of treatment, after which the rate of killing 
decreases markedly due to the residual drug-tolerant mycobacteria [80]. Recently, a new insight 
in the mechanism leading to drug tolerance in mycobacteria has been demonstrated [81]. In this 
model, drug tolerance appears in actively replicating mycobacteria due to bacterial efflux pumps 
whose expression is likely induced by antimicrobial peptides upon macrophage entry, and is 
retained for a period of time after bacteria resume extracellular growth. 
1.4.3. Virulence 
Not only efflux pumps have a role in drug resistance and drug tolerance, but also in virulence. 
LpqY, which is among these virulence-related proteins, is a component of a putative sugar ABC 
transporter of Mtb and lpqY forms an operon with sugC, sugB and sugA. It has been shown that 
this importer plays a role in recycling of extracellular trehalose, released from trehalose-
containing molecules (such as DAT, PAT, etc) synthesized by the bacillus. Moreover, the 
attenuation of the lpqY mutant in mice suggests that sugars may be relevant for infection [82]. 
Mce proteins are ABC transporters implicated in virulence. The Mce proteins are encoded by 
the mce1, mce2, mce3 and mce4 operons in the genome of Mtb. The involvement of Mce4 
transport system in cholesterol import and intracellular survival has been confirmed [83, 84], but 
the role of mce1, mce2 and mce3 operons is not clearly established, especially in the case of 
the mce3 operon. As regards to mce1 operon, it has been suggested that these proteins may 
serve as a mycolic acid re-importer [85], and mce2 operon might be related to sulpholipid 
transport [86]. Due to their most probable implication in lipid metabolism, the Mce proteins may 
modulate pathogenicity through changes in Mtb lipid pathways. 
The Mtb genome possesses 15 different genes encoding for RND proteins [87], 13 of which 
belong to MmpL (Mycobacterial Membrane Protein Large) protein family. Mutants with 
disruptions in mmpL2, mmpL4, mmpL5, mmpL7, mmpL8, mmpL10, and mmpL11 showed 
significant attenuation for growth in mice lungs [51, 88-90]; only the MmpL4 mutant showed a 
survival defect in the spleen [88]. It should be noted that Mtb mutants harbouring deletions of 
mmpL8 and mmpL11 are attenuated for survival in the chronic stages of infection [90]. It is even 
more striking the fact that MmpL4 and MmpL7 knockout mutants appear to be avirulent [90]. 
Four mmpL genes appear to be in operons also containing an mmpS gene. The latter encode 
for proteins equivalent to the MFPs in other bacterial RND systems [91]. MmpL and MmpS 
(Mycobacterial Membrane Protein Small) protein families mediate transport of important cell 
wall lipids across the mycobacterial membrane, which are known to play a significant role in 
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pathogenesis. In Mtb, MmpL3 [92, 93], MmpL7 [94, 95] and MmpL8 [89, 96] have been shown 
to transport TMM, PDIM and SL-1 respectively. Moreover, the translocation of DAT and 
biosynthesis of PAT is likely due to MmpL10 [97]. In other mycobacteria, M. smegmatis, 
MmpL11 is responsible for the mycolic acid-containing lipids monomeromycolyl diacylglycerol 
(MMDAG) export [98]. Besides drug efflux and lipid transport, MmpL and MmpS proteins are 
involved in siderophore export [99] (MmpL4/MmpS4 and MmpL5/MmpS5), and heme uptake 
[100, 101] (MmpL3 and MmpL11); the acquisition of iron is an essential attribute of pathogenic 
bacteria so as to establish a successful infection. 
Interestingly, some efflux pumps have a dual role in Mtb contributing to drug resistance and 
virulence. It has been proven that Rv1258c efflux pump induces tolerance to Rif, and promotes 
intracellular bacterial growth as well, contributing to Mtb virulence [81]. Moreover, LprG (an 
antigenic lipoprotein) and P55 (a MFS efflux pump) are encoded in an operon that is related to 
the transport of toxic compounds, including some drugs, and the cell wall permeability of the 
bacterium [66, 67, 102, 103]. 
1.5. The MmpL4-MmpS4 efflux system 
In this work, we have studied the efflux system composed by Rv0450c (MmpL4) and Rv0451c 
(MmpS4) proteins of Mtb. Identical proteins can be found in M. bovis AF2122/97 strain 
(http://genolist.pasteur.fr/BoviList/), which are named BCG_0489c and BCG_0490c, 
respectively, in the genome of M. bovis BCG strain. 
MmpL4, a protein of 967 amino acids with a molecular mass of 105.2 kDa, has been predicted 
to have 11 transmembrane domains (TMDs), a short cytoplasmic loop between TMD 1 and 
TMD 2, and a large extra-cytoplasmic loop between TMD 6 and TMD 7. All of these 
characteristics are similar to those described as typical of RND efflux pumps [104]. 
 
Figure 5. Prediction of TMS of Rv0450c efflux pump, using Hidden Markov Models 
(http://www.cbs.dtu.dk/services/TMHMM/). 
	   35	  
 
Figure 6. Prediction of TMS of Rv0451c efflux pump, using Hidden Markov Models 
(http://www.cbs.dtu.dk/services/TMHMM/). 
However, MmpS4, a small protein of 423 amino acids with a molecular mass of 15.4 kDa, 
shows no structural similarity to any periplasmic adapter proteins from RND drug efflux systems 
of Gram-negative bacteria, indicating that the mycobacterial MmpS proteins constitute a novel 
class of accessory proteins in complex transporter systems [99]. MmpS4 has been predicted to 
have a TMD in the extreme N-terminal region, and an extra-cytoplasmic domain that has seven 
consecutive β-strands [99]. 
As it has been mentioned in the previous section, MmpL4/MmpS4 and MmpL5/MmpS5 are 
components of siderophore export systems that have been demonstrated to be essential for 
virulence of Mtb. These apparently redundant pairs of transporters are not only required for 
export but also for efficient siderophore synthesis [99]. The mutants’ attenuation is due to two 
effects: the restricting access to iron, and the toxic intracellular siderophore accumulation [105]. 
Furthermore, it has been demonstrated that mmpL4a, mmpL4b and mmpS4 are involved in 
glycopeptidolipid biosynthesis and transport in other mycobacteria. In M. smegmatis, single 
mutants deleted in mmpL4a, mmpL4b and mmpS4 have altered colony morphology, reduced 
sliding motility and biofilm formation [106-108]. Apart from these phenotypic characteristics, M. 
abscessus mmpL4b knockout mutants have shown immunostimulatory and invasive bacterial 
phenotype [109]. 
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2. Objectives 
The main objective of this work is the characterization of the MmpL4/MmpS4 efflux system in 
Mycobacterium tuberculosis. To deal with this issue, the following objectives will be tackled: 
• To construct the M. tuberculosis H37Rv knockout mutants deleted in rv0450c, in 
rv0451c, and in both rv0450c and rv0451c, besides their complemented strains. 
• To overexpress both rv0450c and rv0451c in M. tuberculosis H37Rv wt. 
• To discover whether this efflux system is involved in intrinsic drug resistance in M. 
tuberculosis. 
• To characterise the in vitro phenotype of the M. tuberculosis strains covering cell and 
colony morphology and growth in synthetic media. 
• To study the in vivo phenotype of the M. tuberculosis strains including growth and 
cytotoxicity in infected macrophages. 
• To find out the influence of MmmpL4 and MmpS4 efflux pumps in the expression of the 
MmpL and MmpS protein families. 
• To figure out the involvement of MmpL4/MmpS4 efflux system in lipid transport by 
lipidomics. 
• To analyse the proteome of the M. tuberculosis strains. 
• To carry out complementary analyses in M. bovis so as to improve the knowledge of the 
MmpL4/MmpS4 efflux system. 
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3. Material and Methods 
3.1. Basic procedures 
3.1.1. Bacterial strains, growth media and general culture conditions 
E. coli HB101, XL1-Blue, DH10β, and TOP10 strains were used for cloning experiments. Strains 
were grown at 37ºC in Luria-Bertani (LB) broth or LB agar supplemented with ampicillin (Amp; 
100µg/ml), kanamycin (Km; 20µg/ml), chloramphenicol (Cm; 15µg/ml), hygromycin (Hyg; 
50µg/ml), when necessary. Isopropyl-β-thiogalactopyranoside (IPTG) (0.1mM) and X-Gal 
(40µg/ml) were added when it was required to check Lac phenotype. Liquid cultures were grown 
in glass tubes in a shaker. 
M. smegmatis mc2155 strains were grown at 37ºC in tryptic soy broth (Difco) containing 0.05% 
Tween-80. For propagation of mycobacteriophages, Middlebrook 7H9 (Difco) medium 
supplemented with 1.5% Bacto Agar (Difco) was used as a bottom agar and with 0.75% as a 
top agar. Liquid cultures were grown in inkwells in a shaker. 
M. bovis BCG strains were grown at 37ºC in Middlebrook 7H9 medium supplemented with 10% 
OADC (0.05% oleic acid, 0.5% bovine serum albumin, 0.2% dextrose, 0.085% NaCl, 0.0003% 
beef catalase) (Difco) and 0.05% Tween-80 (7H9T OADC), or on solid Middlebrook 7H10 
medium supplemented with 10% OADC (7H10 OADC). Km (20µg/ml), or Hyg (50µg/ml) were 
added if appropriate. Liquid cultures were done in cell culture flasks without shaking. 
M. tuberculosis strains were grown at 37ºC in Middlebrook 7H9 supplemented with ADC (0.2% 
dextrose, 0.5% BSA fraction V, 0.0003% beef catalase) (Difco). In order to keep the culture 
clump-free, Tween-80 was added to a final concentration of 0.05% (7H9T ADC), except for the 
media used in drug susceptibility assays, which were supplemented with glycerol 0.5% (7H9G 
ADC). Solid medium was Middlebrook 7H10 supplemented with ADC (7H10 ADC), and also 
with 0.05% Tween-80 for colony morphology assays. When required, Km or Hyg were used at 
concentration of 20µg/ml. For obtaining knockout mutants by recombineering method, 
Middlebrook 7H9 supplemented with 0.2% succinate were used to grow the recombineering 
strain Mtb H37Rv pJV53 and 24h before preparing their competent cells, acetamide final 
concentration 0.2% was added. Middlebrook 7H9 supplemented with 0.2% dextrose and 
0.085% NaCl were used for protein extraction. Liquid cultures were done in cell culture flasks 
without shaking. 
Storage of strains was done at -80ºC in 7H9T ADC supplemented with 15% glycerol. 
	   40	  
M. tuberculosis manipulation was carried out in a biosafety level 3 (BSL3) laboratory. 
3.1.2. Neutral-red staining 
This method was adapted from Soto et al. [110]. Mycobacterial strains were grown on 7H10 
ADC medium for 3 to 4 weeks. Cells were placed and gently disaggregated in 15ml Falcon 
tubes containing 4ml of 50% aqueous methanol, and incubated for 1h at 37ºC. Cells were 
pelleted by centrifugation (4,000rpm, 5min), and methanol removed. Then, 4ml barbital buffer 
(1% sodium barbital in 5% NaCl, pH=9.8) were added. Subsequently, 150µl of a solution of 
0.05% aqueous neutral red were added. Results were evaluated after 1h incubation at 37ºC. 
3.1.3. Auramine/rodamine staining and microscopic examination 
Mtb cultures were grown to the late-logarithmic phase in 7H9T ADC medium devoid of Tween-
80. 50µl of each culture were placed on a microscope slide and warmed at 65ºC for 10min to fix 
the cells. After fixation, 200µl of auramine solution (1% auramine O, 0.5% rodamine B in 50% 
glycerol-7% phenol) was added over the cells and incubated for 30min at room temperature 
(RT) in the dark. Slides were rinsed with an acid-alcohol solution (0.5% HCl in 70% ethanol) in 
order to eliminate the excess of auramine not retained by the cells, then rinsed with water and 
finally covered with a solution of 0.5% KMnO4. After 5min at RT slides were again rinsed with 
water. Stained cells were examined under a Nikon Eclipse E400 fluorescent microscope with an 
attached MOTICAM 2500 digital camera. The resulting images are representative of the whole 
slide at a magnification of 1000x. 
3.1.4. In vitro growth 
In order to characterize the growth rate of Mtb H37Rv wt (wild type) and Mtb H37Rv mutants, 
growth curves were performed in 7H9T ADC. Mtb strains were grown until log-phase and then 
inoculated at 105 CFU (colony forming units)/ml. OD600nm was measured at different time points 
for 1 month. When OD600nm reached 1, the culture was diluted ½ and ¼ and OD corrected 
depending on the dilution. 
So as to compare the growth rate of Mtb H37Rv wt and Mtb H37Rv mutants in low iron 
conditions, growth curves were performed in 7H9T ADC 0.1mM 2,2’-dipyridyl (DIP) and 7H9T 
ADC 0.2mM desferrioxamine (DFO). Mtb strains were grown until log-phase and then 
inoculated at 105 CFU/ml. OD600nm was measured for 2 weeks. 
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3.2. Nucleic acid and genetic engineering techniques 
3.2.1. DNA extraction 
3.2.1.1. Extraction of genomic DNA from mycobacteria 
Genomic DNA of mycobacterial strains was isolated using CTAB method [111]. Briefly, 
mycobacteria were resuspended in 400µl TE (100mM Tris/HCl, 10mM EDTA, pH=8.0) and 
heated for 10min at 85ºC. Samples were slightly cooled at RT before adding 50µl of 10mg/ml 
lysozyme and were then incubated for at least 1h at 37ºC. Subsequently, 75µl of a solution 
containing 72.5µl of 10% SDS and 2.5µl of 20mg/ml proteinase K were added and the 
suspension warmed for 10min at 65ºC. Hereafter, 100µl 5M NaCl and 100µl CTAB/NaCl (10% 
CTAB in 0.7M NaCl) pre-warmed at 65ºC were added and samples incubated for further 10min 
at 65ºC. Genomic DNA was extracted by adding 750µl of chloroform:isoamylalcohol 24:1. 
Samples were mixed by vortexing for 10s before centrifugation (13,000rpm for 5min). The upper 
(aqueous) phase was transferred to a fresh tube containing 450µl isopropanol and samples 
incubated overnight at -20ºC. Precipitated nucleic acids were collected by centrifugation 
(13,000rpm for 10min at 4ºC). The pellets were dissolved in 50µl double-distilled water and 
treated with RNAse. DNA was quantified by Abs260nm readings using a ND-1000 
spectrophotometer (NanoDrop Technologies). 
3.2.1.2. Plasmid DNA extraction from E. coli 
3.2.1.2.1. Mini-preparation (Mini-prep) 
1.5ml of a liquid culture grown overnight were centrifuged (10,000rpm for 3min) and the pellet 
resuspended in 100µl of Solution I (50mM glucose, 10mM EDTA, 25mM Tris HCl pH=8). 200µl 
of freshly made Solution II (0.2M NaOH, 1% SDS) were added, and the content mixed by 
inverting the tube several times, until it becomes transparent and viscous. After incubation on 
ice for 5min, 150µl of cold Solution III (5M KAc, 11.5% glacial HAc) were added and the tubes 
were mixed by inversion; as a result, a white pellet is formed. This mix was incubated on ice for 
5min, followed by centrifugation (12,000rpm for 10min). Supernatants (400µl approx.) were then 
transferred to a fresh tube and mixed with the same volume of chloroform: isoamyl alcohol 24:1. 
After centrifugation, the aqueous phase was transferred to a tube containing 900µl EtOH and 
50µl 3M NaAc and incubated at -20ºC for 30min. By centrifugation (12,000rpm for 5min) small 
nucleic acids (plasmids and RNA) were pelleted, and then washed with 100µl 70%EtOH. 
Finally, the pellet was dried in a vacuum drier and resuspended in 30µl double distilled water. 
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RNA, which co-purifies with plasmidic DNA, was removed by adding 1µl RNAse 1mg/ml and 
incubating for 15min at 37ºC. Plasmidic DNA was kept at -20ºC. 
3.2.1.2.2. Maxi-preparation (Maxi-prep) 
This method was used to obtain large quantities of plasmid. The process is the same as the 
mini-preparation, but starting with 100ml of liquid culture. Larger volumes of solutions are 
needed: 5ml Solution I, 10ml Solution II and 7.5ml Solution III. Besides, precipitation of plasmid 
DNA is done by adding 0.7 volumes of isopropanol instead of ethanol. Finally, nucleic acids are 
dissolved in 350µl of double distilled water and treated with 10µl RNase 1mg/ml for 15min at 
37ºC. 
3.2.1.3. BAC DNA extraction from E. coli 
We have available a BAC library derived from vector pBeloBAC11 [112] containing the 
chloramphenicol resistance marker, which contains the genome of M. tuberculosis H37Rv. BAC 
DNA extraction was done as previously described by Birnboim et al. [113] with minor 
modifications. Briefly, 100ml of BAC-transformed E. coli was prepared in LB medium containing 
15µg/ml Cm, and the cultures were grown overnight at 37ºC with vigorous and continuous 
agitation. Then, the bacterial cells were collected by centrifugation. The bacterial pellet was 
softly resuspended in 5ml of Solution I, 5ml of Solution II (see section 3.2.1.2.1 for composition 
of solutions I and II) was added to the tube, and 4ml of ice-cold NaAc pH=4.8 was added to the 
mixture. The tube was placed on ice and the precipitated debris was removed by centrifugation. 
Then, 14ml of chloroform: isoamyl alcohol 24:1 were added to the supernatant, and after 
centrifugation the aqueous phase was transferred to a new microfuge tube. DNA of the BACs 
was precipitated adding the same volume of isopropanol and finally obtained by centrifugation. 
3.2.2. Mycobacterial RNA isolation 
Mtb cultures were grown in 7H9T ADC at 37ºC to mid-logarithmic phase (OD600nm=0.4-0.5) or to 
stationary phase (4 weeks). Cells from 10ml of culture were harvested (4,000rpm for 5min at 
37ºC). To minimize RNA degradation, cells were resuspended in 1ml of RNA protect reactive 
(Qiagen). Cellular suspensions were incubated for 5min at RT and were centrifuged (14,000rpm 
for 5min at RT). Pellets were resuspended in 400µl of lysis buffer (0.5% SDS, 20mM NaAc, 
0.1mM EDTA) and 1ml of acid-phenol:clorophorm (5:1, pH=4.5) was added. Bacterial 
suspensions were transferred to tubes containing glass beads (Qbiogene) and were lysed by 
mechanical traction (Fast-prep instrument) in two cycles (45s at speed 6.5m/s) cooling the 
samples on ice for 5min between the pulses. Samples were centrifuged (14,000rpm for 5min at 
4ºC). The upper phase (aqueous) was recovered and transferred to a fresh tube that contained 
pre-chilled chloroform:isoamyl alcohol 24:1. Tubes were inverted carefully before centrifugation 
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(14,000 rpm for 5min at 4ºC). The upper (aqueous) phase was then transferred to a fresh tube 
containing 90µl of 0.3 M NaAc (pH=5.5) and 900µl of isopropanol and samples were incubated 
overnight at -20ºC. Precipitated nucleic acids were collected by centrifugation (14,000rpm for 1 
hour at 4ºC). The pellets were rinsed with 70% ethanol and air dried before being re-dissolved 
in RNase-free water. DNA was removed from RNA samples using Turbo DNA free (Ambion) by 
incubation at RT for 1 hour 30 min. Then RNA was purified with acid-phenol:chloroform (5:1, 
pH=4.5) and  the same steps to precipitate, collect and dry were repeated to dissolve RNA in 
RNase-free water. The concentration and purity of the extracted RNA was estimated from the 
Abs260/Abs280 readings using a ND-1000 spectrophotometer. RNA integrity was assessed by 
agarose gel electrophoresis. RNA samples were stored at -80ºC. 
3.2.3. Construction of plasmids 
DNA fragments for cloning purposes were amplified by PCR using the Pwo high fidelity DNA 
polymerase (Roche) or the PrimeSTAR HS DNA polymerase (Takara Bio) for larger fragments, 
and gel-purified by using QIAquick Gel Extraction Kit (Qiagen). Plasmids were cut by restriction 
endonucleases and gel-purified by using QIAquick Gel Extraction Kit (Qiagen). Ligations were 
done using T4 DNA ligase (Invitrogen). Allelic exchange substrates (AES) were obtained by 
digestion of plasmid containing AES or amplified by PCR using the PrimeSTAR HS DNA 
polymerase. 
3.2.3.1. Construction of the replicative plasmid pRBZ13 
A 4,390bp DNA fragment containing the operon rv0451c-rv0450c from Mtb H37Rv was 
amplified by PCR with oligonucleotides mmpL4S4-rFw4 and mmpL4S4-rRv (Table 4).  
Table 4. Oligonucleotides to amplify the region containing the operon rv0451c-rv0450c from Mtb H37Rv. 
Oligonucleotide Sequence 5' à 3' Characteristics 
mmpL4S4-rFw4 TTTTAAGCTTCACTTCTTT 
GTGCGAGGTGA 
HindIII site underlined. 
mmpL4S4-rRv TTTTAAGCTTACATCGAC 
ATTTCCGACTCC 
HindIII site underlined. 
The previous PCR fragment was digested with the restriction enzyme HindIII and inserted into 
pSUM36 replicative vector digested with HindIII. The amplified DNA fragment includes the 
promoter of the operon; consequently, the overexpression of mmpL4 and mmpS4 is due to the 
presence of multiples copies of this plasmid. To confirm the absence of PCR-induced mutations 
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in the final plasmid pRBZ13 (Figure 7), it was sequenced using the oligonucleotides included in 
Table 5. 
 
Figure 7. Replicative plasmid pSUM36 and its derivative pRBZ13. (A) pSUM36 has replication origins in E. 
coli and mycobacteria, KmR and lacZ marker genes. (B) pRBZ13 comprises M. tuberculosis H37Rv 
mmpL4 and mmpS4 genes. 
Table 5. Oligonucleotides used for sequencing the replicative plasmid pRBZ13. 
Oligonucleotide Sequence 5' à 3' 
mmpL4-1r TTTTTACTAGTGACACCGATCGCTCTTGG 
mmpL4-2fa GCAGCGGCCACCAGAAC 
mmpL4-a TCCGAAGACAGGAACGACTT 
mmpL4-b CCTGCTTCAGCATGTCGTT 
mmpL4-c GACTTTGAGGAGCCGCTTAG 
mmpL4-d GTGATTGCTGCACATCCTGT 
mmpS4KO-Rv CCACCGTGATCAGCAGGAG 
pSUR1-Rv GACTCTGGGGTTCGAAATGA 
RP-180 ATGCAGCTGGCACGACAGGT 
3.2.3.2. Construction of the integrative plasmid pRBV2 
In order to generate pRBV2 (Figure 8), a 4,104bp DNA fragment containing the operon 
rv0451c-rv0450c from Mtb H37Rv was amplified by PCR with oligonucleotides mmpL4S4-iFw 
and mmpL4S4-iRv (Table 6).  
pRBZ13
9350 bp
lacZ
Rv0499c
Rv0452
mmpL4
mmpS4
KmR
oriMyco
oriE
HindIII
HindIII
pSUM36
5252 bp
KmR
lacZ
oriMyco
oriE
HindIII
A B 
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Table 6. Oligonucleotides to amplify the region containing the operon rv0451c-rv0450c from Mtb H37Rv. 
Oligonucleotide Sequence 5' à 3' Characteristics 
mmpL4S4-iFw TTTTGCTAGCCACTTC 
TTTGTGCGAGGTGA 
NheI site underlined. 
mmpL4S4-iRv TTTTGCTAGCACATCG 
ACATTTCCGACTCC 
NheI site underlined. 
The previous PCR fragment was digested with restriction enzyme NheI and inserted into 
pMV361 integrative vector digested with NheI. The resulting plasmid was sequenced with 
oligonucleotides included in Table 7 to verify the sequence. 
 
Figure 8. Integrative plasmid pMV361 and its derivative pRBV2. (A) pMV361 contains a origin of 
replication in E. coli, a KmR marker, the strong promoter hsp60 and attP site and int gene that mediate 
integration process. (B) pRBZ2 includes M. tuberculosis H37Rv mmpL4 and mmpS4 genes. 
Table 7. Oligonucleotides used for sequencing the integrative plasmid pRBV2. 
Oligonucleotide Sequence 5' à 3' 
mmpL4-1f TTTTGGATCCGCGGCTTCTTC 
mmpL4-2fa GCAGCGGCCACCAGAAC 
mmpL4-a TCCGAAGACAGGAACGACTT 
mmpL4-b CCTGCTTCAGCATGTCGTT 
mmpL4-c GACTTTGAGGAGCCGCTTAG 
mmpS4-1f TTTTAGATCTTGCGCAGACCTGCGACAGCCGTTAAC 
mmpS4KO-Rv CCACCGTGATCAGCAGGAG 
A 
pRBV2
8543 bp
Rv0449c
mmpS4
Rv0452
mmpL4
int
attP
KmR
Phsp60
oriE
NheI
NheI
pMV361
4445 bp
KmR
attP
int
Phsp60
oriE
NheI B 
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pMV361-B GGAAACGTCTTGCTCGAGG 
pMV361-C GATCCGGAGGAATCACTTC 
3.2.4. Electrotransformation of E. coli and mycobacteria 
To prepare E. coli electrocompetent cells, bacteria were grown to an OD600nm of 0.4 to 0.6. 
Then, the growth was stopped for 30min on ice, and bacteria were washed twice in chilled-cold 
water, and once in chilled-cold 10% glycerol. Cells are finally resuspended in 1ml chilled-cold 
10% glycerol. Aliquots of 40µl were directly used or stored at -80ºC for further use. Aliquots of 
40µl were electroporated with 20-30ng of purified plasmid DNA in 0.2cm gap cuvettes (Bio-Rad) 
with a single pulse (2.5kV, 25µF, 200Ω) in a GenePulser XcellTM (Bio-Rad). Cells were 
resuspended in LB to a final volume of 1ml and incubated for 1h at 37ºC if required before 
plating several dilutions on plates containing the needed antibiotic. Colonies appeared after 
incubation overnight. 
M. smegmatis electrocompetent cells were grown to an OD600nm of 0.8 to 1.0, and then were 
incubated on ice for 30min to 2h. After centrifugation, cells were washed thrice in 10% glycerol 
at 4ºC; first wash was done in a half of the initial culture volume, second in a quarter and third in 
an eighth. Subsequently, bacteria were resuspended in 1ml of 10% glycerol, and aliquots of 
100µl were electroporated with 400ng of phasmid DNA using 0.2cm gap cuvettes with a single 
pulse (2.5kV, 25µF, 1000Ω) in a GenePulser XcellTM. Cells were recovered with 1ml of LB and 
incubated at 30ºC for 6h. Then, 100µl and 300µl of the transformed mc2155 were diluted to 
200µl actively growing mc2155 culture. The dilutions were added to 4ml top agar and pour onto 
7H9 agar bottom plates. The plates were incubated at 30ºC for 3 days until plaques were 
observed. Importantly, M. smegmatis cells should be kept cold by using ice-cold glycerol, 
centrifuging at 4°C, and placing tubes on ice whenever possible. 
M. bovis and M. tuberculosis electrocompetent cells were prepared as described by Wards et 
al. [114]. Bacteria were grown until an OD600nm of 0.6 to 0.8. Glycine was added to the cells to a 
final concentration of 0.2M and incubated at 37ºC for 24 hours more. All the process was 
performed at RT. Bacterial pellet was washed twice with 0.05% Tween-80 and once with 10% 
glycerol 0.05% Tween-80, and finally resuspended in 2ml of 10% glycerol 0.05% Tween-80. 
Aliquots of 200-400µl were electroporated with 100-200ng of replicative or integrative plasmid 
DNA (previously purified), using 0.2cm gap cuvettes with a single pulse (2.5kV, 25µF, 1000Ω) in 
a GenePulser XcellTM. Cells were recovered with 1ml of 7H9T ADC and incubated for 24h at 
37ºC, to allow expression of the antibiotic resistance genes, before plating serial decimal 
dilutions on plates containing the relevant antibiotic. Colonies typically appeared in 3-4 weeks. 
For recombineering method, Mtb H37Rv containing the plasmid pJV53 was grown in 50ml 7H9T 
0.2% succinate until an OD600nm of 0.5. Then, acetamide was added to a final concentration of 
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0.2%, and the culture was grown at 37°C overnight. After three washes with 10% sterile 
glycerol, cells were resuspended in 2ml of 10% glycerol. Aliquots of 100µl were directly 
electroporated with 100ng AES in 0.2cm cuvettes with a single pulse in a GenePulser XcellTM 
(2.5 kV, 25 µF, 1000 Ω). Cells were recovered with 1ml of 7H9T ADC, and incubated for 72h at 
37ºC before plating the entire reaction on 7H10 ADC Km Hyg plates. Colonies typically 
appeared in 3-4 weeks. 
3.2.5. Specialised transduction in E. coli and mycobacteria 
To prepare E. coli cells for transduction process, 5ml of LB medium supplemented with 10mM 
MgSO4 and 0.2% maltose were inoculated with 100µl of fresh E. coli culture, incubated at 37ºC 
and shaken at 200rpm, until OD600nm reached 0.8-1.0. The culture was centrifuged at 3,000rpm 
at 4ºC for 10min and resuspended in 500µl. The E. coli cells can be stored at 4ºC for 1 week 
until ready to use. 
Regarding M. bovis BCG, 500ml of 7H9T OADC were inoculated with 10ml of BCG culture, 
incubated at 37ºC till the OD600nm reached 0.8-1.0. The culture was centrifuged at 4,000rpm for 
15min. The pellet was washed twice with MP buffer (50mM Tris–HCl, pH=7.6, 150mM NaCl, 
10mM MgCl2 and 2mM CaCl2), resuspended in 5ml of MP buffer, and 5 aliquots of 1ml were 
obtained. 
Washes with MP buffer are necessary to remove traces of the Tween-80 detergent, which can 
inhibit phage infection. 
3.2.6. Construction of knockout mutant strains of mycobacteria 
3.2.6.1. Recombineering 
Knockout mutants of Mtb H37Rv were constructed following the method described by van 
Kessel and Hatfull [115]. 
Firstly, it was necessary to construct AES for each gene of interest: rv0450c (mmpL4 AES) and 
both rv0450c and rv0451c (mmpL4-mmpS4 AES). 
The general procedure for obtaining AES for homologous recombination by using the 
recombineering method is depicted in the following figure: 
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Figure 9. Construction and preparation of targeting substrate for recombineering. Primers are designed 
with restriction sites (A–D) to amplify upstream and downstream regions flanking the target gene. The 
amplification products are digested, and directionally cloned into a vector flanking a HygR cassette. The 
plasmid is then linearized by double-digestion with enzymes A and D at the ends of the targeting 
substrate. Black boxes indicate γδ res sites that can be used to remove the hygromycin cassette after 
mutagenesis [115]. 
Specifically, for obtaining the mmpL4 AES, primers were designed with restriction sites to 
amplify upstream and downstream regions flanking mmpL4 gene; mmpL4-1f (BamHI) and 
mmpL4-1r (SpeI) primers amplified a 540bp region upstream mmpL4, and mmpL4-2f (KpnI) and 
mmpL4-2r (KpnI) a 549bp region downstream mmpL4, using H37Rv genomic DNA as the 
template (Table 8). The PCR products were cloned into pWM27 vector flanking a Hyg-
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resistance cassette in the same orientation as they are in the H37Rv genomic DNA and 
sequenced (Table 8). The resulting plasmid pRBZ2 (Figure 10) was linearized by restriction 
digest with BamHI and FspI. 
Table 8. Oligonucleotides to amplify upstream and downstream regions flanking mmpL4 and to sequence 
these regions in pRBZ2. 
Oligonucleotide Sequence 5' à 3' Use 
mmpL4-1f TTTTGGATCCGCGGCTTCTTC To amplify and sequence. 
BamHI site underlined. 
mmpL4-1r TTTTTACTAGTGACACCGATC 
GCTCTTGG 
To amplify and sequence. 
SpeI site underlined. 
mmpL4-2f TTTTGGTACCGTTCTGGTGGC 
CGCTGC 
To amplify and sequence. 
KpnI site underlined. 
mmpL4-2r TGCACAGGTACCGTGGC To amplify. 
KpnI site underlined. 
pWM27-Rv CACGACGTTGTAAAACGACG To sequence. 
The fragment that contains the Hyg-cassette flanked by the two regions adjacent to mmpL4 
gene was separated by gel extraction, microdialized and quantified by Abs260nm readings using a 
ND-1000 spectrophotometer. 
 
Figure 10. Vector pWM27 and its derivate pRBZ2. (A) pWM27 has a origin of replication in E. coli, 
recombination sites res1 and res2, and AmpR and HygR marker genes. (B) pRBZ2 carries the mmpL4 
AES. 
pWM27
6099 bp
Hyg B
AmpR
oriE
res1
res2
BamHI SpeI
KpnI
pRBZ2
7151 bp
Rv0449c
mmpS4
mmpL4
mmpL4
Hyg B
AmpR
oriE
res1
res2
BamHI
SpeI
FspI
FspI
KpnI
KpnI
A B 
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For deleting both mmpL4 and mmpS4 genes, a different approach was followed: the mmpL4-
mmpS4 AES was constructed using the λ-Red system [116] to manipulate a BAC, which 
contains the region with the targeted gene, through homologous recombination. 
E. coli DH10β containing the BAC313 [112, 117], which has a large fragment of DNA where 
mmpL4-mmpS4 are included, was transformed with pKD46. The recombinogenic plasmid, 
pKD46, contains the λ-Red recombinase under control of the inducible arabinose operon 
(Figure 11). 
 
Figure 11. pKD46 plasmid and its components. pKD46 includes λ-Red genes (λ exonuclease, β protein 
and δ protein), its repressor AraC, RepA temperature sensitive origin in E. coli and AmpR cassette. 
L4S4-bacFw primer was designed to include 20bp of the end region of HygR cassette of 
pYUB854 in its 3’ end, and 50bp of the region upstream of mmpS4 in its 5’ end. Similarly, L4S4-
bacRv primer includes 20bp of the other end region of HygR cassette in its 3’ end and 50bp of 
the region downstream mmpL4 in its 5’ end. Using the plasmid pYUB854 as a template, these 
primers amplified a 2,182bp fragment containing the Hyg cassette flanked by 50bp regions 
identical to sequences adjacent to mmpL4 and mmpS4 genes. A culture of DH10β BAC313 
pKD46 strain was induced with arabinose for 3h to trigger expression of λ-Red recombinase, 
and competent cells were prepared. This strain was transformed with the PCR product 
described above, which integrated in BAC313 replacing the original mmpL4 and mmpS4 genes. 
From the HygR colonies, the recombinant BAC313::Hyg was extracted and the mmpL4-mmpS4 
AES, which contains regions of 1,000bp upstream and downstream of the target genes flanking 
a HygR cassette was amplified with L4S4aes-Fw and L4S4aes-Rv oligonucleotides (Figure 12) 
(Table 9). 
pKD46
6329 bp
araC protein
gam protein
bet protein
exonuclease
repA101 protein
AmpR
oriR101
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Figure 12. Construction and preparation of AES of the target genes mmpL4 and mmpS4 using λ-Red 
system. 
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Table 9. Oligonucleotides used for the construction of the mmpL4-mmpS4 AES. 
Oligonucleotide Sequence 5' à 3' 
L4S4-bacFw CGTGCACCGGATCCGCGGCTTCTTCGGCTCCGAAAA 
CCGCCCGTCGTACTGATATCTGGATCCACGAAGC 
L4S4-bacRv TTTCGCTGGGTACGGTCGGGGTCCGGGCGGGCCGG 
GAACGCACCCGCAGCTGGTCTGACAGTTACCAATGC 
L4S4aes-Fw TTTTGCGGCCGCGCAAAGTCGAGGTTCCACTC 
L4S4aes-Rv TTTTTTAATTAACGGGTGTCACCAGGTAGTTC 
Once both AESs were achieved, mycobacterial recombineering strains were generated using 
the plasmid pJV53 (Figure 13). 
 
Figure 13. pJV53 and its components. pJV53 plasmid which contains replication origins for E. coli and 
mycobacteria, a KmR marker and the che9c 60–61 genes expressed under control of the inducible 
acetamidase promoter. 
Mtb H37Rv pJV53 strain was grown to mid-log phase in 7H9T 0.2% succinate. It is necessary to 
growth the cells in media containing succinate instead of ADC because succinate enhances 
proper production of the recombination enzymes. Once Mtb H37Rv pJV53 strain was cultured 
with acetamide to induce expression of Che9c gp60 and gp61 recombinases, competent cells 
were prepared. This strain was transformed independently with either mmpL4 AES or mmpL4-
mmpS4 AES that contain regions of 500bp and 1,000bp sequence identity respectively to the 
locus flanking a HygR cassette (Figure 14). 
pJV53
8812 bp
Che9c 60-61
KmR
Pacetamidase
oriE
oriMyco
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Figure 14. Schematic representation of double crossovers occurred when AES is transformed into the 
mycobacteria to yield a marked allelic replacement mutant [28]. 
Hygromycin-resistant recombinant colonies were obtained, and the replacement of the target 
gene by the AES was verified by Southern Blot and PCR analysis with the oligonucleotides in 
Table 10. 
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Table 10. Oligonucleotides used for confirming M. tuberculosis knockout mutants deleted in mmpL4 and in 
mmpL4-mmpS4. 
Oligonucleotide Sequence 5' à  3' 
mmpL4KO-Fw CACTCCAGCGAACGAGG 
Hyg-out TGATCCGGTGGATGACC 
mmpL4KO-1f GCGCGCGGAGTCGTAG 
mmpL4KO-1r GCTGACCGGCATTTTGC 
mmpL4S4KO-Fw AAGCGTGAGTTTGGTCACCT 
mmpL4S4KO-Rv TGCTGATGTCGTAGCTGACC 
Hyg-cFw GCATTGGTAACTGTCAGACCA 
Hyg-cRv GCTTCGTGGATCCAGATATC 
Finally, the recombineering expression plasmid pJV53 was removed by growing the cells 
without selection for Km-resistance for 6 weeks. This resulted in two strains, H37Rv L4KO and 
H37Rv L4S4KO containing a deletion in mmpL4 and mmpL4-mmpS4, respectively. 
3.2.6.2. Specialised transduction 
The deletion of the BCG_0489c (mmpL4), BCG_0490c (mmpS4) and both BCG_0489c and 
BCG_0490c from M. bovis BCG was performed using the method of specialised transduction as 
described previously by Bardarov et al [27]. Approximately 1kb of upstream and downstream 
flanking sequences of mmpL4 and mmpS4 were PCR amplified from M. bovis BCG genomic 
DNA using the primers L4-LL, L4-LR, L4-RL, L4-RR, S4-LL, S4-LR, S4-RL and S4-RR 
incorporating Van91I and DraIII sites, given in Table 11 and Table 12. 
Table 11. Amplified regions of mmpL4 and mmpS4 M. bovis BCG and the primers used in the 
amplification. 
Gene Upstream 
PCR (bp) 
Downstream 
PCR (bp) 
Upstream 
primers 
Downstream 
primers 
BCG_0489c (mmpL4) 1120 1066 L4-LL vs L4-LR L4-RL vs L4-RR 
BCG_0490c (mmpS4) 962 1074 S4-LL vs S4-LR S4-RL vs S4-RR 
BCG_0489c- BCG_0490c 
(mmpL4-mmpS4) 
962 1066 S4-LL vs S4-LR L4-RL vs L4-RR 
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Table 12. Sequence of the primers used to amplify upstream and downstream regions of mmpL4 and 
mmpS4 M. bovis BCG. 
Oligonucleotide Sequence 5' à 3' Characteristics 
L4-LL TTTTTTTTCCATAAATTGGAAC 
GCACACCGTGTGATTTG 
Van91I site underlined. 
L4-LR TTTTTTTTCCATTTCTTGGGCC 
TTGCCGTCGTTACTTTG 
Van91I site underlined. 
L4-RL TTTTTTTTCACAGAGTGTGTTG 
GCGGTGGGATCTGAC 
DraIII site underlined. 
L4-RR TTTTTTTTCACCTTGTGACAGA 
TACCGGGCCGGATAG 
DraIII site underlined. 
S4-LL TTTTTTTTCCATAAATTGGGGC 
CAGCAGGATGTCGAATG 
Van91I site underlined. 
S4-LR TTTTTTTTCCATTTCTTGGGGG 
TCCGAAGATCTCGTAAG 
Van91I site underlined. 
S4-RL TTTTTTTTCCATAGATTGGGGC 
GGTGATGGGAAATATCG 
Van91I site underlined. 
S4-RR TTTTTTTTCCATCTTTTGGCGC 
GGTACATGGTGTAGTAG 
Van91I site underlined. 
The amplification products were digested with Van91I and DraIII enzymes, the resulting 
fragments were cloned into Van91I-digested p0004S [27]. Allelic exchange plasmids pΔL4, 
pΔS4 and pΔL4S4 were selected and propagated following transformation of E. coli TOP10 to 
HygR. Sequences of inserted DNA fragments were verified (Table 13). 
Table 13. Oligonucleotides used to sequence the cloned DNA fragments in pΔL4, pΔS4 and pΔL4S4. 
Oligonucleotide Sequence 5' à  3' 
HL AGGATCCAGGACCTGCCAAT 
HR CTTCACCGATCCGGAGGAAC 
OL CGGCCGATAATACGACTCA 
OR CTGACGCTCAGTCGAACGAA 
Allelic exchange plasmids were digested with PacI and ligated to PacI-digested phAE159, a 
temperature-sensitive phage [27, 118], to yield the recombinant phasmids phΔL4, phΔS4 and 
phΔL4S4. Ligation products were packaged using MaxPlax™ Lambda Packaging Extracts 
(Epicentre Biotechnologies) and transduced into E. coli HB101 for propagation. Phasmids were 
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purified and electroporated into M. smegmatis mc2155 for phage propagations at the permissive 
temperature (30°C). The phage propagations were carried out by an agar-layer technique using 
MP buffer as phage diluent. High titer lysates were prepared from phage propagated in M. 
smegmatis mc2155 (OD600nm = 1.0) grown on 7H9 agar. Phage titers were determined by 
spotting 10µl of phage diluted in MP buffer onto lawns of M. smegmatis mc2155 on 7H9 agar. 
BCG aliquots prepared for specialised transduction were mixed with high titre recombinant-
phage (typically at least 109 plaque forming unit/ml) lysates at an MOI of 10:1, and incubated at 
non-permissive temperature (37ºC) overnight to allow for infection. The mixtures were 
centrifuged and the pellet resuspended in 3ml 7H9T OADC. After incubating overnight at 37ºC, 
the recombinant strains with integration of the allelic exchange marker were selected on 7H10 
OADC plates containing 75µg/ml Hyg (Figure 15). 
	   57	  
 
Figure 15. Schematic representation of the process for obtaining knockout mutants by specialised 
transduction. Adapted from van Kessel [119]. 
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3.2.7. Southern blot 
Approximately 3µg of extracted genomic DNA were digested with BamHI. The fragments were 
separated by electrophoresis through 0.8% agarose gels in Tris-Borate-EDTA (TBE) buffer for 
18h at 0.8V/cm. After migration, a standard treatment of the gel was performed. DNA was fixed 
by UV light for 5min and subjected to a depurination treatment (0.25M HCl for 10min), washing, 
denaturalization (0.5M NaOH, 1.5M NaCl for 20min) and neutralization (1.5M NaCl, 1M Tris, 
pH=8.0 for 20min). Hereafter, DNA was vacuum blotted (45-60mbar for 1h 30min) onto a 
Hybond-N+nylon membrane (Amersham) using 10x SSC buffer (1.5M NaCl, 150mM sodium 
citrate). Blotted DNA was fixed by UV light for 4min and hybridized with a specific probe. This 
probe was made by PCR with Taq Gold polymerase (Applied Biosystems) using specific 
oligonucleotides (Table 14). This PCR product was then purified using GFXTM PCR kit and 
adjusted to 10ng/µl. After labelling the probe, hybridization patterns were visualized using 
ECLTM Direct Nucleic Acid Labelling and Detection System (Amersham). 
Table 14. Restriction enzymes used for digesting genomic DNA and construction of specific probes for 
Southern Blot. 
M. tuberculosis H37Rv 
deleted gene 
DNA digested 
with 
Probe 
PCR with oligonucleotides Size bp 
rv0450c (mmpL4) BamHI mmpL4-1f vs mmpS4KO-Rv 1046 
rv0451c-rv0450c 
(mmpL4-mmpS4) 
BamHI mmpL4-2f vs mmpL4S4KO-Rv 1175 
3.3. Methods for phenotypic characterization 
3.3.1. Ethidium Bromide accumulation assay 
Mtb strains were grown in 7H9T ADC at 37ºC until an OD600nm of 0.6 to 0.8. Cultures were 
centrifuged at 4,000rpm for 10 min, the supernatant discarded, the pellet washed in PBS 
(pH=7.4) and the OD600nm adjusted to 0.8 with PBS with 0.05% Tween-80. Aliquots of 100µl of 
bacterial suspension were transferred into wells of a 96-well plate containing serial dilutions of 
ethidium bromide concentrations that ranged from 2-0.125µg/ml. 
To determine the effect of chlorpromazine (CPZ) and verapamil (VP) on the accumulation of 
ethidium bromide, inhibitors were added to a selected concentration of ethidium bromide. Each 
inhibitor was used at ½ the MIC in order to not compromise the cellular viability. Relative 
fluorescence was acquired every 51 seconds for 60 minutes at 37ºC, in a SynergyTM HT 
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Detection Microplate Reader (Biotek® Instruments), using 530/25nm and 590/20nm as 
excitation and detection wavelengths, respectively. 
3.3.2. Susceptibility assays: Minimum Inhibitory Concentration 
3.3.2.1. Resazurin Microtiter Assay (REMA) 
Serial two-fold dilutions of antibiotics were performed in 7H9G ADC medium, in 96-well 
microtiter plates, with a final volume of 100µl per well. 
Liquid cultures of Mtb strains in logarithmic phase were adjusted to 105 CFU/ml in 7H9G ADC. 
100µl of this suspension were added to each well and plates were incubated 6 days at 37ºC. 
30µl of 0.1mg/ml resazurin solution were then added to each well, and results were observed 
after 48h of incubation at 37ºC. Resazurin (blue) is an indicator of bacterial growth, since 
metabolic activity of bacteria reduces it to resofurin (pink). 
Minimum Inhibitory Concentration (MIC) is the concentration of antibiotic of the well with the 
lowest concentration of drug that does not change colour from blue to pink. 
3.3.2.2. BacTiter-Glo Microbial Cell Viability Assay 
The BacTiter-Glo Microbial Cell Viability Assay (Promega) is a method for determining the 
number of viable bacterial cells in a sample based on quantitation of the ATP present. It is used 
when drugs with redox activity interfere with resazurin. 
The assay is very similar to REMA described above. In an opaque-walled 96-well-plate, double 
of the desired concentrations of the antibiotic are added in 100µl of 7H9G ADC. Wells are 
inoculated by adding 100µl of a culture whose concentration is 105 CFU/ml. After 7 days of 
incubation, 100µl of BacTiter-Glo Reagent was added to each well, incubated 30min at RT, and 
recorded luminescence (integration time = 1 second per well) in a SynergyTM HT Detection 
Microplate Reader. 
3.3.3. Infection assays 
3.3.3.1. Intracellular replication in MH-S cells 
Intracellular replication of Mtb strains were tested in MH-S (murine alveolar macrophages) cells. 
MH-S cells were grown in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS) and 4mM L-glutamine (“complete DMEM” from now). 
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Infections were performed at a multiplicity of infection (MOI) of 1:1 bacteria per macrophage, 
with 20,000 MH-S cells per well. After 4h, infection was stopped by removing bacterial 
suspension and cells were washed three times with 1ml PBS, and finally cultured in 2ml 
complete DMEM per well to allow intracellular replication. Medium was replaced when needed 
(typically every 1-2 days) by removing 1.5ml of overlaying DMEM and adding the same volume 
of fresh complete DMEM. 
In order to know the number of intracellular bacteria at the end of time of infection (4h) and days 
3, 5 and 7 post-infection, DMEM medium was removed, and 300µl 0.1% triton X-100 were 
added to each well in order to lyse the cells. 700µl of PBS were added per well and the solution 
carefully mixed. Several dilutions of this lysate were plated on 7H10 ADC plates and viable 
bacteria numbers was estimated after 2-3 weeks by counting the number of colonies. 
3.3.3.2. Apoptosis induction in MH-S cells 
Apoptosis induction of Mtb strains were tested in MH-S (murine alveolar macrophages) cells. 
MH-S cells were seeded in wells, in complete DMEM. Infections were performed at a multiplicity 
of infection (MOI) of 5-10 bacteria per macrophage, with 400,000 MH-S cells per well. After 4h, 
infection was stopped by removing bacterial suspension and cells were washed three times with 
1ml PBS, and finally cultured in 6ml complete DMEM per well to allow intracellular replication. 
At day 3 post-infection, both supernatant and trypsinized cells were collected together in 15 ml 
screw-cup tubes. Phosphatidylserine exposure and membrane integrity were analysed by using 
Annexin-V and 7-actinomycinD (BD Biosciences) and flow cytometry according to manufacturer 
instructions. Briefly, cells were incubated with Annexin-V and 7AAD in Annexin-binding buffer 
for 15min. After that, cells were fixed with 4% paraformaldehyde during 30min. PFA 
Paraformaldehyde solution contained 2.5mM CaCl2. 
3.3.4. Ziehl-Neelsen Staining on infected MH-S cells 
In parallel with intracellular replication assays, infected MH-S cells were stained by Ziehl-
Neelsen method. Infections were performed at an MOI of 1:1 bacteria per macrophage, with 
100,000 MH-S cells per well. 
MH-S cells were seed on circular glass slide covers of 12mm diameter (Knittel-Gläser) in 24-
well cell culture plates, incubated at 37ºC 5% CO2 for 24h, and then infected as it has been 
described in infection assay section. Cells were fixed with 500µl of 4% paraformaldehyde for 
30min at RT, and washed with 500µl PBS. In order to enable phenol-carbol fuchsin stain to 
penetrate the waxy mycobacterial cell wall, the slide covers were heated at 60-65ºC for 5min, 
washed off with water, and covered with an acid alcohol solution (0.5% HCl, 70% ethanol) until 
they were decolorized. After washing, the slide covers were covered with methylene blue stain 
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for 5min, washed again, and dried. Finally, slide covers were stuck up-side down on a 
microscope slide, and examined under a Nikon Eclipse E400 microscope linked to a MOTICAM 
2500 digital camera, using the 100x oil immersion objective. 
3.3.5. Real-Time Quantitative PCR (qRT-PCR) 
Reverse transcription was done from 1µg of RNA using 0.5µg of Random Hexamers (Integrated 
DNA Technologies) and the SuperScript III (Invitrogen – Life Technologies), performing the 
reaction at 25ºC for 5min, 50ºC for 2 hours and 70ºC for 15min. Actinomycin D (Sigma) was 
added to each sample in order to prevent second-strand cDNA synthesis during reverse 
transcription. cDNA prepared in this way was diluted 1:10 prior to use it to Real Time PCR 
amplification in the StepOne Plus Real Time PCR System (Applied Biosystems) using Master 
Mix containing Syber Green (Roche), and the suitable set of primers (Table 15), which were 
designed using the Primer Express Software (Applied Biosystems). A melting curve was 
performed for every pair of primers to verify that they produce a single product. PCR 
amplification was carried out as recommended for the manufacturer (95ºC for 10min; and 40 
cycles of 95ºC for 15s, 60ºC for 1min). All the reactions were performed in triplicate, and the 
levels of mRNA were calculated relative to sigA mRNA and the reference strain H37Rv by the 
ΔΔCt method. 
Table 15. Oligonucleotides used in RT-PCR. 
Oligonucleotide Sequence 5' -> 3' Gene 
RTL1-Fw GCGCCCCCTCAGAAGTTT mmpL1 
RTL1-Rv CGACCAGCAGATGGGAATGT mmpL1 
RTL2-Fw ACCACAACATTTTCAGCCTTTCA mmpL2 
RTL2-Rv CCGCAATCGCCATGAGA mmpL2 
RTL3-Fw CGCCCTGGAGCTGGATT mmpL3 
RTL3-Rv TCGTGGTGGTCAGCAGGAT mmpL3 
RTL4-Fw CGCCCTGCCTGGATACAA mmpL4 
RTL4-Rv GGGTATGAAGTCCGGTAGGTAGTC mmpL4 
RTL5-Fw TGCCACGTTCTGTCTGAGCTT mmpL5 
RTL5-Rv GGCACACCGAGGGTCTGA mmpL5 
RTL6-Fw GCGGCCTGAAATTGTTCCT mmpL6 
RTL6-Rv ATCGCCTTCATGGGAGATGA mmpL6 
RTL7-Fw CGCGGAACCTCAAAAACAAA mmpL7 
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RTL7-Rv GGTGTGGATCGTTTCCAGGTATT mmpL7 
RTL8-Fw CGGCTTCCGTCGAGAGTTC mmpL8 
RTL8-Rv GGTTAGACGGGAAATGCTTGTC mmpL8 
RTL9-Fw TGGGTGAAGCACTCGCAAA mmpL9 
RTL9-Rv CGGTGTACTATTCGCCACAATTT mmpL9 
RTL10-Fw CGTCGAACGCATCGTGAA mmpL10 
RTL10-Rv GCGGGTCCTGTCACGTTT mmpL10 
RTL11-Fw ACGCGGGCACCAGTGA mmpL11 
RTL11-Rv GCAGTTTGCCCGGACTGAT mmpL11 
RTL12-Fw GGTCAACGATATCCTCCGTGTT mmpL12 
RTL12-Rv GGCATCCTCGAGTTCGGTATT mmpL12 
RTL13a-Fw TCGAGGTGTTGACCGACAAG mmpL13a 
RTL13a-Rv CGTAACCACGATCAGCATTTTC mmpL13a 
RTL13b-Fw TCGTGGTCCCAGCATTCAT mmpL13b 
RTL13b-Rv CTCGGTGCCCACCAATTC mmpL13b 
RTS1-Fw ACCCGATCATCGCGTTTTAC mmpS1 
RTS1-Rv TGGCGGGCCGAAGAC mmpS1 
RTS2-Fw TCTTCGGTGTTCACGAGCAA mmpS2 
RTS2-Rv GCGGGACGTCGAAATCAG mmpS2 
RTS3-Fw TGTGTACATCCCGTGGTCCAT mmpS3 
RTS3-Rv GAGCCAACGTCGGATTGC mmpS3 
RTS4-Fw GAAAACCGCCCGTCGTACT mmpS4 
RTS4-Rv TTAGGGTTGAATGGTTTGCTGTT mmpS4 
RTS5-Fw AGGCGACGGCACTTCCA mmpS5 
RTS5-Rv GTCCGCTCGTCCTTCACTTC mmpS5 
sigA-Fw CCGATGACGACGAGGAGATC sigma factor sigA 
sigA-Rv CGGAGGCCTTGTCCTTTTC sigma factor sigA 
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3.3.6. Extraction and analysis of mycobacterial lipids 
3.3.6.1. Extraction of free lipids 
Mtb strains were grown in 300ml 7H9T ADC at 37ºC for one month. Cultures were centrifuged 
and bacterial pellets were autoclaved. Afterwards, cell pellets were washed with PBS, and two 
consecutive extractions with 4ml of petroleum ether (60-80C) were performed; pellets were kept 
for extraction of non-polar lipids (below). Both supernatants were collected to a new glass tube 
sealed with a polytetrafluoroethene (Teflon®)-lined screw cap. Solvent was completely 
evaporated on a heating block (50ºC) under a stream of nitrogen gas and dried free lipids were 
resuspended in 400µl of chloroform:methanol 2:1. 
3.3.6.2. Extraction of non-polar lipids 
2ml of methanol: 0.3% NaCl (10:1) were added to the pellets from the protocol above, followed 
by 2ml of petroleum ether (60-80C). After stirring, the upper layer was transferred to a new 
glass tube. 2ml of petroleum ether (60-80C) were added to the lower layer in the previous tube, 
mixed, centrifuged, and the upper layer collected to the previous glass tube; tubes containing 
the lower layer were kept for extraction of polar lipids (below). The non-polar lipid extracts were 
dried and resuspended as free lipids. 
3.3.6.3. Extraction of polar lipids 
2.3ml of chloroform: methanol: 0.3% NaCl in a 9:10:3 ratio were added to the tubes from the 
procedure above. The mixture was stirred for 1h, and the supernatants were re-extracted twice 
using 5:10:4 mixture of chloroform: methanol: 0.3% NaCl. Equal volumes of chloroform and 
0.3% NaCl were added and the mixture stirred for 5min, after which the organic phase was 
discarded and the aqueous phase containing the polar lipids was removed, dried and 
resuspended as free lipids. The remaining pellets were also dried, and kept for the following 
protocol. 
3.3.6.4. Extraction of FAMEs and MAMEs 
Dried pellets from the procedure above were then subjected to alkaline hydrolysis using 2 ml 
5% tetrabutylammonium hydroxide (TBAH) at 95°C overnight and mixed with 2ml of water, 4ml 
of dichloromethane, and 500µl of iodomethane for 30min. The upper aqueous phase was 
discarded after centrifugation and the lower organic phase was washed twice with water and 
dried. The resultant mixture of fatty acid methyl esters (FAMEs) and mycolic acid methyl esters 
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(MAMEs) were extracted using diethyl ether, re-dried and resuspended in 400µl of 
chloroform:methanol 2:1. 
3.3.6.5. Thin layer chromatography analysis 
Free, non-polar and polar lipid extracts were analysed by two-dimensional thin layer 
chromatography (2D-TLC) and FAMEs and MAMEs were analysed by one-dimensional thin 
layer chromatography (1D-TLC). Free and non-polar lipids were analysed using four different 
solvent systems (A-D) (Table 16), polar lipids by two different systems (D and E) (Table 17), 
and FAMEs and MAMEs by one single system (F) (Table 18) according to Dobsong et al [120]. 
Approximately 400µg of each lipid sample were spotted on TLC plates (5554 silica gel 60F524, 
Merck) for 1D and 2D-TLC analysis using following solution systems and allowing plates to dry 
between each run. Finally, lipids in TLCs were revealed by staining with a solution of 5% 
molybdophosphoric acid (MPA) in 95% ethanol and heating. 
Table 16. Solvent systems for 2D-TLC for free and non-polar lipid analysis. 
System Direction 1 Runs 
A Petroleum ether 60-80/ Ethyl acetate (98:2) 3 
B Petroleum ether 60-80/ Acetone (92:8) 3 
C Chloroform/ Methanol (96:4) 1 
D Chloroform/ Methanol/ Water (100:14:0.8) 1 
System Direction 2 Runs 
A Petroleum ether 60-80/ Acetone (98:2) 1 
B Toluene/ Acetone (95:5) 1 
C Toluene/ Acetone (80:20) 1 
D Chloroform/ Acetone/ Methanol / Water (50:60:2.5:3) 1 
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Table 17. Solvent systems for 2D-TLC for polar lipid analysis. 
System Direction 1 Runs 
D Chloroform/ Methanol/ Water (100:14:0.8) 1 
E Chloroform/ Methanol/ Water (60:30:6) 1 
System Direction 2 Runs 
D Chloroform/ Acetone/ Methanol / Water (50:60:2.5:3) 1 
E Chloroform/ Acetic acid (glacial)/ Methanol / Water (40:25:3:6) 1 
Table 18. Solvent systems for 1D-TLC FAMEs and MAMEs analysis. 
System Solvents Runs 
F Petroleum ether/ Acetone (95:5) 1 
3.3.7. Protein extraction from mycobacteria 
3.3.7.1. Extraction of cellular proteins 
2ml of a 7H9T ADC culture of Mtb in log-phase was pelleted by centrifugation (4,000rpm for 
5min at RT). The pellet was washed twice with PBS in order to remove BSA, resuspended in 
7H9T dextrose NaCl, and then transferred to 10ml of 7H9T dextrose NaCl to grow during 3 
weeks. Cells were pelleted by centrifugation (4,000rpm for 10min at RT) and resuspended in 
PBS. To avoid proteolytic degradation, protease inhibitors (cOmplete Protease Inhibitor Cocktail 
Tablets – Roche) were added prior to cell lysis. Mycobacterial cells were disrupted by sonication 
using the BioRuptor (Bio-Rad) for 15min (30s at high power) allowing cooling in an ice-water 
bath for 30s between pulses. The samples were centrifuged at 4,000rpm for 20min at 4ºC and 
the supernatant containing whole-cell protein extracts was filtered through a 0.22µm-pore-size 
low protein binding filter (Millex). Proteins were precipitated with 10% trichloroacetic acid (TCA) 
final concentration on ice for 1h. After centrifugation at 4,000rpm for 1h at 4ºC, the pelleted 
proteins were washed with pre-chilled acetone, dried briefly and resuspended in 500µl of 2D 
buffer (2M thiourea, 7M urea, 2% (w/v) CHAPS). Cellular proteins were quantified using the RC 
DC protein assay (Bio-Rad) and stored at -80ºC. 
3.3.7.2. Extraction of culture filtrate proteins 
4ml of a 7H9T ADC culture of Mtb in log-phase was pelleted by centrifugation (4,000rpm for 
5min at RT). The pellet was washed twice with PBS in order to remove BSA, resuspended in 
7H9T dextrose NaCl, and then transferred to 40ml of 7H9T dextrose NaCl to grow during 3 
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weeks. Cells were pelleted by centrifugation (4,000rpm for 10min at RT) and resuspended in 
PBS. The supernatant containing culture proteins was filtered through a 0.22µm-pore-size low 
protein binding filter. Proteins were precipitated with 10% TCA final concentration on ice for 1h. 
After centrifugation at 4000rpm for 1h at 4ºC, the pelleted proteins were washed with pre-chilled 
acetone, dried briefly and resuspended in 100µl of 2D buffer. Culture proteins were quantified 
using the RC DC protein assay and stored at -80ºC. 
3.3.8. Gel electrophoresis of proteins 
3.3.8.1. One-dimensional SDS-polyacrylamide gel electrophoresis 
10µg of each protein extract were boiled (for 5min) in presence of 3µl of 150mM Tris/HCl 
pH=7.4, 3% SDS, 0.3mM sodium molybdate, 30mM sodium pyrophosphate, 30mM NaF, 30% 
glycerol, 30% mercaptoethanol and 0.06% bromophenol blue. Cellular and culture filtrate 
proteins were separated by electrophoresis through a 5% stacking gel over a 12 % resolving 
polyacrylamide gel containing 0.1% SDS in running buffer (25mM Tris, 192mM glycine, 3.4mM 
SDS) at constant amperage of 30mA/gel. PageRuler Plus Prestained Protein Ladder (Thermo 
Scientific) were used as molecular weight marker. The gels were stained with Coomassie 
brilliant blue. 
3.3.8.2. Two-dimensional SDS-polyacrylamide gel electrophoresis 
100µg of each culture filtrate protein sample was dissolved in the necessary quantity of 
rehydration buffer (2D buffer + 65mM DTT, 0.5% IPG buffer, 0.002% (w/v) bromophenol blue) 
up to reach 125µl final volume, and loaded onto 7 cm IPG strips (pH 4–7; Amersham 
Biosciences). Loaded IPG strips were rehydrated overnight at room temperature. Isoelectric 
focusing (IEF) was performed on Protean IEF cell (Bio-rad) and focused for 10min at 50V, 
30min at 300V, 1h at 300V, 90min at 4,000V, and finally for 1h at 4,000 V. Following IEF, 
individual strips were equilibrated for 15min in 375mM Tris-HCl, 6M urea, 20% (v/v) glycerol, 2% 
(w/v) sodium dodecyl sulfate (SDS), 2% (w/v) DTT, and in a solution of the same composition 
that also contained 2.5% (w/v) iodoacetamide. The strips were placed onto a 12% (w/v) SDS 
polyacrylamide gel and sealed with 0.5% (w/v) agarose. SDS-PAGE electrophoretic separation 
was carried out for 90min at 100V until the bromophenol blue dye reached the bottom of the gel. 
200µg of each cellular protein sample was dissolved in the necessary quantity of rehydration 
buffer (2D buffer + 65mM DTT, 0.5% IPG buffer, 0.002% (w/v) bromophenol blue) up to reach 
450µl final volume, and loaded onto 24 cm IPG strips (pH 3–7; Amersham Biosciences). 
Loaded IPG strips were rehydrated overnight at room temperature. Isoelectric focusing (IEF) 
was performed on Protean IEF cell (Bio-rad) and focused for 10min at 50V, 2h at 500V, 1h at 
1,000V, and finally for 11h at 10,000V. Following IEF, individual strips were equilibrated for 15 
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min in 375mM Tris-HCl, 6M urea, 20% (v/v) glycerol, 2% (w/v) sodium dodecyl sulfate (SDS), 
2% (w/v) DTT, and in a solution of the same composition that also contained 2.5% (w/v) 
iodoacetamide. The strips were placed onto a 12% (w/v) SDS polyacrylamide gel and sealed 
with 0.5% (w/v) agarose. SDS-PAGE electrophoretic separation was carried out for 20h at 
2W/gel. 
After electrophoresis, gels were stained with colloidal Coomassie Blue G-250 (Fisher Scientific). 
3.3.9. Analysis and identification of proteins 
Spot scanning was performed using GS-800 Densitometer (Bio-rad) and Quantity One software 
(Bio-rad). Stained gels were analyzed by using progenesis SameSpots software (Nonlinear 
Dynamics). Statistically significant changes in protein spots were determined using ANOVA test 
(p<0.05) followed by a posteriori test, and finally the False Discovery Rate (FDR) procedure 
(q<0.05). 
Protein spots of interest were excised from SDS-PAGE gels using EXQuest Spot Cutter (Bio-
rad) and washed with water, ammonium bicarbonate (25mM NH4HCO3) and acetonitrile. Next, 
samples were reduced by incubation with dithiotreitol (10mM) at 60ºC for 45min and alkylated 
by incubation with iodoacetamide (50mM) at room temperature for 30min. Finally proteins were 
trypsin digested overnight at 37ºC with a ratio enzyme:protein of 1:10 (Trypsin Gold, Promega). 
Digestion was stopped by addition of 0.1% TFA and tryptic peptides were extracted sequentially 
with increasing concentrations of acetonitrile in water. Peptides were concentrated and desalted 
by passing it through ZipTip C18 columns (Millipore) following the manufacturer’s instructions 
and eluting with 50%ACN/0.1%TFA. 
Sample (0.5µl) and matrix (0.7µl saturated solution of alpha-Cyano-4-hydroxycinnamic acid 
(CHCA) in 50% ACN/0.1% TFA) were spotted in duplicate onto an Opti-Tof 384 well insert plate 
(Applied Biosystems). MALDI-TOF MS was performed using a 4800plus MALDI-TOFTOF 
(ABSciex) in the reflector mode with accelerating voltage of 20 kV, mass range of 800 to 4000 
Da, 1000 shots/spectrum and laser intensity of 3000. MSMS spectra was performed 
automatically on twenty of most intense precursors, with 1000 shots/spectrum and laser 
intensity of 4000. Spectra were calibrated externally using a standard protein mixture (4700 
Calmix, Applied Biosystems). 
Proteins were identified with the search engine Mascot using the SwissProt database (546,439 
sequence entries) and UnitProt database (57412064 sequences entries). Search parameters 
used were: missed cleavage 1, fixed modifications carbamidomethyl (cysteines) and peptide 
and fragment mass tolerance 0.2Da and 0.3Da, respectively. Individual ions scores >39 were 
considered a positive hit. To identify the correct protein from a Mascot results list, score and 
specie had to be considered.  
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4. Results and Discussion 
4.1. Generation of M. tuberculosis strains for the study of the efflux 
pumps MmpL4 and MmpS4 
4.1.1. Construction of M. tuberculosis knockout mutants 
The construction of the Mtb H37Rv knockout mutants deleted in rv0450c (H37Rv L4KO) and in 
both rv0450c and rv0451c (H37Rv L4S4KO) was carried out following the recombineering 
method [115]. 
Electrocompetent cells of Mtb H37Rv strain containing plasmid pJV53 were transformed 
independently with either 100ng of mmpL4 AES or mmpL4-mmpS4 AES. The resulting cells 
were plated in 7H10 ADC Hyg, and incubated at 37°C until colonies were of sufficient size for 
subculturing in 7H9T ADC Hyg liquid medium. After 10 to 15 days, genomic DNA was extracted 
and checked by PCR according to the reactions shown in Table 19. 
Table 19. PCRs for confirming M. tuberculosis knockout mutants deleted in mmpL4 and in mmpL4-
mmpS4. 
mmpL4 Size of expected PCR product (bp) 
PCR H37Rv wt L4KO 
mmpL4KO-Fw vs Hyg-out - 1047 
mmpL4KO-1f vs mmpL4KO-1r 796 - 
mmpL4-mmpS4 Size of expected PCR product (bp) 
PCR H37Rv wt L4S4KO 
mmpL4S4KO-Fw vs Hyg-cRv - 1145 
mmpL4S4KO-Rv vs Hyg-cFw - 1184 
Regarding mmpL4-mmpS4 AES construction, we first used an AES having 500bp of sequence 
identity at each side of the hygromycin resistant cassette; however, DNA samples from most of 
the colonies isolates by the procedure above did not resulted in amplification products of the 
expected size according to Table 19, which were assumed to have originated by illegitimate 
recombination events. Then, it was necessary to construct a new AES with 1,000bp of 
sequence identity at each side of the hygromycin resistant cassette; in this case 40% of 
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candidate colonies were finally confirmed as H37Rv L4S4KO and 15% were H37Rv L4KO since 
they produced amplification products consistent with the size expected (Table 19). 
4.1.2. Confirmation of M. tuberculosis knockout mutants by Southern Blot 
Southern Blot was the definitive test to validate the knockout mutants. Genomic DNA of H37Rv 
wt and both knockout mutants (Figure 16 and Figure 17) were digested with BamHI, a 
restriction enzyme that has little number of recognition sites in the genome, generating 
fragments of different sizes. Two specific probes were amplified and hybridized in different 
analysis, revealing the fragments that contained either wild-type or disrupted gene by the Hyg 
cassette. 
 
Figure 16. Southern blot analysis of 4 representative H37Rv L4KO strains. (A) DNAs were digested with 
BamHI and hybridized with a probe of 1046bp containing part of mmpS4 and mmpL4 coding sequences 
(wavy line in panel B). The 2505-bp band for H37Rv wt was replaced by 6880-bp band for L4KO knockout 
mutants. (B) Schematic representation rv0449c-mmpS4-mmpL4 operon in the reference strain and in 
L4KO (not to scale). 
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Figure 17. Southern blot analysis of 3 representative H37Rv L4S4KO strains. (A) DNAs were digested with 
BamHI and hybridized with a probe of 1175bp containing part of rv0449c and mmpL4 coding sequences. 
The 3810-bp band for H37Rv wt was replaced by 5237-bp band for L4S4KO knockout mutants. (B) 
Schematic representation rv0449c-mmpS4-mmpL4 operon in the reference strain and in L4S4KO. 
4.1.3. Generation of complemented strains of the M. tuberculosis knockout 
mutants 
With the aim of constructing these strains, the integrative plasmid pRBV2 was obtained. This 
vector has a fragment containing the operon rv0451c-rv0450c with its natural promoter detected 
by RNAseq, in order to keep the physiological expression of these genes. 
After transformation of pRBV2 in H37Rv L4KO and L4S4KO, and selection of colonies, the 
presence of the plasmid was verified by PCR (Table 20). 
Table 20. PCRs to verify complemented knockout mutant strains. 
Strain Description 
PCR verification 
Primers 
Expected size of 
PCR product (bp) 
H37Rv L4c 
H37Rv L4KO 
complemented 
with pRBV2 
mmpL4-2f vs pMV361B 614 
H37Rv L4S4c 
H37Rv L4S4KO 
complemented 
with pRBV2 
mmpL4-2f vs pMV361B 614 
A B 
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4.1.4. Generation of the overexpression strain in M. tuberculosis 
First, the replicative plasmid pRBZ13 was obtained, and then was transformed in H37Rv wt. 
After selection of colonies, the presence of the plasmid was verified by PCR (Table 21). 
Regarding pRBZ13, it has the same fragment as pRBV2 containing the operon rv0451c-
rv0450c with its natural promoter. In this case, the increase in the expression of mmpL4 and 
mmpS4 is due to the presence of multiples copies of pRBZ13. 
Table 21. PCRs to verify the overexpression strain in M. tuberculosis. 
Strain Description 
PCR verification 
Primers 
Expected size of 
PCR product (bp) 
H37Rv pRBZ13 
Overexpression 
strain for mmpL4 
and mmpS4 
RP-180 vs mmpL4-2f 657 
4.2. In vitro phenotypic characterization of M. tuberculosis strains 
4.2.1. The generated strains were positive for neutral red 
Considering that the generated Mtb strains were going to be tested in infection assays, it was 
necessary to confirm that they had not lost their virulence during genetic manipulations such as 
electroporation. To this aim, neutral-red staining was performed on all the strains because 
neutral red fixation is considered a marker of virulence. Besides, neutral-red staining is a fast 
screening technique for testing integrity of the mycobacterial cell envelope, since it has been 
proved that a negative neutral-red reaction given by a mycobacterial strain is owing to the lack 
of more than one type of methyl-branched lipids [121]. Nevertheless, further lipid analyses were 
needed to assure the integrity of the cell envelope. 
Two strains were used as controls: H37Rv, a virulent strain, as positive control; and MTVBAC, 
an attenuated strain, as negative control. MTBVAC, which has double unmarked phoP and 
fadD26 deletions, is not able to fix neutral red because the fadD26 gene is required for PDIM 
biosynthesis [122]. All strains showed a positive neutral-red reaction (Figure 18), so they were 
selected for following experiments. 
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Figure 18. Neutral-red staining of the generated strains in Falcon tubes. 
4.2.2. There were not differences in cell morphology between knockout mutant 
strains and wild-type 
After auramine staining, no significant differences were observed in terms of size and shape of 
bacterial cells (Figure 19) between H37Rv wt and the single mutant H37Rv L4KO or the double 
mutant H37Rv L4S4KO. Also, the overexpression strain H37Rv L4sb was checked, but there 
were not differences in cell morphology in comparison to the wild-type strain. 
 
Figure 19. Auramine staining of H37Rv wt, L4KO, L4S4KO, and L4sb bacilli. 
4.2.3. Colonies of the overexpression strain L4sb were smaller and smoother 
than H37Rv wt colonies 
H37Rv L4KO and L4S4KO as well as L4sb were plated on 7H10 ADC (Figure 20) in order to 
check any phenotypic change in colony morphology in comparison with the parental strain 
H37Rv wt.  
 
Figure 20. H37Rv, L4KO and L4S4KO colonies on 7H10 ADC. 
H37Rv wt L4KO L4S4KO L4sb 
H37Rv wt MTBVAC L4KO L4c L4sb L4S4KO L4S4c 
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The colonies of both knockout mutants L4KO and L4S4KO exhibited neither difference in size 
nor in appearance in relation to the wild-type strain H37Rv. Nevertheless, H37Rv L4sb showed 
(Figure 20) smooth colony morphology with less ruffled edges and slightly smaller size than 
H37Rv wt colonies. When the overexpression strain was subcultivated and plated again, two 
different colony morphologies appeared (Figure 21): small smooth colonies with less ruffled 
edges equal to the colonies obtained before, and rough colonies with ruffled edges similar to 
H37Rv wt colonies. Each kind of colony was plated separately and both the smooth and the 
rough colonies resulted again in a mixture of both morphologies; from the smooth colony the 
proportion of smooth colonies to roughs was 3/7, and from the rough colony was 5/95. 
	  
Figure 21. Morphological changes of H37Rv L4sb colonies on 7H10 ADC. 
It is likely that these morphological changes undergone by H37Rv L4sb strain could be due to 
point mutations in genes responsible for architecture and/or composition of the mycobacterial 
cell wall. 
Moreover, H37Rv L4KO, L4S4KO and L4sb were plated on 7H10 ADC with 0.05% Tween-80 
(Figure 22) taking H37Rv wt as a reference. It has been demonstrated that Tween-80 is able to 
alter colony morphology besides preventing mycobacterial clumpling in liquid medium [123-
125]. So, the addition of Tween-80 can exhibit a morphological change in the mycobacterial 
L4sb L4sb mixture
smooth L4sb 
colony
rough L4sb 
colony
Colonies from 
smooth L4sb
Colonies from 
rough L4sb
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colony which might pass unnoticed in regular 7H10 ADC plates lacking Tween-80. In these 
conditions (Figure 22), H37Rv L4sb colonies were even smaller than the colonies obtained in 
7H10 ADC (Figure 21), suggesting a marked toxic effect caused by Tween-80. However, no 
other morphological change could be appreciated in either the overexpression strain or single 
and double mutant colonies. 
 
Figure 22. H37Rv L4KO, L4S4KO and L4sb plated on 7H10 ADC with 0.05% Tween-80. 
4.2.4. H37Rv wt and the knockout mutants presented similar growth in iron-
replete and iron-restricted liquid media 
According to Wells et al [99], MmpL4/MmpS4 and MmpL5/MmpS5 efflux systems are involved 
in siderophore export. Specifically, it seems that MmpL4/MmpS4 and MmpL5/MmpS5 take part 
in the biosynthesis and transport of mycobactins and carboximycobactins. These small 
molecules capture iron from the medium or the human host, since iron is an essential 
micronutrient for most forms of life on earth due to its vital role as a redox cofactor of proteins 
required for critical cellular processes. 
In the same study, the growth of the single and double knockout mutants in mmpS4 and 
mmpS5 were checked in iron-replete and iron-deplete media, and it was observed that both 
proteins are required for normal growth of Mtb under low iron conditions [99]. Therefore, we 
H37Rv wt L4KO
L4S4KO L4sb
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decided to examine the growth of H37Rv L4KO and L4S4KO in the same conditions. 7H9T 
ADC was used as an iron-replete medium; 7H9T ADC 0.1mM 2,2’-dipyridyl (DIP; a ferrous 
chelator) and 7H9T ADC 0.2mM desferrioxamine (DFO; a ferric chelator) were used as the iron-
deplete media. 
H37Rv wt, L4KO and L4S4KO cultures were started out with an inoculum of 105 CFU/ml and 
optical densities were measured at regular intervals for 14 days. Triplicate cultures of each 
strain were grown and standard deviations are shown in Figure 23. 
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Figure 23. Growth of H37Rv wt, L4KO and L4S4KO in 7H9 media containing different quantities of iron. 
(A) 7H9T ADC (iron-replete medium), (B) 7H9T ADC DIP (iron-depleted medium), and (C) 7H9T ADC 
DFO. 
There were no significant differences between the growth of the wild-type strain and the single 
and double knockout mutants neither in iron-replete nor in iron-deplete medium. However, it 
should be noted that the growth of H37Rv L4KO and L4S4KO was slightly slower than H37Rv 
wt in both 7H9T ADC and 7H9T ADC DFO in a repetitive and systematic way. 
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The fact that both H37Rv L4KO and L4S4KO did not exhibit a low-iron growth defect phenotype 
could be explained because of the presence of MmpL5 and MmpS5. This efflux system might 
be counteracting the lack of function of MmpL4 and MmpS4 due to their suggested redundant 
role in siderophore transport. 
4.2.5. MmpL4/MmpS4 efflux system does not play a critical role in drug 
resistance 
Drug susceptibility assays were performed with single and double knockout mutants (L4KO, 
L4S4KO), the overexpression strain (L4sb), along with the parental strain H37Rv. The 
compounds tested (Table 22) included the most widely used antituberculosis drugs, as well as 
other drugs known to be efflux substrates for RND proteins from other organisms. Also, the 
common efflux pump substrate ethidium bromide and the efflux inhibitors chlorpromazine and 
verapamil were tested (Table 23). Finally, those compounds increasing or decreasing 
expression of mmpL4 RNA in the microarray analysis prepared by Boshoff et al [126] were also 
tested (Table 24). 
Table 22. MIC values of various antituberculosis medicines and other antibiotics for H37Rv wt, L4KO, 
L4S4KO, and L4sb obtained by REMA. 
Compound 
MIC (µg/ml) 
H37Rv L4KO L4S4KO L4sb 
INH 0.5 0.5 0.5 0.5 
RIF 0.05 0.05 0.05 0.05 
EMB 4-8 4 4 4 
SM 0.25 0.25 0.25 0.25 
PAS 0.03 0.03 0.03 0.03 
VAN 64 64-128 128 64-128 
GM 4 4 4 4 
SP 2-4 2 4 2-4 
AC 2 2 2 2 
AK 0.5 0.5 0.5 0.5 
TC 1-2 1-2 2 1-2 
Inh, isoniazid; Rif, rifampicin; Emb, ethambutol; Sm, streptomycin; PAS, para-aminosalicylic acid; Van, 
vancomycin; Gm, gentamicin; Sp, spectinomycin; Ac, acriflavine; Ak, amikacine; Tc, tetraciclyne. 
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Table 23. MIC values of ethidium bromide, chlorpromazine and verapamil for H37Rv wt, L4KO, L4S4KO, 
and L4sb obtained by REMA. 
Compound 
MIC (µg/ml) 
H37Rv L4KO L4S4KO L4sb 
EtBr 2 2 1 2 
CPZ 16 16 16 8 
VP 256 128 256 128 
EtBr, ethidium bromide; Cpz, chlorpromazine; Vp, verapamil. 
Table 24. MIC values of the selected redox compounds for H37Rv wt, L4KO, L4S4KO, and L4sb obtained 
by BacTiter-Glo Microbial Cell Viability Assay. 
Compound 
CIM (µg/ml) 
H37Rv L4KO L4S4KO L4sb 
CLO 0.03 0.016 0.016 0.016 
TRC 16 16 16 16 
TRZ 4 4 4 4 
PA824 50 100 100 50 
CAP 1 1 1 1 
DCCD 50 50 50 50 
H2O2 544 544 544 544 
Clo, clofazimine; Trc, triclosan; Trz, tioridazine; PA824, pretomanid; Cap, capreomycin; DCCD, 
diciclohexilcarbodiimida. 
None of the strains of our study displayed significant alterations in susceptibility to the 
compounds tested despite multiple independent experiments. These results suggest that the 
MmpL4 and MmpS4 proteins do not play a major role in intrinsic Mtb drug resistance, although 
compensatory effects caused by other different MmpL proteins or any other efflux pump cannot 
be ruled out. 
4.2.6. There were differences in the ethidium bromide accumulation among the 
strains studied 
The ethidium bromide (EtBr) accumulation assay was selected so as to evaluate efflux activity 
in H37Rv wt and the rest of the strains generated in this study: H37Rv L4KO, L4S4KO, L4c, 
L4S4c and L4sb. EtBr is a very common efflux pump substrate which emits weak fluorescence 
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in aqueous solution (external to the cell) and becomes strongly fluorescent when enters the 
bacterial cells due to its binding to nucleic acids [127]. 
First, each of the strains was tested (Figure 24) at different EtBr concentrations. The L4KO and 
L4S4KO mutants showed an increased accumulation of EtBr relative to wild-type H37Rv strain, 
whereas the overexpression L4sb strain presented noticeable decreased accumulation of EtBr. 
Nonetheless, complemented strains of both mutants, L4c and L4S4c, exhibited an increased 
accumulation of EtBr in relation to H37Rv wt in the manner of their respective knockout 
mutants. All strains tested maintained the detected changes in the accumulation of EtBr at all 
concentrations tested. 
The strong reduction in the accumulation of EtBr exhibited by L4sb suggests that 
MmpL4/MmpS4 efflux system transports EtBr efficiently. Keeping this in mind, a greater 
increase in the EtBr accumulation of both knockout mutants would be expected [75]. Since 
accumulation of EtBr in the knockout mutants is lower than expected, this can be explained by 
the fact that other Mtb efflux pumps are able to transport EtBr, hence compensating the lack of 
MmpL4/MmpS4; in addition, their contribution to the global EtBr transport might be bigger than 
that of the MmpL4/MmpS4 proteins. Moreover, the lack of MmpL4 and MmpL4/MmpS4 
membrane proteins in L4KO and L4S4KO respectively, might cause other alterations in the 
mycobacterial membrane permeability, which may explain the rise in EtBr accumulation. 
It should be pointed out that there were significant differences in the transport of EtBr among 
knockouts and the wild-type strain during EtBr accumulation assays (normally lasting for 
60min), which were not appreciated in susceptibility assays (which usually last for 8 days). This 
suggests that regular MIC determination could not be the most suitable assay for investigating 
the substrate profile of efflux pumps, so that more sensitive assays are necessary to evaluate 
the possible transport of the tested compounds by the knockout mutants. 
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Figure 24. Accumulation of ethidium bromide at 8 µg/ml, 4 µg/ml, 2 µg/ml, and 1 µg/ml by H37Rv wt, L4sb, 
L4KO, L4c, L4S4KO, and L4S4c. Data were expressed as arbitrary units of fluorescence and obtained 
from two independent wells in one representative experiment. 
Second, we decided to use 1µg/ml EtBr concentration to check the effect of efflux inhibitors 
(Figure 25), CPZ and VP, in the accumulation of EtBr in each of the strains. Ethidium bromide 
and efflux inhibitors were used at half of the MIC so as not to compromise cellular viability. 
	   81	  
According to the results obtained, VP is the best inhibitor because it caused greater 
accumulation of EtBr in all the strains tested; this agrees with previous publications in which VP 
changes notably EtBr accumulation levels on mycobacterial strains [75, 128]. On the contrary, 
CPZ seems to exert no significant influence in EtBr accumulation, at least for the first 60min 
after the addition to the mycobacteria. 
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Figure 25. Effect of efflux inhibitors CPZ and VP on the accumulation of EtBr at 1 µg/ml for H37Rv wt, 
L4sb, L4KO, L4c, L4S4KO, and L4S4c. Data were expressed as arbitrary units of fluorescence and 
obtained from two independent wells in one representative experiment. 
H37Rv L4c and L4S4c showed an increased accumulation of EtBr for each condition compared 
to H37Rv wt. That is to say, the complemented strains exhibited similar EtBr levels to their 
respective knockout mutants again, suggesting that the process of complementation could have 
failed. It is difficult to figure out where the failure might be: mRNA expression, regulation or 
protein translation. In an alternative explanation, Mtb could be forced to get a compensatory 
mutation to counteract the lack of MmpL4-MmpS4 because of their important role, which would 
allow complementation strains to maintain a level of EtBr accumulation similar to wild-type 
strain; if this were the case, complementation would have little effect, if any. This hypothesis of 
selection of compensatory mutations could explain the morphological change in L4sb colonies 
described previously; the overexpression of these important proteins without any regulation may 
oblige Mtb to acquire mutations quickly to compensate it, resulting in a change in colony 
morphology. 
4.2.7. The overexpression of mmpL4 and mmpS4 caused pronounced decrease 
in intracellular replication of L4sb in MH-S cells 
To investigate the role of MmpL4 and MmpS4 in virulence of Mtb, MH-S cells were infected 
independently with L4KO, L4c, L4S4KO, and L4S4c strains, taking the virulent strain H37Rv 
and the attenuated strain BCG as controls. Mycobacterial replication (Figure 26) was analysed 
at 0, 3, 5 and 7 days post-infection. According to the results, both knockout mutants and their 
complemented strains were able to replicate between 0.5 and 1 logarithm less than H37Rv wt. 
This decrease could be an effect caused by the slight drop showed in the growth of the strains 
in liquid medium or because of the own function of MmpL4 and MmpS4. In any case, the 
decrease in intracellular replication of L4KO and L4S4KO was not significant in comparison with 
the reference strain. 
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Figure 26. Replication of H37Rv wt, BCG, L4KO, L4c, L4S4KO, and L4S4c in MHS-infected cells. Data 
were expressed as Log10 ± SD of CFU counts per millilitre and obtained from two independent wells in 
three independent experiments. 
Interestingly, L4sb showed a significant drop of more than 1 logarithm compared to H37Rv wt 
(Figure 27). We think this fall in L4sb intracellular replication could be produced by a reduction 
in the bacterial growth rate which was shown in liquid and solid media repeatedly. However, 
what caused this modification in L4sb growth rate? Our hypothesis is that the overexpression of 
mmpL4 and mmpS4 changed L4sb fitness. Bacterial fitness can be affected by the amount of 
protein processing, which includes synthesis, maturation, maintenance, and disposal. Specially, 
membrane proteins damage fitness when overexpressed by membrane piercing, engaging 
membrane-specific folding pathways, or interfering with other membrane proteins [129]. But it is 
also true that depending on the role of the membrane protein, growth rate and other 
characteristics like virulence or drug resistance are affected [70, 75, 130, 131]. Nevertheless, 
the recently discovered role of MmpL4/MmpS4 in siderophore export does not seem to have 
effect on bacterial growth when they are overexpressed unlike Mtb siderophore export mutant 
(double mmpS4/mmpS5 knockout mutant). This mutant exhibited a growth defect due to 
impaired iron acquisition and self-poisoning by continuously synthesizing siderophores in order 
to overcome iron starvation [105]. 
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Figure 27. Replication of H37Rv wt and L4sb in MHS-infected cells. Data were expressed as Log10 ± SD of 
CFU counts per millilitre and obtained from two independent wells in three independent experiments. 
In parallel with replication assays, progression of MH-S infection was studied by Ziehl-Neelsen 
staining (Figure 28). No phenotypical differences were observed among the strains of study: 
H37Rv wt, L4KO, L4c, L4S4KO, L4S4c, and L4sb. 
 
Figure 28. Ziehl-Neelsen staining of infected MH-S at MOI 1:1. Macrophages appear as violet and bacteria 
appear as fuchsia. 
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4.2.8. The L4S4KO double knockout mutant and the L4sb overexpression strain 
were less cytotoxic than the wild-type strain 
Apoptotic induction assays were performed in MH-S cells so as to find out mycobacterial 
cytotoxicity. The strains tested were L4KO, L4S4KO and L4sb. H37Rv wt was the positive 
control of cytotoxicity and BCG the negative one. Also, non-infected MHS was the negative 
control of the assay to confirm the basal cell death. Two different MOI were chosen (5:1 and 
10:1) in order to be able to see significant differences between controls and the tested strains. 
After 3 days, cell death was determined by flow cytometry. 
With MOI of 5:1 and 10:1, L4S4KO showed a significant drop in cytotoxicity compared to H37Rv 
wt (Figure 29, green bars); in the case of the L4KO mutant, although exhibited a low decrease 
compared to the reference H37Rv, this was not significant. It appears that it is necessary the 
loss of both efflux pump components, i.e. MmpL4 and MmpS4 to exhibit an attenuated 
phenotype. 
 
Figure 29. Cell death caused by H37Rv wt, BCG, L4KO and L4S4KO at MOI of 5:1 and 10:1 in MH-S 
cells. Data were expressed as percentage ± SD of cell death and obtained from three independent 
experiments. 
Nonetheless, there is a possibility that the decrease in cytotoxicity observed in Figure 29 could 
be due to reduced efficiency of infection of the mutant strain, instead of a real this decrease in 
cytotoxicity due to the absence of both MmpL4 and MmpS4 proteins. To prove this hypothesis, 
mycobacteria infecting MH-S cells were recovered 4 hours post-infection and plated (Figure 30). 
The number of bacilli of H37Rv wt, L4KO and L4S4KO infecting MH-S cells was similar, so all of 
them had the same ability to infect cells. Then, we confirmed that deletion of mmpL4/mmpS4 
genes results in a lower capability of the bacillus for inducing cell death. 
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Figure 30. Number of mycobacteria infecting MH-S cells in intracellular replication assays 4 hours post-
infection. Data were expressed as Log10 ± SD of CFU counts per millilitre and obtained from two 
independent wells in three independent experiments. 
Regarding the overexpression strain, L4sb manifested significant reduction in cytotoxicity 
(Figure 31) in comparison to H37Rv wt at MOI 5:1 and 10:1. This marked fall in cytotoxicity 
could be related to the decrease in intracellular replication that this strain showed in MH-S cells 
(Figure 27, above); if a strain had intracellular growth impairment, fewer bacteria there would be 
inside the infected cell, and consequently, less cytotoxicity would produce. It should be pointed 
out that L4sb caused equal level of cell death at both MOI. This suggests that the decrease in 
cytotoxicity might be due to the role of MmpL4/MmpS4 rather than the amount of L4sb bacilli. 
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Figure 31. Cell death caused by H37Rv wt and L4sb at MOI of 5:1 and 10:1 in MH-S cells. Data were 
expressed as percentage ± SD of cell death and obtained from three independent experiments. 
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4.3. Molecular study of M. tuberculosis strains 
4.3.1. The loss of mmpL4 increased the expression of mmpL5 and mmpS5 at 
logarithmic phase 
Firstly, the mmpL4 expression was checked by RT-PCR in the strains of study: H37Rv wt, 
single mutant L4KO, its complemented strain L4c, and the overexpression strain L4sb. As might 
be expected, in both logarithmic and stationary phases (Figure 32), there were no amplification 
signal of mmpL4 in L4KO, and mmpL4 expression was detected in L4c at levels similar to those 
in the reference strain H37Rv. In addition, L4sb showed a 10–fold increase in mmpL4 
expression in stationary phase and almost a 30-fold increase in logarithmic phase of growth, in 
comparison with H37Rv. These results verified that all strains used for this work showed an 
expression level of mmpL4 consistent with their genetic features. 
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Figure 32. Relative quantification (RQ) of mmpL4 in H37Rv wt, L4KO, L4c and L4sb strains with respect to 
H37Rv wt at logarithmic (log) and stationary (st) phases by qRT-PCR. The RNA levels were normalized to 
the levels of sigA mRNA. Result is a representative experiment of three independent experiments. 
Then, we decided to test whether the lack of mmpL4 had an influence on the expression of 
other mmpL and mmpS genes. In logarithmic phase (Figure 33, left panel), mmpL5 and mmpS5 
expression increased about two times, whereas expression levels of the other mmpL and 
mmpS genes scarcely changed in L4KO strain. As MmpL5/MmpS5 and MmpL4/MmpS4 efflux 
systems appear to have a redundant role in siderophore export [99], it is likely that the rise in 
	   88	  
transcriptional expression of the mmpL5 and mmpS5 might try to compensate for the absence 
of the other export system.  
Although widespread changes were observed in mmpL and mmpS genes in L4KO at stationary 
phase, they were slight rises which were not significant. Only mmpL6, mmpL9, mmpL10, and 
mmpL13a expression levels increased up to two times in comparison to H37Rv wild-type. 
Unfortunately, out of these four proteins, just the role of MmpL10 is known, hence hampering to 
figure out a putative functional network connecting all these five transporters. Nevertheless, the 
fact that MmpL10 is involved in translocation of DAT and biosynthesis of PAT may support a 
similar role of MmpL4 in lipid transport. In fact, it has been demonstrated that MmpL3 transports 
TMM and take parts in iron metabolism as heme importer. Hence, the hypothesis of 
MmpL4/MmpS4 involving two different roles in Mtb is plausible. Moreover, this is supported by 
morphological changes exhibited in L4sb colonies which can be caused by differences in 
membrane lipid composition. 
Concerning the complemented strain of L4KO (namely, L4c), it appears to restore mmpL5 and 
mmpS5 expression levels similar to those of H37Rv wt at logarithmic phase (Figure 33, left 
panel). However, L4c showed an expression pattern of all other mmpL and mmpS genes 
comparable to that of L4KO at stationary phase (Figure 33, right panel). It should be noted that 
mmpS4 RNA level in L4c was twice as much as L4KO at logarithmic and stationary phase 
because the complemented strain had two copies of mmpS4. 
 
Figure 33. Relative quantification (RQ) of 13 mmpL genes and 5 mmpS genes in H37Rv wt, L4KO and L4c 
strains with respect to H37Rv wt at logarithmic and stationary phases by qRT-PCR. The RNA levels of 
mmpL and mmpS genes were normalized to the levels of sigA mRNA. Results were the means of three 
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independent experiments. Green and red colours indicate increased or decreased expression, 
respectively, in comparison with wt strain. 
4.3.2. Main lipids of M. tuberculosis were not affected by the loss of mmpL4 and 
mmpS4 
There are 13 mmpL genes in the genome of Mtb. Currently, the role of 7 of the 13 MmpL 
transporters is known. As 5 of these 7 MmpL proteins (MmpL3, MmpL7, MmpL8, MmpL10, and 
MmpL11) are dedicated to biosynthesis and transport of mycobacterial cell wall lipids, we 
decided to check if MmpL4/MmpS4 efflux system was involved in lipid transport too. Besides, 2 
of these 5 MmpL transporters (MmpL3 and MmpL11) also take part in iron uptake mechanism. 
Four fractions of lipids were extracted from each strain (H37Rv wt, L4KO, L4c, L4S4KO, L4S4c, 
and L4sb): free lipids from the envelope, non-polar lipids, polar lipids, and fatty acid methyl 
esters (FAMEs) and mycolic acid methyl esters (MAMEs). 
Each fraction was a mixture of lipids, which were resolved using thin layer chromatography 
(TLC) and different combinations of solvent systems. Then, TLCs were stained and the patterns 
of spots obtained from free, non-polar and polar lipid extracts were compared with those got by 
Bhatt et al [132] in order to identify the main lipids of Mtb. Moreover, TLC containing FAMEs 
and MAMEs was compared to that obtained by Belardinelli et al [133]. However, no significant 
changes were seen in the patterns of lipids from any fraction (Annex I). Possibly, the use of 
other techniques such as mass spectrometry, which can quantify lipid content more accurately 
than TLC, could reveal subtle differences between fractions from different strains that could not 
be detected by using TLC. 
4.3.3. The loss of mmpL4 and mmpS4 activated lipid metabolism 
Finally, we decided to analyse the proteome of H37Rv wt, L4KO, L4c, L4S4KO, L4S4c and 
L4sb as an alternative approach to investigate whether MmpL4/MmpS4 efflux system was really 
involved in lipid metabolism. 
For this purpose, cellular proteins of each strain of study expressed at stationary phase were 
separated by 2D-PAGE (two-dimensional polyacrylamide gel electrophoresis). Once the gels 
were scanned, SameSpots software was utilized for a differential gel analysis. To start with the 
study, three groups of strains were created: H37Rv vs L4KO vs L4c, H37Rv vs L4S4KO vs 
L4S4c, and H37Rv vs L4sb. For the first two groups, spot intensity differences were statistically 
analysed by one-way ANOVA with the post hoc Tukey's test to establish significant differences 
among group means. For the third group, spot intensity differences were examined by Student's 
t-test. Afterwards, the False Discovery Rate (FDR) procedure was used to detect false positives 
derived from multiple testing. Unfortunately, for all the spots with p<0.05 their q value was 
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>0.05, which means that there were no statistically significant changes in the expression of 
none of the proteins. Statistical analysis was carried out using the data obtained from 3 different 
sets of independent biological samples. 
However, despite the fact that the overall results were not statistically significant, we considered 
that there were a few proteins whose abundance changed moderately from one strain to 
another, and this could be easily identified even by the naked eye, so we speculated whether 
they might be biologically relevant. Then, we decided to be more demanding and restrictive and 
select those spots with p<0.01 to be excised and trypsin digested. Five proteins were then 
identified (Figure 34) with the search engine Mascot using SwissProt and UnitProt databases. 
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Figure 34. 2D-PAGE analysis of changes in the proteome of Mycobacterium tuberculosis strains. (A) 
Representative Coomassie-stained 2D-PAGE gel image of L4S4c strain showing spots with p<0.05 
numbered according to pI and Mw. The numbered protein spots marked with squares 849 (FadB), 893 
(OpcA), 908 (DesA), 913 (Rv0148), and 937 (SucD) were the differentially abundant proteins with p<0.01. 
(B) 2D-PAGE comparison of up-regulated spots 849 and 908. 
The identified proteins were classified according to functional category using TubercuList 
database [23]. 3 of these 5 proteins (Table 25) were related to intermediary metabolism and 
respiration, and 2 of them were involved in lipid metabolism. 
Table 25. Identified proteins with p<0.01. 
Spot Protein name 
Gene 
name 
Rv number Functional category 
849 
3-hydroxyacyl-CoA 
dehydrogenase FadB 
fadB Rv0860 Lipid metabolism 
893 Oxidoreductase OpcA opcA Rv1446c 
Intermediary 
metabolism and 
respiration 
908 
Acyl-[acyl-carrier protein] 
desaturase DesA1 
desA1 Rv0824c Lipid metabolism 
913 
Probable short-chain type 
dehydrogenase/reductase 
rv0148 Rv0148 
Intermediary 
metabolism and 
respiration 
937 
Succinyl-CoA synthetase  
SucD 
sucD Rv0952 
Intermediary 
metabolism and 
respiration 
Interestingly, the proteins involved in lipid metabolism increased their expression in both 
knockouts (and their complemented strains) more than twice (Table 26) with respect to the 
reference strain. On the other hand, those related to intermediary metabolism and respiration 
showed slight decrease in their expression in L4S4KO, L4S4c, and L4c compared with H37Rv 
wt. 
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Table 26. Fold changes of the identified proteins with p<0.01 in the strains of study. 
Spot Protein name 
Rv 
number 
L4KO L4c L4S4KO L4S4c 
+/- FC +/- FC +/- FC +/- FC 
849 
3-hydroxyacyl-CoA 
dehydrogenase FadB 
Rv0860 + 2.4 + 2.1 + 2.7 + 2.1 
893 
Oxidoreductase  
OpcA 
Rv1446c   - 1.2 - 1.1 - 1.2 
908 
Acyl-[acyl-carrier 
protein] desaturase 
DesA1 
Rv0824c + 2.2 + 1.9 + 2.7 + 2.2 
913 
Probable short-chain 
type dehydrogenase/ 
reductase 
Rv0148     - 1.4 - 1.1 
937 
Succinyl-CoA 
synthetase SucD 
Rv0952   - 1.2     
Abbreviations: FC (Fold change). 
+/-: + means this protein was overexpressed in this strain in comparison to the reference strain H37Rv. 
 - means this protein was less expressed in this strain than in H37Rv wt. 
Regarding L4sb, three proteins (Table 27) only exhibited certain change in their expression 
(p<0.05) in comparison to H37Rv wt. Again, there were proteins related to the functional 
categories lipid metabolism, and intermediary metabolism and respiration. 
Table 27. Identified proteins with p<0.05 in the overexpression strain L4sb. 
Spot Protein name 
Gene 
name 
Rv number Functional category +/- FC 
285 
Probable 3-ketoacyl-
ACP reductase 
FabG4 
fabG4 Rv0242c Lipid metabolism + 1.3 
622 Flavodoxin rv0925c Rv0925c 
Intermediary 
metabolism and 
respiration 
- 1.3 
876 
60 kDa chaperonin 
1 GroEL1 
groEL1 Rv3417c 
Virulence, detoxification, 
adaptation 
- 1.3 
Abbreviations: FC (Fold change). 
+/-: + means this protein was overexpressed in this strain in comparison to the reference strain H37Rv. 
 - means this protein was less expressed in this strain than in H37Rv wt. 
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Concerning culture filtrate proteins, it was not possible to carry out the statistical analysis since 
the number of sets was insufficient. 
To sum up, although the statistical analysis revealed that protein expression differences among 
the strains were not significant, both the fold change and the strains suffering those changes 
were consistent and sound. For example, in the instance of FadB, this protein showed 
differential expression in L4KO, L4c, L4S4KO, and L4S4c in comparison to the reference strain. 
Avoiding the complemented strains due to their apparent lack of complementation, FadB 
expression increased not only in the single knockout mutant but also in the double. Besides 
FadB, DesA1 and other spots in the Annex II support the fact that the expression of these 
proteins has changed owing to the absence of MmpL4 and MmpS4. Consequently, these 
proteins with altered expression have biological relevance. Interestingly, all the proteins in the 
functional category of lipid metabolism were related to a specific class of lipid: fatty acids. 
In conclusion, taking into account that most of the identified proteins have a connection with 
fatty acids, we suggest that MmpL4/MmpS4 efflux pump is clearly involved in lipid metabolism. 
4.4. Generation of M. bovis BCG strains for the study of the efflux 
pumps MmpL4 and MmpS4 
4.4.1. Construction of M. bovis knockout mutants 
M. bovis BCG has got genes identical to mmpL4 and mmpS4, so we decided to inactivate them 
as well, in a similar manner to those in M. tuberculosis. The reason for constructing M. bovis 
BCG knockout mutants was to carry out lipid analysis complementary to those made with the M. 
tuberculosis mutants (section 4.3.2), including radioactive analyses that are more sensitive and 
easier to do in a BSL-2 laboratory. 
Basically, the construction of M. bovis BCG knockout mutants delected in BCG_0489c (BCG 
L4KO), in BCG_0490c (BCG S4KO), in both BCG_0489c and BCG_0490c (BCG L4S4KO) was 
performed using the method of specialised transduction developed by Bardarov et al [27]. 
Briefly, phΔL4, phΔS4 and phΔL4S4 recombinant phages were designed to replace mmpL4, 
mmpS4 and mmpL4-mmpS4 in M. bovis BCG wt, respectively. These temperature sensitive 
phages included a hygromycin resistance marker interrupting each target genes. Transductants 
were selected at the non-permissive temperature of 37ºC on selective plates containing 
150µg/ml hygromycin. 
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4.4.2. Generation of the overexpression M. bovis BCG L4sb strain 
Considering that sequences of rv0450c and rv0451c are the same as BCG_0489c and 
BCG_0490c, the replicative plasmid pRBZ13 used to generate Mtb H37Rv L4sb strain was 
utilized to construct M. bovis BCG L4sb strain. After transformation of pRBZ13 in BCG wt, the 
resulting strain was verified by PCR using RP-180 and mmpL4-2f primers. 
4.5. Comparative lipid analysis of M. bovis BCG wt and M. bovis 
BCG overexpressing mmpL4 and mmpS4 
4.5.1. The overexpression of mmpL4 and mmpS4 caused a decrease in PDIM 
production in M. bovis BCG 
Three extracts were obtained from both BCG wt and BCG L4sb strains: free lipids from the 
envelope, non-polar and polar lipids. In order to identify individual lipid components within these 
extracts, radiolabeled lipids were subjected to 2D-TLC analysis using solvent systems of 
increasing polarity. Then, TLCs were developed and the patterns of spots obtained from free, 
non-polar and polar lipid extracts were compared with those got by Pirson et al [134] so as to 
identify the main lipids of M. bovis BCG. 
Analysis of the free (Figure 35A) and non-polar lipids (Figure 35B) using the least polar TLC 
system identified the presence of phthiocerol dimycocerosates (PDIMs), and triacyl glycerol 
(TAG), which were quantified. Interestingly, the amount of PDIMs showed a strong decrease in 
BCG L4sb in comparison with the reference strain in both extracts. At the same time, several 
other spots located in the lower part of the TLC increased greatly, and another spot appeared 
next to one of the PDIM spots in BCG L4sb in the free lipid extract. It should be pointed out that 
this group of overproduced lipids were located not only inside the bacterium but also in its 
envelope, suggesting that these lipids were transported across the membrane. 
Based on these results, our hypothesis is that MmpL4 and MmpS4 might be involved in the 
biosynthesis/transport of a precursor of PDIM in BCG. In other words, we believe that the 
overexpression of MmpL4/MmpS4 efflux system decreases the availability of a precursor of 
PDIM because this precursor biomolecule would be now more demanded in other pathway to 
synthesize one or several different lipids, according to the results of the TLCs. 
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Figure 35. 2D-TLC analysis of lipids from BCG wt and BCG L4sb using system A. (A) Free lipids extract. 
(B) Non-polar lipids extract. 
However, no significant changes were seen neither in the rest of the lipids from free-lipid and 
non-polar extracts nor in the patterns of lipids from the polar fraction (Annex III). 
4.6. Comparative morphological analysis of M. bovis BCG wt and 
M. bovis BCG L4sb colonies 
4.6.1. BCG L4sb showed slight modification in its colony morphology 
Considering morphological changes observed in H37Rv L4sb (section 4.2.3), a culture of BCG 
L4sb was plated in order to verify if the same changes took place in the BCG strain. The 
morphology of BCG L4sb was compared with BCG wt and MmpL3 BCG overexpression strain 
(BCG L3sb) so as to check if the differences were due to an increment of membrane proteins or 
the effect of MmpL4 and MmpS4 proteins themselves.  
Slighter changes in colony morphology appeared in BCG L4sb in comparison with H37Rv L4sb 
(Figure 36) when they were compared to their respective wild types. The minor morphological 
changes in BCG L4sb could be explained because BCG wt had already lost several membrane 
proteins and lipids during the process of attenuation for getting the tuberculosis vaccine, which 
affected its colony morphology. As a consequence, the overexpression of MmpL4 and MmpS4 
could have little effect on its morphology. No differences were observed in BCG L3sb colonies. 
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Therefore, it is likely that slight changes observed in BCG L4sb were due to the effect of the 
efflux system MmpL4/MmpS4. 
 
Figure 36. Colonies of M. bovis BCG parental (wt), BCG overexpressing mmpL4 and mmpS4 (BCG L4sb), 
and BCG overexpressing mmpL3 (BCG L3sb) strains on 7H11 plates after incubation at 37ºC for 3 weeks. 
4.6.2. BCG L4sb hardly grew on plates with Tween-80 detergent 
Interestingly, BCG L4sb had impaired growth when Tween-80 was present in the solid culture 
medium (Figure 37), whereas BCG wt and BCG L3sb grew without problems in the same 
medium. Also, H37Rv L4sb showed the same inability to growth on plates containing Tween-80, 
similarly to BCG L4sb. Thus, overexpression of MmpL4 and MmpS4 in mycobacteria results in 
increased toxicity of Tween-80. In other words, the MmpL4/MmpS4 efflux system would have 
an additional role to that in siderophore transport, making mycobacteria more susceptible to 
Tween-80 detergent. 
 
Figure 37. Colonies of M. bovis BCG parental (wt), BCG overexpressing mmpL4 and mmpS4 (BCG L4sb), 
and BCG overexpressing mmpL3 (BCG L3sb) strains on 7H11 plates with Tween-80 after incubation at 
37ºC for 3 weeks. 
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5. Future perspectives 
During this PhD thesis, the role of the MmpL4/MmpS4 efflux system in mycobacteria has been 
investigated, and some interesting insights have been obtained. Simultaneously, new questions 
have arisen, which will be addressed in the near future. 
The morphological changes in colony aspect related to MmpL4/MmpS4 overexpression in M. 
tuberculosis will be further investigated. It is likely that compensatory mutations could be 
responsible for this alteration, so first, whole genome of smooth and rough variants will be 
investigated. Once genomic DNAs have been sequenced, the obtained short DNA sequence 
reads will be aligned to the reference H37Rv wt sequence. Afterwards, single nucleotide 
polymorphisms (SNPs) in smooth and rough L4sb strains will be searched and analysed their 
potential involvement with the observed colony morphology changes in the overexpression 
strains. 
In order to confirm the involvement of MmpL4/MmpS4 in lipid metabolism, it will be necessary to 
check by qRT-PCR the expression levels of those genes encoding proteins related to fatty acids 
that have been identified by proteomics. For this purpose, new cultures of the strains of study 
will be grow in Middlebrook 7H9 supplemented with 0.2% dextrose and 0.085% NaCl (the same 
medium used for protein extraction) so as to extract their RNA at stationary phase. It is 
important to grow the strains in the same medium in which proteins have been extracted since 
differences in both media would make impossible to compare the results obtained. 
The construction of knock-out mutants BCG L4KO, BCG S4KO, and BCG L4S4KO will be 
confirmed by PCR and southern blot before analysing their lipid content. In addition, BCG L4sb 
lipid profile will be analysed by mass spectrometry to discover its likely implication in PDIM 
production. 
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6. Conclusions 
• The MmpL4 and MmpS4 efflux pumps of M. tuberculosis are not involved in intrinsic 
resistance to the drugs and compounds that have been assayed. 
• The MmpL4/MmpS4 efflux system is active in transporting ethidium bromide. 
• Deletion of MmpL4/MmpS4 efflux system does not result in a growth defect of M. 
tuberculosis in iron-depleted media, concluding that its role in siderophore transport is 
redundant with that of MmpL5/MmpS5 efflux system. 
• The loss of mmpL4 alters genes related to siderophore export (mmpL5 and mmpS5) 
and lipid biosynthesis and transport (mmpL10) suggesting MmpL4/MmpS4 efflux 
system probably plays both roles in M. tuberculosis. 
• The overexpression of the MmpL4/MmpS4 efflux system in M. tuberculosis caused a 
morphological change in its colonies, a decrease in its in vitro growth rate, and an 
alteration in its membrane permeability suggesting that these proteins have an influence 
in the mycobacterial membrane composition. 
• The MmpL4 and MmpS4 efflux pumps are necessary for the complete virulence of M. 
tuberculosis in infecting macrophages. 
• Main lipids of M. tuberculosis were not affected by the deletion of mmpL4 and mmpS4 
genes. 
• Proteomic data suggests that the lack of MmpL4 and MmpS4 proteins increased the 
fatty acid metabolism in M. tuberculosis. 
• The overexpression of MmpL4/MmpS4 efflux system appears to change the PDIM 
production in M. bovis. 
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Conclusiones 
• Las bombas de eflujo MmpL4 y MmpS4 de M. tuberculosis no están implicadas en la 
resistencia intrínseca a los fármacos y compuestos que se han ensayado. 
• El sistema de eflujo MmpL4/MmpS4 transporta bromuro de etidio. 
• La deleción del sistema de eflujo MmpL4/MmpS4 no produce ningún defecto en el 
crecimiento de M. tuberculosis en medios con escasa concentración de hierro debido a 
la función redundante que posee este sistema y el sistema de eflujo MmpL5/MmpS5 en 
el transporte de sideróforos. 
• La pérdida de mmpL4 altera la expresión de genes relacionados con el transporte de 
sideróforos (mmpL5 y mmpS5) y la biosíntesis y transporte de lípidos (mmpL10), 
sugiriendo que el sistema de eflujo MmpL4/MmpS4 probablemente desempeñe ambas 
funciones en M. tuberculosis. 
• La sobreexpresión del sistema de eflujo MmpL4/MmpS4 en M. tuberculosis causa 
cambios en la morfología de sus colonias, disminuye su velocidad de crecimiento in 
vitro y altera la permeabilidad de su membrana, lo cual indica que estas proteínas 
influyen en la composición de la membrana micobacteriana. 
• Las bombas de eflujo MmpL4 y MmpS4 son necesarias para la completa virulencia de 
M. tuberculosis cuando infecta macrófagos. 
• Los principales lípidos de M. tuberculosis no se ven afectados por la deleción de los 
genes mmpL4 y mmpS4. 
• Los datos de proteómica sugieren que la pérdida de las proteínas MmpL4 y MmpS4 
incrementa el metabolismo de ácidos grasos en M. tuberculosis. 
• La sobreexpresión del sistema de eflujo MmpL4/MmpS4 parece influir en la producción 
de PDIM en M. bovis. 
  
	   104	  
  
	   105	  
7. References 
1.	   Nerlich,	  A.G.	  and	  S.	  Losch,	  Paleopathology	  of	  human	  tuberculosis	  and	  the	  potential	  role	  
of	  climate.	  Interdiscip	  Perspect	  Infect	  Dis,	  2009.	  2009:	  p.	  437187.	  
2.	   Comas,	  I.,	  et	  al.,	  Out-­‐of-­‐Africa	  migration	  and	  Neolithic	  coexpansion	  of	  Mycobacterium	  
tuberculosis	  with	  modern	  humans.	  Nat	  Genet,	  2013.	  45(10):	  p.	  1176-­‐82.	  
3.	   Supply,	  P.,	  et	  al.,	  Genomic	  analysis	  of	  smooth	  tubercle	  bacilli	  provides	  insights	  into	  
ancestry	  and	  pathoadaptation	  of	  Mycobacterium	  tuberculosis.	  Nat	  Genet,	  2013.	  45(2):	  
p.	  172-­‐9.	  
4.	   Gagneux,	  S.,	  Host-­‐pathogen	  coevolution	  in	  human	  tuberculosis.	  Philos	  Trans	  R	  Soc	  Lond	  
B	  Biol	  Sci,	  2012.	  367(1590):	  p.	  850-­‐9.	  
5.	   WHO,	  Global	  tuberculosis	  report	  2014.	  World	  Health	  Organization.	  2014.	  
6.	   Kernodle,	  D.S.,	  Decrease	  in	  the	  effectiveness	  of	  Bacille	  Calmette-­‐Guerin	  vaccine	  against	  
pulmonary	  tuberculosis:	  a	  consequence	  of	  increased	  immune	  suppression	  by	  microbial	  
antioxidants,	  not	  overattenuation.	  Clin	  Infect	  Dis,	  2010.	  51(2):	  p.	  177-­‐84.	  
7.	   CDC.	  Diagnosis	  of	  Tuberculosis	  Disease.	  Centers	  for	  Disease	  Control	  and	  Prevention.	  	  
2011;	  Available	  from:	  
http://www.cdc.gov/tb/publications/factsheets/testing/diagnosis.htm.	  
8.	   Babady,	  N.E.	  and	  N.L.	  Wengenack,	  Clinical	  Laboratory	  Diagnostics	  for	  Mycobacterium	  
tuberculosis.	  Chapter	  1.,	  P.-­‐J.	  Cardona,	  Editor.	  2012.	  
9.	   Clayden,	  P.,	  et	  al.,	  2014	  Pipeline	  Report.	  HIV,	  Hepatitis	  C	  Virus	  (HCV),	  and	  Tuberculosis	  
(TB)	  drugs,	  diagnostics,	  vaccines,	  preventive	  technologies,	  research	  toward	  a	  cure,	  and	  
immune-­‐based	  and	  gene	  therapies	  in	  development.,	  A.	  Benzacar,	  Editor.	  2014.	  
10.	   Zumla,	  A.,	  P.	  Nahid,	  and	  S.T.	  Cole,	  Advances	  in	  the	  development	  of	  new	  tuberculosis	  
drugs	  and	  treatment	  regimens.	  Nat	  Rev	  Drug	  Discov,	  2013.	  12(5):	  p.	  388-­‐404.	  
11.	   WHO/IUATLD,	  Anti-­‐tuberculosis	  drug	  resistance	  in	  the	  world.	  Report	  nº2.	  Prevalence	  
and	  Trends.	  2000.	  253.	  
12.	   Cohen,	  K.A.,	  W.R.	  Bishai,	  and	  A.S.	  Pym,	  Molecular	  basis	  of	  drug	  resistance	  in	  
Mycobacterium	  tuberculosis.	  Microbiology	  Spectrum,	  2014.	  2(3).	  
13.	   Almeida	  Da	  Silva,	  P.E.	  and	  J.C.	  Palomino,	  Molecular	  basis	  and	  mechanisms	  of	  drug	  
resistance	  in	  Mycobacterium	  tuberculosis:	  classical	  and	  new	  drugs.	  J	  Antimicrob	  
Chemother,	  2011.	  66(7):	  p.	  1417-­‐30.	  
14.	   Gandhi,	  N.R.,	  et	  al.,	  Extensively	  drug-­‐resistant	  tuberculosis	  as	  a	  cause	  of	  death	  in	  
patients	  co-­‐infected	  with	  tuberculosis	  and	  HIV	  in	  a	  rural	  area	  of	  South	  Africa.	  Lancet,	  
2006.	  368(9547):	  p.	  1575-­‐80.	  
15.	   Dheda,	  K.,	  et	  al.,	  Global	  control	  of	  tuberculosis:	  from	  extensively	  drug-­‐resistant	  to	  
untreatable	  tuberculosis.	  Lancet	  Respir	  Med,	  2014.	  2(4):	  p.	  321-­‐38.	  
16.	   WGONTD.	  Working	  Group	  on	  New	  TB	  Drugs.	  	  2015;	  Available	  from:	  
http://www.newtbdrugs.org/.	  
17.	   Stackebrandt,	  E.,	  F.	  A.	  Riney,	  and	  N.L.	  Ward-­‐Rainey,	  Proposal	  for	  a	  New	  Hierarchic	  
classification	  System,	  Actinobacteria	  classis	  now.	  International	  Journal	  of	  Systematic	  
Bacteriology,	  1997.	  47:	  p.	  479-­‐491.	  
18.	   Trifiro,	  S.,	  et	  al.,	  Ghost	  mycobacteria	  on	  Gram	  stain.	  J	  Clin	  Microbiol,	  1990.	  28(1):	  p.	  
146-­‐7.	  
19.	   Bifani,	  P.,	  et	  al.,	  Molecular	  characterization	  of	  Mycobacterium	  tuberculosis	  H37Rv/Ra	  
variants:	  distinguishing	  the	  mycobacterial	  laboratory	  strain.	  J	  Clin	  Microbiol,	  2000.	  
38(9):	  p.	  3200-­‐4.	  
	   106	  
20.	   Cole,	  S.T.,	  et	  al.,	  Deciphering	  the	  biology	  of	  Mycobacterium	  tuberculosis	  from	  the	  
complete	  genome	  sequence.	  Nature,	  1998.	  393(6685):	  p.	  537-­‐44.	  
21.	   Camus,	  J.C.,	  et	  al.,	  Re-­‐annotation	  of	  the	  genome	  sequence	  of	  Mycobacterium	  
tuberculosis	  H37Rv.	  Microbiology,	  2002.	  148(Pt	  10):	  p.	  2967-­‐73.	  
22.	   Lew,	  J.M.,	  et	  al.,	  TubercuList-­‐-­‐10	  years	  after.	  Tuberculosis	  (Edinb),	  2010.	  91(1):	  p.	  1-­‐7.	  
23.	   Cole,	  S.T.	  Tuberculist.	  	  2013	  March	  2013;	  Available	  from:	  http://tuberculist.epfl.ch/.	  
24.	   Sayes,	  F.,	  et	  al.,	  Strong	  immunogenicity	  and	  cross-­‐reactivity	  of	  Mycobacterium	  
tuberculosis	  ESX-­‐5	  type	  VII	  secretion:	  encoded	  PE-­‐PPE	  proteins	  predicts	  vaccine	  
potential.	  Cell	  Host	  Microbe,	  2012.	  11(4):	  p.	  352-­‐63.	  
25.	   Ekiert,	  D.C.	  and	  J.S.	  Cox,	  Structure	  of	  a	  PE-­‐PPE-­‐EspG	  complex	  from	  Mycobacterium	  
tuberculosis	  reveals	  molecular	  specificity	  of	  ESX	  protein	  secretion.	  Proc	  Natl	  Acad	  Sci	  U	  
S	  A,	  2014.	  111(41):	  p.	  14758-­‐63.	  
26.	   Parish,	  T.	  and	  N.G.	  Stoker,	  Use	  of	  a	  flexible	  cassette	  method	  to	  generate	  a	  double	  
unmarked	  Mycobacterium	  tuberculosis	  tlyA	  plcABC	  mutant	  by	  gene	  replacement.	  
Microbiology,	  2000.	  146	  (	  Pt	  8):	  p.	  1969-­‐75.	  
27.	   Bardarov,	  S.,	  et	  al.,	  Specialized	  transduction:	  an	  efficient	  method	  for	  generating	  
marked	  and	  unmarked	  targeted	  gene	  disruptions	  in	  Mycobacterium	  tuberculosis,	  M.	  
bovis	  BCG	  and	  M.	  smegmatis.	  Microbiology,	  2002.	  148(Pt	  10):	  p.	  3007-­‐17.	  
28.	   van	  Kessel,	  J.C.	  and	  G.F.	  Hatfull,	  Mycobacterial	  recombineering.	  Methods	  Mol	  Biol,	  
2008.	  435:	  p.	  203-­‐15.	  
29.	   Hoffmann,	  C.,	  et	  al.,	  Disclosure	  of	  the	  mycobacterial	  outer	  membrane:	  cryo-­‐electron	  
tomography	  and	  vitreous	  sections	  reveal	  the	  lipid	  bilayer	  structure.	  Proc	  Natl	  Acad	  Sci	  
U	  S	  A,	  2008.	  105(10):	  p.	  3963-­‐7.	  
30.	   Zuber,	  B.,	  et	  al.,	  Direct	  visualization	  of	  the	  outer	  membrane	  of	  mycobacteria	  and	  
corynebacteria	  in	  their	  native	  state.	  J	  Bacteriol,	  2008.	  190(16):	  p.	  5672-­‐80.	  
31.	   Groenewald,	  W.,	  et	  al.,	  Differential	  spontaneous	  folding	  of	  mycolic	  acids	  from	  
Mycobacterium	  tuberculosis.	  Chem	  Phys	  Lipids,	  2014.	  180:	  p.	  15-­‐22.	  
32.	   Lemassu,	  A.,	  et	  al.,	  Extracellular	  and	  surface-­‐exposed	  polysaccharides	  of	  non-­‐
tuberculous	  mycobacteria.	  Microbiology,	  1996.	  142	  (	  Pt	  6):	  p.	  1513-­‐20.	  
33.	   Sani,	  M.,	  et	  al.,	  Direct	  visualization	  by	  cryo-­‐EM	  of	  the	  mycobacterial	  capsular	  layer:	  a	  
labile	  structure	  containing	  ESX-­‐1-­‐secreted	  proteins.	  PLoS	  Pathog,	  2010.	  6(3):	  p.	  
e1000794.	  
34.	   Ouellet,	  H.,	  J.B.	  Johnston,	  and	  P.R.	  de	  Montellano,	  Cholesterol	  catabolism	  as	  a	  
therapeutic	  target	  in	  Mycobacterium	  tuberculosis.	  Trends	  Microbiol,	  2011.	  19(11):	  p.	  
530-­‐9.	  
35.	   Lopez-­‐Marin,	  L.M.,	  Nonprotein	  structures	  from	  mycobacteria:	  emerging	  actors	  for	  
tuberculosis	  control.	  Clin	  Dev	  Immunol,	  2012.	  2012:	  p.	  917860.	  
36.	   Hossain,	  M.M.	  and	  M.N.	  Norazmi,	  Pattern	  recognition	  receptors	  and	  cytokines	  in	  
Mycobacterium	  tuberculosis	  infection-­‐-­‐the	  double-­‐edged	  sword?	  Biomed	  Res	  Int,	  2013.	  
2013:	  p.	  179174.	  
37.	   Killick,	  K.E.,	  et	  al.,	  Receptor-­‐mediated	  recognition	  of	  mycobacterial	  pathogens.	  Cell	  
Microbiol,	  2013.	  15(9):	  p.	  1484-­‐95.	  
38.	   Ehlers,	  S.	  and	  U.E.	  Schaible,	  The	  granuloma	  in	  tuberculosis:	  dynamics	  of	  a	  host-­‐
pathogen	  collusion.	  Front	  Immunol,	  2013.	  3:	  p.	  411.	  
39.	   Guirado,	  E.	  and	  L.S.	  Schlesinger,	  Modeling	  the	  Mycobacterium	  tuberculosis	  Granuloma	  
-­‐	  the	  Critical	  Battlefield	  in	  Host	  Immunity	  and	  Disease.	  Front	  Immunol,	  2013.	  4:	  p.	  98.	  
40.	   Russell,	  D.G.,	  et	  al.,	  Mycobacterium	  tuberculosis	  wears	  what	  it	  eats.	  Cell	  Host	  Microbe,	  
2010.	  8(1):	  p.	  68-­‐76.	  
41.	   Paulson,	  T.,	  Epidemiology:	  A	  mortal	  foe.	  Nature,	  2013.	  502(7470):	  p.	  S2-­‐3.	  
42.	   Flannagan,	  R.S.,	  G.	  Cosio,	  and	  S.	  Grinstein,	  Antimicrobial	  mechanisms	  of	  phagocytes	  
and	  bacterial	  evasion	  strategies.	  Nat	  Rev	  Microbiol,	  2009.	  7(5):	  p.	  355-­‐66.	  
	   107	  
43.	   Wang,	  J.	  and	  M.A.	  Behr,	  Building	  a	  better	  bacillus:	  the	  emergence	  of	  Mycobacterium	  
tuberculosis.	  Front	  Microbiol,	  2014.	  5:	  p.	  139.	  
44.	   Behar,	  S.M.,	  M.	  Divangahi,	  and	  H.G.	  Remold,	  Evasion	  of	  innate	  immunity	  by	  
Mycobacterium	  tuberculosis:	  is	  death	  an	  exit	  strategy?	  Nat	  Rev	  Microbiol,	  2010.	  8(9):	  
p.	  668-­‐74.	  
45.	   Sun,	  J.,	  et	  al.,	  Mycobacterial	  nucleoside	  diphosphate	  kinase	  blocks	  phagosome	  
maturation	  in	  murine	  RAW	  264.7	  macrophages.	  PLoS	  One,	  2010.	  5(1):	  p.	  e8769.	  
46.	   Russell,	  D.G.,	  Mycobacterium	  tuberculosis	  and	  the	  intimate	  discourse	  of	  a	  chronic	  
infection.	  Immunol	  Rev,	  2011.	  240(1):	  p.	  252-­‐68.	  
47.	   Vergne,	  I.,	  et	  al.,	  Mechanism	  of	  phagolysosome	  biogenesis	  block	  by	  viable	  
Mycobacterium	  tuberculosis.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  2005.	  102(11):	  p.	  4033-­‐8.	  
48.	   Ehrt,	  S.	  and	  D.	  Schnappinger,	  Mycobacterial	  survival	  strategies	  in	  the	  phagosome:	  
defence	  against	  host	  stresses.	  Cell	  Microbiol,	  2009.	  11(8):	  p.	  1170-­‐8.	  
49.	   Forrellad,	  M.A.,	  et	  al.,	  Virulence	  factors	  of	  the	  Mycobacterium	  tuberculosis	  complex.	  
Virulence,	  2012.	  4(1):	  p.	  3-­‐66.	  
50.	   McKinney,	  J.D.,	  et	  al.,	  Persistence	  of	  Mycobacterium	  tuberculosis	  in	  macrophages	  and	  
mice	  requires	  the	  glyoxylate	  shunt	  enzyme	  isocitrate	  lyase.	  Nature,	  2000.	  406(6797):	  p.	  
735-­‐8.	  
51.	   Camacho,	  L.R.,	  et	  al.,	  Identification	  of	  a	  virulence	  gene	  cluster	  of	  Mycobacterium	  
tuberculosis	  by	  signature-­‐tagged	  transposon	  mutagenesis.	  Mol	  Microbiol,	  1999.	  34(2):	  
p.	  257-­‐67.	  
52.	   Zhang,	  M.,	  et	  al.,	  Expression	  and	  characterization	  of	  the	  carboxyl	  esterase	  Rv3487c	  
from	  Mycobacterium	  tuberculosis.	  Protein	  Expr	  Purif,	  2005.	  42(1):	  p.	  59-­‐66.	  
53.	   Raynaud,	  C.,	  et	  al.,	  Phospholipases	  C	  are	  involved	  in	  the	  virulence	  of	  Mycobacterium	  
tuberculosis.	  Mol	  Microbiol,	  2002.	  45(1):	  p.	  203-­‐17.	  
54.	   Bretl,	  D.J.,	  C.	  Demetriadou,	  and	  T.C.	  Zahrt,	  Adaptation	  to	  environmental	  stimuli	  within	  
the	  host:	  two-­‐component	  signal	  transduction	  systems	  of	  Mycobacterium	  tuberculosis.	  
Microbiol	  Mol	  Biol	  Rev,	  2011.	  75(4):	  p.	  566-­‐82.	  
55.	   Parish,	  T.,	  et	  al.,	  Deletion	  of	  two-­‐component	  regulatory	  systems	  increases	  the	  virulence	  
of	  Mycobacterium	  tuberculosis.	  Infect	  Immun,	  2003.	  71(3):	  p.	  1134-­‐40.	  
56.	   Meher,	  A.K.,	  et	  al.,	  Analysis	  of	  complex	  formation	  and	  immune	  response	  of	  CFP-­‐10	  and	  
ESAT-­‐6	  mutants.	  Vaccine,	  2007.	  25(32):	  p.	  6098-­‐106.	  
57.	   Copenhaver,	  R.H.,	  et	  al.,	  A	  mutant	  of	  Mycobacterium	  tuberculosis	  H37Rv	  that	  lacks	  
expression	  of	  antigen	  85A	  is	  attenuated	  in	  mice	  but	  retains	  vaccinogenic	  potential.	  
Infect	  Immun,	  2004.	  72(12):	  p.	  7084-­‐95.	  
58.	   Mishra,	  A.K.,	  et	  al.,	  Lipoarabinomannan	  and	  related	  glycoconjugates:	  structure,	  
biogenesis	  and	  role	  in	  Mycobacterium	  tuberculosis	  physiology	  and	  host-­‐pathogen	  
interaction.	  FEMS	  Microbiol	  Rev,	  2011.	  35(6):	  p.	  1126-­‐57.	  
59.	   Li,	  X.Z.	  and	  H.	  Nikaido,	  Efflux-­‐mediated	  drug	  resistance	  in	  bacteria:	  an	  update.	  Drugs,	  
2009.	  69(12):	  p.	  1555-­‐623.	  
60.	   Kwon,	  H.H.,	  H.	  Tomioka,	  and	  H.	  Saito,	  Distribution	  and	  characterization	  of	  beta-­‐
lactamases	  of	  mycobacteria	  and	  related	  organisms.	  Tuber	  Lung	  Dis,	  1995.	  76(2):	  p.	  
141-­‐8.	  
61.	   Burian,	  J.,	  et	  al.,	  The	  mycobacterial	  antibiotic	  resistance	  determinant	  WhiB7	  acts	  as	  a	  
transcriptional	  activator	  by	  binding	  the	  primary	  sigma	  factor	  SigA	  (RpoV).	  Nucleic	  Acids	  
Res,	  2013.	  41(22):	  p.	  10062-­‐76.	  
62.	   Ainsa,	  J.A.,	  et	  al.,	  Molecular	  cloning	  and	  characterization	  of	  Tap,	  a	  putative	  multidrug	  
efflux	  pump	  present	  in	  Mycobacterium	  fortuitum	  and	  Mycobacterium	  tuberculosis.	  J	  
Bacteriol,	  1998.	  180(22):	  p.	  5836-­‐43.	  
63.	   Rodrigues,	  L.,	  et	  al.,	  Contribution	  of	  efflux	  activity	  to	  isoniazid	  resistance	  in	  the	  
Mycobacterium	  tuberculosis	  complex.	  Infect	  Genet	  Evol,	  2011.	  12(4):	  p.	  695-­‐700.	  
	   108	  
64.	   Siddiqi,	  N.,	  et	  al.,	  Mycobacterium	  tuberculosis	  isolate	  with	  a	  distinct	  genomic	  identity	  
overexpresses	  a	  tap-­‐like	  efflux	  pump.	  Infection,	  2004.	  32(2):	  p.	  109-­‐11.	  
65.	   Reeves,	  A.Z.,	  et	  al.,	  Aminoglycoside	  cross-­‐resistance	  in	  Mycobacterium	  tuberculosis	  due	  
to	  mutations	  in	  the	  5'	  untranslated	  region	  of	  whiB7.	  Antimicrob	  Agents	  Chemother,	  
2013.	  57(4):	  p.	  1857-­‐65.	  
66.	   Bianco,	  M.V.,	  et	  al.,	  Role	  of	  P27	  -­‐P55	  operon	  from	  Mycobacterium	  tuberculosis	  in	  the	  
resistance	  to	  toxic	  compounds.	  BMC	  Infect	  Dis,	  2011.	  11:	  p.	  195.	  
67.	   Ramon-­‐Garcia,	  S.,	  et	  al.,	  Role	  of	  the	  Mycobacterium	  tuberculosis	  P55	  efflux	  pump	  in	  
intrinsic	  drug	  resistance,	  oxidative	  stress	  responses,	  and	  growth.	  Antimicrob	  Agents	  
Chemother,	  2009.	  53(9):	  p.	  3675-­‐82.	  
68.	   Ramon-­‐Garcia,	  S.,	  et	  al.,	  Contribution	  of	  the	  Rv2333c	  efflux	  pump	  (the	  Stp	  protein)	  from	  
Mycobacterium	  tuberculosis	  to	  intrinsic	  antibiotic	  resistance	  in	  Mycobacterium	  bovis	  
BCG.	  J	  Antimicrob	  Chemother,	  2007.	  59(3):	  p.	  544-­‐7.	  
69.	   De	  Rossi,	  E.,	  et	  al.,	  The	  multidrug	  transporters	  belonging	  to	  major	  facilitator	  
superfamily	  in	  Mycobacterium	  tuberculosis.	  Mol	  Med,	  2002.	  8(11):	  p.	  714-­‐24.	  
70.	   Gupta,	  A.K.,	  et	  al.,	  jefA	  (Rv2459),	  a	  drug	  efflux	  gene	  in	  Mycobacterium	  tuberculosis	  
confers	  resistance	  to	  isoniazid	  &	  ethambutol.	  Indian	  J	  Med	  Res,	  2010.	  132:	  p.	  176-­‐88.	  
71.	   Wilson,	  M.,	  et	  al.,	  Exploring	  drug-­‐induced	  alterations	  in	  gene	  expression	  in	  
Mycobacterium	  tuberculosis	  by	  microarray	  hybridization.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  
1999.	  96(22):	  p.	  12833-­‐8.	  
72.	   Choudhuri,	  B.S.,	  et	  al.,	  Overexpression	  and	  functional	  characterization	  of	  an	  ABC	  (ATP-­‐
binding	  cassette)	  transporter	  encoded	  by	  the	  genes	  drrA	  and	  drrB	  of	  Mycobacterium	  
tuberculosis.	  Biochem	  J,	  2002.	  367(Pt	  1):	  p.	  279-­‐85.	  
73.	   Pasca,	  M.R.,	  et	  al.,	  Rv2686c-­‐Rv2687c-­‐Rv2688c,	  an	  ABC	  fluoroquinolone	  efflux	  pump	  in	  
Mycobacterium	  tuberculosis.	  Antimicrob	  Agents	  Chemother,	  2004.	  48(8):	  p.	  3175-­‐8.	  
74.	   Wang,	  K.,	  et	  al.,	  The	  expression	  of	  ABC	  efflux	  pump,	  Rv1217c-­‐Rv1218c,	  and	  its	  
association	  with	  multidrug	  resistance	  of	  Mycobacterium	  tuberculosis	  in	  China.	  Curr	  
Microbiol,	  2012.	  66(3):	  p.	  222-­‐6.	  
75.	   Rodrigues,	  L.,	  et	  al.,	  Role	  of	  the	  Mmr	  efflux	  pump	  in	  drug	  resistance	  in	  Mycobacterium	  
tuberculosis.	  Antimicrob	  Agents	  Chemother,	  2012.	  57(2):	  p.	  751-­‐7.	  
76.	   Pasca,	  M.R.,	  et	  al.,	  mmpL7	  gene	  of	  Mycobacterium	  tuberculosis	  is	  responsible	  for	  
isoniazid	  efflux	  in	  Mycobacterium	  smegmatis.	  Antimicrob	  Agents	  Chemother,	  2005.	  
49(11):	  p.	  4775-­‐7.	  
77.	   Andries,	  K.,	  et	  al.,	  Acquired	  resistance	  of	  Mycobacterium	  tuberculosis	  to	  bedaquiline.	  
PLoS	  One,	  2014.	  9(7):	  p.	  e102135.	  
78.	   Hartkoorn,	  R.C.,	  S.	  Uplekar,	  and	  S.T.	  Cole,	  Cross-­‐resistance	  between	  clofazimine	  and	  
bedaquiline	  through	  upregulation	  of	  MmpL5	  in	  Mycobacterium	  tuberculosis.	  
Antimicrob	  Agents	  Chemother,	  2014.	  58(5):	  p.	  2979-­‐81.	  
79.	   Milano,	  A.,	  et	  al.,	  Azole	  resistance	  in	  Mycobacterium	  tuberculosis	  is	  mediated	  by	  the	  
MmpS5-­‐MmpL5	  efflux	  system.	  Tuberculosis	  (Edinb),	  2009.	  89(1):	  p.	  84-­‐90.	  
80.	   Szumowski,	  J.D.,	  et	  al.,	  Antimicrobial	  efflux	  pumps	  and	  Mycobacterium	  tuberculosis	  
drug	  tolerance:	  evolutionary	  considerations.	  Curr	  Top	  Microbiol	  Immunol,	  2012.	  374:	  
p.	  81-­‐108.	  
81.	   Adams,	  K.N.,	  et	  al.,	  Drug	  tolerance	  in	  replicating	  mycobacteria	  mediated	  by	  a	  
macrophage-­‐induced	  efflux	  mechanism.	  Cell,	  2011.	  145(1):	  p.	  39-­‐53.	  
82.	   Kalscheuer,	  R.,	  et	  al.,	  Trehalose-­‐recycling	  ABC	  transporter	  LpqY-­‐SugA-­‐SugB-­‐SugC	  is	  
essential	  for	  virulence	  of	  Mycobacterium	  tuberculosis.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  2010.	  
107(50):	  p.	  21761-­‐6.	  
83.	   Pandey,	  A.K.	  and	  C.M.	  Sassetti,	  Mycobacterial	  persistence	  requires	  the	  utilization	  of	  
host	  cholesterol.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  2008.	  105(11):	  p.	  4376-­‐80.	  
84.	   Miner,	  M.D.,	  et	  al.,	  Role	  of	  cholesterol	  in	  Mycobacterium	  tuberculosis	  infection.	  Indian	  J	  
Exp	  Biol,	  2009.	  47(6):	  p.	  407-­‐11.	  
	   109	  
85.	   Forrellad,	  M.A.,	  et	  al.,	  Role	  of	  the	  Mce1	  transporter	  in	  the	  lipid	  homeostasis	  of	  
Mycobacterium	  tuberculosis.	  Tuberculosis	  (Edinb),	  2014.	  94(2):	  p.	  170-­‐7.	  
86.	   Marjanovic,	  O.,	  A.T.	  Iavarone,	  and	  L.W.	  Riley,	  Sulfolipid	  accumulation	  in	  
Mycobacterium	  tuberculosis	  disrupted	  in	  the	  mce2	  operon.	  J	  Microbiol,	  2011.	  49(3):	  p.	  
441-­‐7.	  
87.	   Paulsen,	  I.T.	  TransportDB.	  	  2013	  08/07/13;	  Available	  from:	  
http://www.membranetransport.org/.	  
88.	   Lamichhane,	  G.,	  S.	  Tyagi,	  and	  W.R.	  Bishai,	  Designer	  arrays	  for	  defined	  mutant	  analysis	  
to	  detect	  genes	  essential	  for	  survival	  of	  Mycobacterium	  tuberculosis	  in	  mouse	  lungs.	  
Infect	  Immun,	  2005.	  73(4):	  p.	  2533-­‐40.	  
89.	   Converse,	  S.E.,	  et	  al.,	  MmpL8	  is	  required	  for	  sulfolipid-­‐1	  biosynthesis	  and	  
Mycobacterium	  tuberculosis	  virulence.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  2003.	  100(10):	  p.	  
6121-­‐6.	  
90.	   Domenech,	  P.,	  M.B.	  Reed,	  and	  C.E.	  Barry,	  3rd,	  Contribution	  of	  the	  Mycobacterium	  
tuberculosis	  MmpL	  protein	  family	  to	  virulence	  and	  drug	  resistance.	  Infect	  Immun,	  
2005.	  73(6):	  p.	  3492-­‐501.	  
91.	   Alvarez-­‐Ortega,	  C.,	  J.	  Olivares,	  and	  J.L.	  Martinez,	  RND	  multidrug	  efflux	  pumps:	  what	  are	  
they	  good	  for?	  Front	  Microbiol,	  2013.	  4:	  p.	  7.	  
92.	   Tahlan,	  K.,	  et	  al.,	  SQ109	  targets	  MmpL3,	  a	  membrane	  transporter	  of	  trehalose	  
monomycolate	  involved	  in	  mycolic	  acid	  donation	  to	  the	  cell	  wall	  core	  of	  
Mycobacterium	  tuberculosis.	  Antimicrob	  Agents	  Chemother,	  2012.	  56(4):	  p.	  1797-­‐809.	  
93.	   Grzegorzewicz,	  A.E.,	  et	  al.,	  Inhibition	  of	  mycolic	  acid	  transport	  across	  the	  
Mycobacterium	  tuberculosis	  plasma	  membrane.	  Nat	  Chem	  Biol,	  2012.	  8(4):	  p.	  334-­‐41.	  
94.	   Camacho,	  L.R.,	  et	  al.,	  Analysis	  of	  the	  phthiocerol	  dimycocerosate	  locus	  of	  
Mycobacterium	  tuberculosis.	  Evidence	  that	  this	  lipid	  is	  involved	  in	  the	  cell	  wall	  
permeability	  barrier.	  J	  Biol	  Chem,	  2001.	  276(23):	  p.	  19845-­‐54.	  
95.	   Jain,	  M.	  and	  J.S.	  Cox,	  Interaction	  between	  polyketide	  synthase	  and	  transporter	  suggests	  
coupled	  synthesis	  and	  export	  of	  virulence	  lipid	  in	  M.	  tuberculosis.	  PLoS	  Pathog,	  2005.	  
1(1):	  p.	  e2.	  
96.	   Domenech,	  P.,	  et	  al.,	  The	  role	  of	  MmpL8	  in	  sulfatide	  biogenesis	  and	  virulence	  of	  
Mycobacterium	  tuberculosis.	  J	  Biol	  Chem,	  2004.	  279(20):	  p.	  21257-­‐65.	  
97.	   Rodriguez,	  J.E.,	  et	  al.,	  Transcription	  of	  genes	  involved	  in	  sulfolipid	  and	  polyacyltrehalose	  
biosynthesis	  of	  Mycobacterium	  tuberculosis	  in	  experimental	  latent	  tuberculosis	  
infection.	  PLoS	  One,	  2013.	  8(3):	  p.	  e58378.	  
98.	   Pacheco,	  S.A.,	  et	  al.,	  MmpL11	  protein	  transports	  mycolic	  acid-­‐containing	  lipids	  to	  the	  
mycobacterial	  cell	  wall	  and	  contributes	  to	  biofilm	  formation	  in	  Mycobacterium	  
smegmatis.	  J	  Biol	  Chem,	  2013.	  288(33):	  p.	  24213-­‐22.	  
99.	   Wells,	  R.M.,	  et	  al.,	  Discovery	  of	  a	  siderophore	  export	  system	  essential	  for	  virulence	  of	  
Mycobacterium	  tuberculosis.	  PLoS	  Pathog,	  2013.	  9(1):	  p.	  e1003120.	  
100.	   Owens,	  C.P.,	  et	  al.,	  The	  Mycobacterium	  tuberculosis	  secreted	  protein	  Rv0203	  transfers	  
heme	  to	  membrane	  proteins	  MmpL3	  and	  MmpL11.	  J	  Biol	  Chem,	  2013.	  288(30):	  p.	  
21714-­‐28.	  
101.	   Tullius,	  M.V.,	  et	  al.,	  Discovery	  and	  characterization	  of	  a	  unique	  mycobacterial	  heme	  
acquisition	  system.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  2011.	  108(12):	  p.	  5051-­‐6.	  
102.	   Bigi,	  F.,	  et	  al.,	  The	  knockout	  of	  the	  lprG-­‐Rv1410	  operon	  produces	  strong	  attenuation	  of	  
Mycobacterium	  tuberculosis.	  Microbes	  Infect,	  2004.	  6(2):	  p.	  182-­‐7.	  
103.	   Silva,	  P.E.,	  et	  al.,	  Characterization	  of	  P55,	  a	  multidrug	  efflux	  pump	  in	  Mycobacterium	  
bovis	  and	  Mycobacterium	  tuberculosis.	  Antimicrob	  Agents	  Chemother,	  2001.	  45(3):	  p.	  
800-­‐4.	  
104.	   Nikaido,	  H.,	  Structure	  and	  mechanism	  of	  RND-­‐type	  multidrug	  efflux	  pumps.	  Adv	  
Enzymol	  Relat	  Areas	  Mol	  Biol,	  2011.	  77:	  p.	  1-­‐60.	  
	   110	  
105.	   Jones,	  C.M.,	  et	  al.,	  Self-­‐poisoning	  of	  Mycobacterium	  tuberculosis	  by	  interrupting	  
siderophore	  recycling.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  2014.	  111(5):	  p.	  1945-­‐50.	  
106.	   Recht,	  J.,	  et	  al.,	  Genetic	  analysis	  of	  sliding	  motility	  in	  Mycobacterium	  smegmatis.	  J	  
Bacteriol,	  2000.	  182(15):	  p.	  4348-­‐51.	  
107.	   Sonden,	  B.,	  et	  al.,	  Gap,	  a	  mycobacterial	  specific	  integral	  membrane	  protein,	  is	  required	  
for	  glycolipid	  transport	  to	  the	  cell	  surface.	  Mol	  Microbiol,	  2005.	  58(2):	  p.	  426-­‐40.	  
108.	   Deshayes,	  C.,	  et	  al.,	  MmpS4	  promotes	  glycopeptidolipids	  biosynthesis	  and	  export	  in	  
Mycobacterium	  smegmatis.	  Mol	  Microbiol,	  2010.	  78(4):	  p.	  989-­‐1003.	  
109.	   Nessar,	  R.,	  et	  al.,	  Deletion	  of	  the	  mmpL4b	  gene	  in	  the	  Mycobacterium	  abscessus	  
glycopeptidolipid	  biosynthetic	  pathway	  results	  in	  loss	  of	  surface	  colonization	  capability,	  
but	  enhanced	  ability	  to	  replicate	  in	  human	  macrophages	  and	  stimulate	  their	  innate	  
immune	  response.	  Microbiology,	  2011.	  157(Pt	  4):	  p.	  1187-­‐95.	  
110.	   Soto,	  C.Y.,	  et	  al.,	  Simple	  and	  rapid	  differentiation	  of	  Mycobacterium	  tuberculosis	  H37Ra	  
from	  M.	  tuberculosis	  clinical	  isolates	  through	  two	  cytochemical	  tests	  using	  neutral	  red	  
and	  nile	  blue	  stains.	  J	  Clin	  Microbiol,	  2002.	  40(8):	  p.	  3021-­‐4.	  
111.	   van	  Soolingen,	  D.,	  et	  al.,	  DNA	  fingerprinting	  of	  Mycobacterium	  tuberculosis.	  Methods	  
Enzymol,	  1994.	  235:	  p.	  196-­‐205.	  
112.	   Brosch,	  R.,	  et	  al.,	  Use	  of	  a	  Mycobacterium	  tuberculosis	  H37Rv	  bacterial	  artificial	  
chromosome	  library	  for	  genome	  mapping,	  sequencing,	  and	  comparative	  genomics.	  
Infect	  Immun,	  1998.	  66(5):	  p.	  2221-­‐9.	  
113.	   Birnboim,	  H.C.	  and	  J.	  Doly,	  A	  rapid	  alkaline	  extraction	  procedure	  for	  screening	  
recombinant	  plasmid	  DNA.	  Nucleic	  Acids	  Res,	  1979.	  7(6):	  p.	  1513-­‐23.	  
114.	   Wards,	  B.J.	  and	  D.M.	  Collins,	  Electroporation	  at	  elevated	  temperatures	  substantially	  
improves	  transformation	  efficiency	  of	  slow-­‐growing	  mycobacteria.	  FEMS	  Microbiol	  
Lett,	  1996.	  145(1):	  p.	  101-­‐5.	  
115.	   Davis,	  G.	  and	  K.J.	  Kayser,	  Methods	  in	  molecular	  biology	  -­‐	  Chromosomal	  mutagenesis,	  
ed.	  J.M.	  Walker.	  2008.	  
116.	   Datsenko,	  K.A.	  and	  B.L.	  Wanner,	  One-­‐step	  inactivation	  of	  chromosomal	  genes	  in	  
Escherichia	  coli	  K-­‐12	  using	  PCR	  products.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  2000.	  97(12):	  p.	  
6640-­‐5.	  
117.	   Institut	  Pasteur	  -­‐	  Unité	  de	  Génétique	  Moléculaire	  Bactérienne.	  Bacterial	  Artificial	  
Chromosome	  Libraries	  of	  Mycobacterium	  tuberculosis	  H37Rv	  and	  M.	  bovis	  BCG	  
Pasteur.	  2000.	  
118.	   Lee,	  S.,	  et	  al.,	  Bxz1,	  a	  new	  generalized	  transducing	  phage	  for	  mycobacteria.	  FEMS	  
Microbiol	  Lett,	  2004.	  241(2):	  p.	  271-­‐6.	  
119.	   van	  Kessel,	  J.C.,	  Recombineering	  in	  mycobacteria	  using	  mycobacteriophage	  proteins.	  
Biological	  Sciences,	  2008.	  Doctor	  of	  Philosophy:	  p.	  264.	  
120.	   Dobsong,	  G.,	  et	  al.,	  Systematic	  analysis	  of	  complex	  mycobacterial	  lipids.	  Chemical	  
Methods	  in	  Bacterial	  Systematic,	  1985.	  
121.	   Cardona,	  P.J.,	  et	  al.,	  Neutral-­‐red	  reaction	  is	  related	  to	  virulence	  and	  cell	  wall	  methyl-­‐
branched	  lipids	  in	  Mycobacterium	  tuberculosis.	  Microbes	  Infect,	  2006.	  8(1):	  p.	  183-­‐90.	  
122.	   Simeone,	  R.,	  et	  al.,	  Delineation	  of	  the	  roles	  of	  FadD22,	  FadD26	  and	  FadD29	  in	  the	  
biosynthesis	  of	  phthiocerol	  dimycocerosates	  and	  related	  compounds	  in	  Mycobacterium	  
tuberculosis.	  FEBS	  J,	  2010.	  277(12):	  p.	  2715-­‐25.	  
123.	   Dao,	  D.N.,	  et	  al.,	  Mycolic	  acid	  modification	  by	  the	  mmaA4	  gene	  of	  M.	  tuberculosis	  
modulates	  IL-­‐12	  production.	  PLoS	  Pathog,	  2008.	  4(6):	  p.	  e1000081.	  
124.	   Piddock,	  L.J.,	  K.J.	  Williams,	  and	  V.	  Ricci,	  Accumulation	  of	  rifampicin	  by	  Mycobacterium	  
aurum,	  Mycobacterium	  smegmatis	  and	  Mycobacterium	  tuberculosis.	  J	  Antimicrob	  
Chemother,	  2000.	  45(2):	  p.	  159-­‐65.	  
125.	   van	  Boxtel,	  R.M.,	  R.S.	  Lambrecht,	  and	  M.T.	  Collins,	  Effect	  of	  polyoxyethylene	  sorbate	  
compounds	  (Tweens)	  on	  colonial	  morphology,	  growth,	  and	  ultrastructure	  of	  
Mycobacterium	  paratuberculosis.	  APMIS,	  1990.	  98(10):	  p.	  901-­‐8.	  
	   111	  
126.	   Boshoff,	  H.I.,	  et	  al.,	  The	  transcriptional	  responses	  of	  Mycobacterium	  tuberculosis	  to	  
inhibitors	  of	  metabolism:	  novel	  insights	  into	  drug	  mechanisms	  of	  action.	  J	  Biol	  Chem,	  
2004.	  279(38):	  p.	  40174-­‐84.	  
127.	   Paixao,	  L.,	  et	  al.,	  Fluorometric	  determination	  of	  ethidium	  bromide	  efflux	  kinetics	  in	  
Escherichia	  coli.	  J	  Biol	  Eng,	  2009.	  3:	  p.	  18.	  
128.	   Coelho,	  T.,	  et	  al.,	  Enhancement	  of	  antibiotic	  activity	  by	  efflux	  inhibitors	  against	  
multidrug	  resistant	  Mycobacterium	  tuberculosis	  clinical	  isolates	  from	  Brazil.	  Front	  
Microbiol,	  2015.	  6:	  p.	  330.	  
129.	   Tomala,	  K.	  and	  R.	  Korona,	  Evaluating	  the	  fitness	  cost	  of	  protein	  expression	  in	  
Saccharomyces	  cerevisiae.	  Genome	  Biol	  Evol,	  2013.	  5(11):	  p.	  2051-­‐60.	  
130.	   Cosson,	  P.,	  et	  al.,	  Pseudomonas	  aeruginosa	  virulence	  analyzed	  in	  a	  Dictyostelium	  
discoideum	  host	  system.	  J	  Bacteriol,	  2002.	  184(11):	  p.	  3027-­‐33.	  
131.	   Warner,	  D.M.,	  et	  al.,	  Regulation	  of	  the	  MtrC-­‐MtrD-­‐MtrE	  efflux-­‐pump	  system	  modulates	  
the	  in	  vivo	  fitness	  of	  Neisseria	  gonorrhoeae.	  J	  Infect	  Dis,	  2007.	  196(12):	  p.	  1804-­‐12.	  
132.	   Bhatt,	  A.,	  et	  al.,	  Deletion	  of	  kasB	  in	  Mycobacterium	  tuberculosis	  causes	  loss	  of	  acid-­‐
fastness	  and	  subclinical	  latent	  tuberculosis	  in	  immunocompetent	  mice.	  Proc	  Natl	  Acad	  
Sci	  U	  S	  A,	  2007.	  104(12):	  p.	  5157-­‐62.	  
133.	   Belardinelli,	  J.M.	  and	  H.R.	  Morbidoni,	  Mutations	  in	  the	  essential	  FAS	  II	  beta-­‐
hydroxyacyl	  ACP	  dehydratase	  complex	  confer	  resistance	  to	  thiacetazone	  in	  
Mycobacterium	  tuberculosis	  and	  Mycobacterium	  kansasii.	  Mol	  Microbiol,	  2012.	  86(3):	  
p.	  568-­‐79.	  
134.	   Pirson,	  C.,	  et	  al.,	  Differential	  effects	  of	  Mycobacterium	  bovis-­‐-­‐derived	  polar	  and	  apolar	  
lipid	  fractions	  on	  bovine	  innate	  immune	  cells.	  Vet	  Res,	  2012.	  43:	  p.	  54.	  
	  
 
  
	   112	  
 
  
	   113	  
Annex I 
Results of TLC analysis of free lipids, non-polar and polar lipids, and FAMEs and MAMEs from 
H37Rv wt, L4KO, L4c, L4S4KO, L4S4c, and L4sb in different solvent systems. 
Table 1-AI. Summary of solvent systems for TLC lipid analysis. 
System Direction 1 Runs 
A Petroleum ether 60-80/ Ethyl acetate (98:2) 3 
B Petroleum ether 60-80/ Acetone (92:8) 3 
C Chloroform/ Methanol (96:4) 1 
D Chloroform/ Methanol/ Water (100:14:0.8) 1 
E Chloroform/ Methanol/ Water (60:30:6) 1 
F Petroleum ether/ Acetone (95:5) 1 
System Direction 2 Runs 
A Petroleum ether 60-80/ Acetone (98:2) 1 
B Toluene/ Acetone (95:5) 1 
C Toluene/ Acetone (80:20) 1 
D Chloroform/ Acetone/ Methanol / Water (50:60:2.5:3) 1 
E Chloroform/ Acetic acid (glacial)/ Methanol / Water (40:25:3:6) 1 
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Figure 1-AI. 2D-TLC analysis of free lipids from H37Rv, L4KO, L4c, L4S4KO, L4S4c, and L4sb using 
solvent systems A. 
 
Figure 2-AI. 2D-TLC analysis of free lipids from H37Rv, L4KO, L4c, L4S4KO, L4S4c, and L4sb using 
solvent systems B. 
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Figure 3-AI. 2D-TLC analysis of free lipids from H37Rv, L4KO, L4c, L4S4KO, L4S4c, and L4sb using 
solvent systems C. 
 
Figure 4-AI. 2D-TLC analysis of free lipids from H37Rv, L4KO, L4c, L4S4KO, L4S4c, and L4sb using 
solvent systems D. 
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Figure 5-AI. 2D-TLC analysis of non-polar lipids from H37Rv, L4KO, L4c, L4S4KO, L4S4c, and L4sb using 
solvent systems A. 
 
Figure 6-AI. 2D-TLC analysis of non-polar lipids from H37Rv, L4KO, L4c, L4S4KO, L4S4c, and L4sb using 
solvent systems B. 
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Figure 7-AI. 2D-TLC analysis of non-polar lipids from H37Rv, L4KO, L4c, L4S4KO, L4S4c, and L4sb using 
solvent systems C. 
 
Figure 8-AI. 2D-TLC analysis of non-polar lipids from H37Rv, L4KO, L4c, L4S4KO, L4S4c, and L4sb using 
solvent systems D. 
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Figure 9-AI. 2D-TLC analysis of polar lipids from H37Rv, L4KO, L4c, L4S4KO, L4S4c, and L4sb using 
solvent systems D. 
 
Figure 10-AI. 2D-TLC analysis of polar lipids from H37Rv, L4KO, L4c, L4S4KO, L4S4c, and L4sb using 
solvent systems E. 
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Figure 11-AI. TLC analysis of FAMEs and MAMEs from H37Rv, L4KO, L4c, L4S4KO, L4S4c, and L4sb 
using solvent system F. 
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Annex II 
Table 1-AII. Variation in the expression of the proteins with p<0.05 in L4KO, L4c, L4S4KO, and L4S4c in 
comparison with H37Rv wt. 
Spot 
number 
Protein name 
Rv 
number 
L4KO L4c L4S4KO L4S4c 
+/- FC +/- FC +/- FC +/- FC 
409 
Probable ribonucleotide 
transport ATP-binding 
protein ABC transporter Mkl 
Rv0655 + 1.9   + 1.8 + 1.8 
492 
Quinone oxidoreductase 
Qor 
Rv1454c - 1.3 - 1.3 - 1.3 - 1.3 
524 Hypothetical protein Rv1794 - 1.4       
618 
NADH-dependent enoyl-
ACP reductase InhA 
Rv1484     + 1.5   
653 
Probable short-chain type 
dehydrogenase/reductase 
Rv0927c       - 1.4 
695 Adenylate kinase Adk Rv0733 - 1.4   - 1.5   
750 Conserved protein TB16.3 Rv2185c   - 1.4     
848 
Biotin carboxyl carrier 
protein AccA3 
Rv3285   + 2.5     
849 
3-hydroxyacyl-CoA 
dehydrogenase FadB 
Rv0860 + 2.4 + 2.1 + 2.7 + 2.1 
886 Uncharacterized protein Rv2557 - 1.3 - 1.2 - 1.3 - 1.3 
893 
Putative OXPP cycle 
protein OpcA 
Rv1446c   - 1.2 - 1.1 - 1.2 
899 
Enoyl-CoA hydratase 
EchA3 
Rv0632c     - 1.8   
908 
Acyl-[acyl-carrier protein] 
desaturase DesA1 
Rv0824c + 2.2 + 1.9 + 2.7 + 2.2 
913 
Probable short-chain type 
dehydrogenase/reductase 
Rv0148     - 1.4 - 1.1 
937 
Succinyl-CoA synthetase 
(alpha chain) SucD 
Rv0952   - 1.2     
Abbreviations: FC (Fold change). 
+/-: + means this protein was overexpressed in this strain in comparison to the reference strain H37Rv. 
  - means this protein was less expressed in this strain than in H37Rv wt. 
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Even though the statistical analysis revealed that none of the spots were statistically significant, 
we believed that those proteins with p<0.05 and fold change >1.5 should be studied more 
thoroughly since they might be biologically relevant. 
These proteins were classified (Table 2-AII) according to functional category using TubercuList 
database. The most relevant finding was that 72% of these proteins were related to lipid 
metabolism. In addition, 14% of them were involved in intermediary metabolism and respiration 
and 14% in cell wall and cell processes. Interestingly, all the proteins in lipid metabolism 
category were associated with fatty acids. Nevertheless, it was not possible to link them to any 
specific pathway. 
Table 2-AII. Functional classification and description of the selected cellular proteins differentially 
expressed in Mycobacterium tuberculosis strains. 
Rv 
number Protein name 
Gene 
name Functional category Biological function 
Rv0655 
Probable 
ribonucleotide 
transport ATP-
binding protein ABC 
transporter Mkl 
mkl 
Cell wall and cell 
processes 
Thought to be involved in 
active transport of 
ribonucleotide across the 
membrane 
Rv1484 
NADH-dependent 
enoyl-ACP 
reductase InhA 
inhA Lipid metabolism 
Involved in mycolic acid 
biosynthesis, second 
reductive step in fatty acid 
biosynthesis, and in the 
resistance against 
isoniazid and ethionamide 
Rv0733 
Adenylate kinase 
Adk adk 
Intermediary 
metabolism and 
respiration 
Essential in intracellular 
nucleotide metabolism 
Rv3285 
Biotin carboxyl 
carrier protein 
AccA3 
accA3 Lipid metabolism 
Involved in the first step of 
long-chain fatty acid 
synthesis 
Rv0860 
3-hydroxyacyl-CoA 
dehydrogenase 
FadB 
fadB Lipid metabolism 
Involved in fatty acid 
degradation (probably in 
fatty acid beta-oxidation 
cycle) 
Rv0632c 
Enoyl-CoA 
hydratase EchA3 echA3 Lipid metabolism 
Could possibly oxidize 
fatty acids using specific 
components 
Rv0824c 
Acyl-[acyl-carrier 
protein] desaturase 
DesA1 
desA1 Lipid metabolism 
Catalyzes the principal 
conversion of saturated 
fatty acids to unsaturated 
fatty acids 
Regarding protein expression (Table 3-AII), as it was shown in other experiments, the 
complemented strains did not behave as they were supposed; protein expression levels were 
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not always similar to the wild-type. It should be pointed out that three of the proteins involved in 
lipid metabolism (AccA3, FadB, and DesA1) exhibited the highest rise in their expression 
compared to the reference strain. Furthermore, there were a larger number of proteins whose 
expression changed in L4S4KO than L4KO. 
Table 3-AII. Selected cellular proteins differentially expressed in Mycobacterium tuberculosis knockout 
mutants L4KO and L4S4KO and their complemented strains. 
Spot 
number 
Protein name 
Rv 
number 
L4KO L4c L4S4KO L4S4c 
+/- FC +/- FC +/- FC +/- FC 
409 
Probable ribonucleotide 
transport ATP-binding protein 
ABC transporter Mkl 
Rv0655 + 1.9   + 1.8 + 1.8 
618 
NADH-dependent enoyl-ACP 
reductase InhA 
Rv1484     + 1.5   
695 Adenylate kinase Adk Rv0733 - 1.4   - 1.5   
848 
Biotin carboxyl carrier protein 
AccA3 
Rv3285   + 2.5     
849 
3-hydroxyacyl-CoA 
dehydrogenase FadB 
Rv0860 + 2.4 + 2.1 + 2.7 + 2.1 
899 Enoyl-CoA hydratase EchA3 Rv0632c     - 1.8   
908 
Acyl-[acyl-carrier protein] 
desaturase DesA1 
Rv0824c + 2.2 + 1.9 + 2.7 + 2.2 
Abbreviations: FC (Fold change). 
+/-: + means this protein was overexpressed in this strain in comparison to the reference strain H37Rv. 
  - means this protein was less expressed in this strain than in H37Rv wt. 
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Annex III 
Results of TLC analysis of free lipids, non-polar and polar lipids, from BCG wt and BCG L4sb in 
different solvent systems. 
Table 1-AIII. Summary of solvent systems for TLC lipid analysis. 
System Direction 1 Runs 
B Petroleum ether 60-80/ Acetone (92:8) 3 
C Chloroform/ Methanol (96:4) 1 
D Chloroform/ Methanol/ Water (100:14:0.8) 1 
E Chloroform/ Methanol/ Water (60:30:6) 1 
System Direction 2 Runs 
B Toluene/ Acetone (95:5) 1 
C Toluene/ Acetone (80:20) 1 
D Chloroform/ Acetone/ Methanol / Water (50:60:2.5:3) 1 
E Chloroform/ Acetic acid (glacial)/ Methanol / Water (40:25:3:6) 1 
 
 
Figure 1-AIII. 2D-TLC analysis of free lipids from BCG wt and BCG L4sb. (A) Solvent systems B. (B) 
Solvent systems C. (C) Solvent systems D. 
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Figure 2-AIII. 2D-TLC analysis of non-polar lipids from BCG wt and BCG L4sb. (A) Solvent systems B. (B) 
Solvent systems C. (C) Solvent systems D. 
 
Figure 3-AIII. 2D-TLC analysis of polar lipids from BCG wt and BCG L4sb. (A) Solvent systems D. (B) 
Solvent systems E.  
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Annex IV 
During my PhD thesis, I contributed to the construction of the Mmr knockout mutant of M. 
tuberculosis using the recombineering method, which is the routine procedure to generate 
knockouts in our laboratory. In addition, I took part in obtaining its complemented strain 
MmrKO::pCRS5, and the overexpression strain H37Rv::pCVZ2. 
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Efflux pumps are membrane proteins capable of actively transporting a broad range of substrates from the cytoplasm to the exte-
rior of the cell. Increased efflux activity in response to drug treatment may be the first step in the development of bacterial drug
resistance. Previous studies showed that the efflux pumpMmr was significantly overexpressed in strains exposed to isoniazid. In
the work to be described, we constructed mutants lacking or overexpressingMmr in order to clarify the role of this efflux pump
in the development of resistance to isoniazid and other drugs inM. tuberculosis. Themmr knockout mutant showed an in-
creased susceptibility to ethidium bromide, tetraphenylphosphonium, and cetyltrimethylammonium bromide (CTAB). Overex-
pression ofmmr caused a decreased susceptibility to ethidium bromide, acriflavine, and safranin O that was obliterated in the
presence of the efflux inhibitors verapamil and carbonyl cyanidem-chlorophenylhydrazone. Isoniazid susceptibility was not
affected by the absence or overexpression ofmmr. The fluorometric method allowed the detection of a decreased efflux of
ethidium bromide in the knockout mutant, whereas the overexpressed strain showed increased efflux of this dye. This increased
efflux activity was inhibited in the presence of efflux inhibitors. Under our experimental conditions, we have found that efflux
pumpMmr is mainly involved in the susceptibility to quaternary compounds such as ethidium bromide and disinfectants such
as CTAB. The contribution of this efflux pump to isoniazid resistance inMycobacterium tuberculosis still needs to be further
elucidated.
The World Health Organization (WHO) goal to reduce theglobal burden of tuberculosis by 2015 (1, 2) faces many chal-
lenges, namely, the dissemination of severe cases of drug resis-
tance that reduce the therapeutic efficacy of the available antitu-
berculous drugs. These drug-resistant forms of tuberculosis are
known as multidrug and extensively drug-resistant tuberculosis
(MDRTB and XDRTB, respectively), with the former defined to
be resistance to at least the first-line drugs isoniazid and rifampin
and the latter defined to be MDRTB plus resistance to fluoro-
quinolones and to at least one of the three injectable second-line
drugs (kanamycin, amikacin, and capreomycin). Thus, there is a
great effort to understand the mechanisms of drug resistance, as
well as to develop new drugs and new therapeutic approaches.
Clinically relevant drug resistance in Mycobacterium tubercu-
losis occurs mainly by the acquisition of spontaneous chromo-
somal mutations that alter the drug target or the prodrug-activat-
ing enzymes, followed by the selection of drug-resistant mutants
that may occur in the case of exposure to monotherapy or lower
antibiotic doses due to inadequate prescription, poor patient
compliance, and patient pharmacokinetic variability (3–5). How-
ever, these mutations are not found in many low-level-resistant
isolates, suggesting that other mechanisms of resistance may also
be involved, such as mechanisms involving the permeability bar-
rier provided by the cell wall and the activity of efflux systems.
Bacterial efflux pumps aremembrane proteins that are capable
of actively transporting a broad range of substrates, including
drugs, from the cytoplasm to the exterior of the cell. They are
involved in physiological processes, such as cell wall division,
maintenance of the pH homeostasis, and secretion of intracellular
metabolites (6–8). Increased expression of efflux pump genes
confers a low-level-resistant phenotype, and it has been sug-
gested that under these conditions, bacteria have greater
chances of acquiring a chromosomal mutation(s) conferring
higher levels of drug resistance (6, 9). A strategy to prevent this
chain of events would be the inhibition of efflux pumps, which,
in addition, would restore the effectiveness of antimicrobials
that are subject to efflux (10–12).
In M. tuberculosis, several efflux pumps have been described,
but their contribution to clinical drug resistance remains to be
completely clarified (13, 14). One of these pumps is Mmr
(Rv3065) of the small multidrug resistance (SMR) family of trans-
porters. Previous studies involving Mmr were performed in the
heterologous host Mycobacterium smegmatis and showed that it
was involved in the extrusion of several compounds such as tetra-
phenylphosphonium, ethidium bromide (EtBr), erythromycin,
and acriflavine (15, 16). A recent study has shown that Mmr ap-
pears to be involved in the efflux of compounds of the pyrrole class
inM. tuberculosis (17).
In previous works, we and other authors observed that mmr
was one of the efflux pump genes that was significantly overex-
pressed in a number of M. tuberculosis strains exposed to high
levels of isoniazid (9, 18, 19), which suggested that Mmr could be
associated with resistance to isoniazid. In the study to be de-
scribed, we constructed M. tuberculosis mutants lacking or over-
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expressing Mmr in order to clarify the role of this efflux pump in
the development of resistance to isoniazid and other drugs.
MATERIALS AND METHODS
Bacteria and growth conditions. The strains and plasmids used in this
study are listed in Table 1. M. tuberculosis was grown at 37°C in Middle-
brook 7H9 broth (Difco, Detroit, MI) supplemented with 10% (vol/vol)
Middlebrook albumin-dextrose-catalase (ADC; Difco) and 0.05% (vol/
vol) Tween 80 or onMiddlebrook 7H10 (Difco) agar plates supplemented
with 10% (vol/vol) ADC and 0.05% (vol/vol) Tween 80. Escherichia coli
HB101 was grown at 37°C Luria Bertani (LB) broth or on LB agar plates.
Plasmids were maintained in E. coliwith appropriate antibiotics for selec-
tion (50g/ml of hygromycin, 20g/ml of kanamycin). For the selection
of resistance markers in mycobacteria, hygromycin or kanamycin was
added to the culture medium at final concentrations of 50 g/ml and 20
g/ml, respectively.
DNA manipulation. DNA manipulations were carried out by stan-
dard techniques (24). Mycobacterial genomic DNA was isolated as de-
scribed previously (25). Southern blotting was done with an enhanced
chemiluminescence direct nucleic acid labeling and detection system
(AmershamBiosciences), according to themanufacturer’s instructions. A
DNA probe specific for themmr gene was generated by PCR, based upon
an Rv3065 gene sequence fromGenBank (accession number NC_000962;
region 3430387 to 3430710); primer sequences are available upon request.
E. coli andM. tuberculosis were transformed by electroporation with a
Gene Pulser apparatus (Bio-Rad Laboratories Inc., Richmond, CA).
Briefly, E. coli competent cells were prepared according to standard pro-
tocols (24) and transformed by adding DNA to 40-l aliquots of cells
while incubating on ice. Cells were transferred to chilled 0.2-cm cuvettes
(Bio-Rad) and transformed using a Bio-RadGene Pulser set at 2.5 kV, 200
, and 25 F. Cells were recovered in 1 ml LB broth for 1 h at 37°C and
plated on selective medium. M. tuberculosis electrocompetent cells were
prepared as previously described (21). Briefly, the culture was centrifuged
at 2,880 g for 10 min and the supernatant was discarded. The pellet was
resuspended in 1/2 volume of sterile 10% glycerol, and the centrifugation
stepwas repeated. The cells were resuspended in 1/4 volume of sterile 10%
glycerol. This process was repeated until in the last step the cells were
resuspended in 1/25 volume of sterile 10% glycerol.M. tuberculosis com-
petent cells were transformed by electroporation using aGene Pulser set at
2.5 kV, 1,000, and 25F. Cells were recovered in 1ml 7H9 broth for 24
h (for the overexpression and complementationmutants) or 72 h (for the
knockout [KO] mutant) at 37°C and plated on selective medium.
Strain construction. (i) Inactivation. The construction of an M. tu-
berculosis mmr knockout mutant was performed by allelic exchange, as
previously described (20, 21). This method is based on the use of an M.
tuberculosis recombineering strain transformed with a plasmid that con-
tains mycobacteriophage Che9c-encoded recombination proteins gp60
and gp61. Expression of these proteins in M. tuberculosis increases the
recombination frequency of the bacteria, allowing the recovery of gene
replacement mutants following electroporation of linear DNAmolecules
containing segments homologous to the chromosomal DNA (20, 21).
Primers were designed to amplify upstream and downstream DNA
regions flanking the mmr gene (576 and 996 bp, respectively). The PCR
products were cloned into pYUB854 flanking a hygromycin resistance
cassette. The vector obtained, pMmr, was linearized by double digestion
with AvrII and HindIII or amplified by PCR in order to obtain the allelic
exchange substrate (AES) (Fig. 1A).
H37Rv::pJV53 (recombineering strain) was grown at 37°C inMiddle-
brook 7H9 supplemented with 0.05% Tween 80, 20 g/ml kanamycin,
and 0.2% succinate. Once the cells reached an optical density at 600 nm
(OD600) of 0.5 to 0.6, acetamide was added to a final concentration of
0.2% and the culture was grown at 37°C overnight. On the following day,
electrocompetent cells were prepared and transformed with 100 ng of the
AES by electroporation. The transformations were recovered by incuba-
tion at 37°C in 7H9 supplemented with ADC and Tween 80 for 72 h. The
entire reaction mixture was plated on 7H10 agar plates containing kana-
mycin, hygromycin, and ADC and incubated at 37°C for 3 to 4 weeks,
until colonies (potential mmr knockout mutants) developed. Colonies
were inoculated into 7H9 broth containing kanamycin, hygromycin, and
ADC and incubated at 37°C until visible growth was obtained (approxi-
mately 10 to 20 days). The presence of an inactivated copy of themmr gene
was tested by PCR and Southern blot analysis of each recombinant colony
obtained. The mutant strain, namely, M. tuberculosis H37Rv MmrKO,
was grown inmedium lacking kanamycin until it lost the replicating plas-
mid pJV53.
As controls, recombineering-deficient strain M. tuberculosis H37Rv::
pLAM12 was also transformed with AES and no colony was recovered,
andM. tuberculosisH37Rv::pJV53 was used as a negative control for PCR
and hybridization analysis.
(ii) Integrative plasmid for complementation.M. tuberculosisH37Rv
MmrKO was complemented by introducing the integrative plasmid
pCRS5, a derivative of vector pMV361 (22) carrying a 1,177-bp DNA
fragment containing the mmr gene, resulting in M. tuberculosis H37Rv
MmrKO::pCRS5 (Fig. 1B).
TABLE 1 Strains and plasmids used in this study
Strain or plasmid Description Source or reference
M. tuberculosis
H37Rv (ATCC 25618) Wild type Laboratory collection
H37Rv::pLAM12 Control strain 20
H37Rv::pJV53 Recombineering strain 20
MmrKO H37Rv knockout formmr This study
MmrKO::pCRS5 Strain MmrKO containing pCRS5 This study
H37Rv::pCVZ2 Strain H37Rv containing pCVZ2 This study
Plasmids
pLAM12 Replicative plasmid with a kanamycin resistance gene and an acetamidase expression cassette 20
pJV53 Carrying genes for gp60 and gp61 (encoding recombineering enzymes) from mycobacteriophage
Che9c cloned into pLAM12, under the control of the acetamidase promoter
20
pYUB854 E. coli vector containing the Hygr cassette flanked by multiple-cloning sites and  res sites, oriE,
and a cos packaging site
20, 21
pMmr pYUB854 containing the DNA regions flankingmmr This study
pCRS5 Integrative plasmid,mmr cloned into pMV361 (22) This study
pCVZ2 Replicative plasmid,mmr cloned into pSUM36 (23) This study
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(iii) Replicative plasmid for overexpression.An 1,177-bp DNA frag-
ment containing the mmr gene was cloned into the pSUM36 vector (23)
using restriction enzymes HindIII and PstI, yielding plasmid pCVZ2.
Plasmid pCVZ2 was electroporated intoM. tuberculosisH37Rv, resulting
inM. tuberculosisH37Rv::pCVZ2 (Fig. 1C).
Neutral red staining.Neutral red staining was used to ensure that the
constructed strains keep free lipids of the cell wall, such as the virulence
factor phthiocerol dimycocerosates (PDIMs). Neutral red staining was
performed in a test tube, as described previously (26). Briefly, mycobac-
terial strains were grown at 37°C on Middlebrook 7H10 medium supple-
mented with 10% ADC and kanamycin (20 g/ml) or hygromycin B (50
g/ml) when required. Bacterial cells were placed in 15-ml screw-cap
tubes containing 4ml of methanol-H2O (1:1) and incubated at 37°C for 1
h. After centrifugation at 2,880 g for 10min, themethanol was removed
and 4 ml of barbital buffer (1% sodium barbital in 5%NaCl, pH 9.8) and
150 l of neutral red were added. The results were evaluated after 1 h and
24 h of incubation at 37°C.
Drug susceptibility assays. (i) Determination of MICs. The determi-
nationof theMICs for antibiotics, efflux inhibitors, dyes, andbiocides against
M. tuberculosisH37Rv andMmrmutant strains was performed by the resaz-
urin microtiter assay, as previously described (27). Ciprofloxacin, etham-
butol, erythromycin, kanamycin, isoniazid, rifampin, acriflavine,
ethidium bromide, safranin O, tetraphenylphosphonium, cetyltrimethyl-
ammonium bromide (CTAB), carbonyl cyanide m-chlorophenylhydra-
zone (CCCP), chlorpromazine, and verapamil were purchased from
Sigma-Aldrich (Madrid, Spain) and used in the MIC determination.
Briefly, mycobacterial strains were grown at 37°C in Middlebrook 7H9
broth supplemented with 10% ADC and 0.05% Tween 80 until an OD600
of 0.8. Mycobacterial cultures were diluted in 7H9 supplemented with
ADC and 0.5% glycerol in order to obtain a final concentration of 105
CFU/ml. The number of CFU corresponding to aliquots of the inoculum
was routinely calculated in order to ensure a constant number of bacterial
cells from experiment to experiment. Aliquots of 100 l were transferred
to each well of a 96-well plate that contained 100 l of each compound at
concentrations prepared from 2-fold serial dilutions in 7H9-ADC me-
dium. The inoculated plates were incubated for 6 days at 37°C and for an
additional 2 days after the addition of the redox indicator (30 l of a
resazurin solution at 0.1 mg/ml). A change from blue to pink indicates
reduction of resazurin and therefore bacterial growth. Thus, theMIC was
defined as the lowest concentration of compound that prevented this
color change. TheMICs of ethidium bromide, tetraphenylphosphonium,
acriflavine, safranin O, and CTAB in the presence of the efflux inhibitors
chlorpromazine, verapamil, and CCCP were also determined to evaluate
the contribution of efflux activity toM. tuberculosis susceptibility to these
drugs.
(ii) Determination of isoniazid susceptibility on solid medium. To
determine if there was any difference between the wild type and the
knockout mutant when grown in solid medium in the presence of isoni-
azid, aliquots of 10l of 10-fold serial dilutions of 107-CFU/ml exponen-
tial-phase cultures were spotted onto 7H10-ADC medium containing
concentrations of isoniazid ranging from 0.25 to 0.03 g/ml. The plates
were incubated at 37°C until growth was observed. The assay was per-
formed in duplicate. The results were recorded by the observation of the
growth of spots of wild-type and knockout mutant bacterial cells in the
isoniazid-containing plates. The highest concentration of isoniazid and
the highest dilution that resulted in bacterial growth were recorded for
both wild-type and knockout strains and compared. We expected that
growth of bacteria at higher isoniazid concentrations than the wild type
would correlate with increased ability to tolerate isoniazid.
(iii) Rate of killing. The rate of killing by isoniazid inM. tuberculosis
H37Rv and the MmrKO mutant was determined as previously described
(28). Isoniazid was diluted in 10 ml of Middlebrook 7H9 supplemented
FIG 1 (A) Replacement of theM. tuberculosis mmr gene. An allelic exchange substrate (AES) for replacement ofmmr (Rv3065) was generated by cloning 576-bp
upstream and 996-bp downstream regions on either side of the hyg resistance cassette of pYUB854. The AES was obtained by PCR or restriction digestion of this
segment; (B) integrative plasmid pCRS5 that contains a copy of mmr and that was used to complement the Mmr knockout mutant; (C) replicative plasmid
pCVZ2 used to overexpressmmr in H37Rv.
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with 10% ADC to give 2, 4, and 8 MIC. A drug-free control was
included.Mycobacterial cultures at exponential phase were adjusted to an
OD600 of 0.2, and 100 l was added to each tube containing the isoniazid
dilutions. On days 0, 1, 2, 4, 8, and 16, 100-l aliquots were taken for
counting of the numbers of CFU and inoculated in Middlebrook 7H10-
ADC medium. The plates were incubated at 37°C until growth was ob-
served. The assay was performed in duplicate.
(iv) Growth competition assay. The M. tuberculosis wild-type strain
H37Rv and the MmrKO strain were used for growth competition testing
in the presence of isoniazid. Briefly, three flasks containing 10 ml of
Middlebrook 7H9-ADC with isoniazid at 0.25 g/ml (1/2 MIC) were
inoculated independently with H37Rv, MmrKO, and both strains, ensur-
ing that the cell density in each flaskwas 105CFU/ml. The three flaskswere
incubated at 37°C. The three cultures were serially diluted and plated in
duplicate on drug-free Middlebrook 7H10-ADCmedium on days 0, 2, 7,
and 14. In parallel, the culture containing both thewild-type strainH37Rv
and the MmrKO strain was serially diluted and plated in duplicate on
7H10-ADC medium with 50 g/ml of hygromycin. The number of
MmrKO cells in the competition assay was determined from the number
of colonies grown in hygromycin-containing plates; the number of
H37Rv cells in the competition assay was calculated from the number of
colonies in the drug-free plates minus the number of MmrKO cells.
Detection of ethidiumbromide efflux byfluorometry.The detection
of ethidium bromide efflux on a real-time basis by the M. tuberculosis
strains was performed using a fluorometric method previously described
(29), but with some adaptations for use in a 96-well plate fluorometer.
Briefly,M. tuberculosis strains were grown in 7H9-ADC medium at 37°C
until an OD600 of 0.6 to 0.8. Cultures were centrifuged at 2,880 g for 10
min, the supernatant was discarded, the pellet was washed in phosphate-
buffered saline (PBS; pH 7.4), and the OD600 was adjusted to 0.8 with PBS
with 0.05% Tween 80. Aliquots of 100 l of bacterial suspension were
transferred into wells of a 96-well plate containing serial dilutions of
ethidium bromide at concentrations that ranged from 2 to 0.125 g/ml.
To determine the effect of chlorpromazine, CCCP, and verapamil on the
accumulation of ethidium bromide, 10 l of each compound was added
to the corresponding well of the 96-well plate. Each inhibitor was used at
1/2 the MIC in order to not compromise the cellular viability. Relative
fluorescence was acquired every 51 s for 60 min at 37°C in a Synergy HT
detection microplate reader (Biotek Instruments), using 530/25 nm and
590/20 nm as excitation and detection wavelengths, respectively. For a
better comparison of ethidium bromide accumulation experiments, for
each assay we determined the relative final fluorescence (RFF) at the last
time point (minute 60) of the assay in comparison with reference condi-
tions by using the formula (RFassay  RFref)/RFref, where RFassay is the
relative fluorescence at the last time point of the ethidium bromide accu-
mulation assay and RFref is the relative fluorescence at the last time point
of the ethidium bromide accumulation assay under the reference condi-
tions (30, 31).
When assaying different strains and mutants, the reference condition
was the assay of reference strain H37Rv, whereas when assaying the effect
of efflux inhibitors, the reference condition was the assay in the absence of
any efflux inhibitor. In both cases, high RFF values indicated that cells
accumulated more ethidium bromide under the tested conditions than
under the reference conditions and vice versa for negative RFF values. RFF
values correlated with the contribution of the Mmr efflux pump to the
extrusion of this ethidium bromide or the degree of efflux inhibition. The
experiments were repeated three times, and the RFF values presented are
the averages of three independent assays.
RESULTS AND DISCUSSION
It is widely accepted that many bacterial pathogens activate efflux
pumps in response to drug treatment, providing the bacterial cells
with a way of adaptation to a hostile environment. This enables
the bacteria to survive under such conditions, facilitating the ac-
quisition of mutations that will confer higher and stable levels of
drug resistance (6, 12, 32). Therefore, efflux pumps are becoming
attractive for drug discovery programs, with the goal to evaluate if
potential new antituberculous compounds may be subject to ef-
flux or to identify efflux inhibitors of currently used antitubercu-
lous drugs. This is particularly relevant in a time when MDRTB
and XDRTB continue to escalate and fewer alternatives are left to
treat the severe forms of drug-resistant tuberculosis.
In this work, we studied the Mmr efflux pump of M. tubercu-
losis. The basis for this study was provided by previous studies that
showed overexpression ofmmr inM. tuberculosis strains that had
been induced to isoniazid resistance by exposure to this drug for a
prolonged period of time (9, 19). Although the mmr gene was
significantly overexpressed among other overexpressed efflux
pump genes present in theM. tuberculosis genome, a possible as-
sociation between the Mmr efflux pump and isoniazid resistance
was suggested (9, 19). In order to clarify the role of Mmr in the
development of isoniazid resistance, as well as in the resistance to
other drugs that are substrates of efflux pumps, we constructed an
MmrKO mutant in the H37Rv reference strain using a recom-
bineering method (20) and studied the drug susceptibility pro-
file of this mutant (MmrKO), its complemented counterpart
(MmrKO::pCRS5), and an H37Rv derivative strain overexpressing
themmr gene from a replicative plasmid (H37Rv::pCVZ2).
We determined the MICs of several compounds against the
wild-type strainM. tuberculosisH37Rv and theMmrmutants (Ta-
ble 2). For the selected group of antibiotics, only a minor decrease
in the MIC of kanamycin was observed in the knockout mutant.
The remaining antibiotics presented consistent MICs that were
not affected by either the inactivation or overexpression of mmr.
In the particular case of isoniazid, no difference in the MICs was
observed between the strains (MIC, 0.25 g/ml for wild type and
TABLE 2 MICs of several antimicrobial drugs against M. tuberculosis
H37Rv and Mmr mutant strainsd
Compound
MIC (g/ml) forM. tuberculosis strain:
H37Rv MmrKOa MmrKO::pCRS5b H37Rv::pCVZ2c
Antibiotics
Isoniazid 0.25 0.25 0.25 0.25
Rifampin 0.06 0.06 0.06 0.06
Ethambutol 1.25 1.25 1.25 1.25
Kanamycin 0.15 0.07 5d 5d
Ciprofloxacin 0.25 0.25 0.25 0.25
Erythromycin 25 25 25 25
Efflux inhibitors
Chlorpromazine 5 5 5 5
Verapamil 150 150 150 150
CCCPe 1.5 1.5 1.5 1.5
Dyes
Ethidium bromide 2 1 2 4
Tetraphenylphosphonium 12.5 3.1 12.5 12.5
Acriflavine 3.1 3.1 3.1 6.2
Safranin O 1 0.5 1 2
CTABe biocide 12.5 6.2 12.5 12.5
a M. tuberculosisH37Rv withmmr gene inactivated.
b MmrKO complemented with integrative vector pCRS5.
c M. tuberculosisH37Rv containing replicative plasmid pCVZ2.
d Increase of the MIC is due to the kanamycin resistance selection marker present in
these strains.
e CCCP, carbonyl cyanide m-chlorophenylhydrazone; CTAB, cetyltrimethylammonium
bromide.
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all Mmr mutants). This was an unexpected result, since in previ-
ous studies we found overexpression of Mmr after exposure to
isoniazid (9, 18, 19), strongly suggesting that this particular
efflux pump could be directly related to the transport of this
drug. However, we speculated that the determination of the
MIC of isoniazid by 2-fold microdilution assay was possibly
not sensitive enough for detecting phenotypic differences be-
tween wild type and strains with anmmr gene deleted or strains
overexpressing the mmr gene.
Therefore, other approaches were used in order to clarify if the
inactivation ofmmr had an effect, even subtle, on the susceptibil-
ity to isoniazid. No difference between the wild type and the
knockoutmutantwas observedwhen grown in solidmediumwith
isoniazid; both strains grew at a dilution of 104 until a concen-
tration of 0.06 g/ml, and no growth was observed at 0.12 and
0.25 g/ml of isoniazid (data not shown). The rate of killing by
inhibitory concentrations of isoniazid was also determined, but
no difference between the wild type and knockout strain was ob-
served (data not shown).
Moreover, the growth competition assay showed no differ-
ence between the wild-type and mutant strains when simulta-
neously grown in the presence of isoniazid, with both present-
ing 106 CFU/ml after 7 days of exposure to isoniazid (data not
shown).
Therefore, we can hypothesize that Mmr responds to treat-
ment with isoniazid. Although this efflux pump would not di-
rectly transport this drug, it could instead transport any other
bacterial metabolite either derived from isoniazid itself or gener-
ated in response to isoniazid-induced damage. This indicates that
themmr overexpression observed in the isoniazid-induced strains
(9, 19) may be due to a general stress response caused by the
prolonged exposure to this drug. In this case, the M. tuberculosis
efflux pump systems would present an increased activity in order
to extrude any noxious compounds that formed as a direct result
of the mechanism of action of isoniazid. This confirms that isoni-
azid susceptibility was not affected by the inactivation ofmmr and
that the overexpression results observed in the previous studies
may be due to a general response to stress rather than a result of
isoniazid being a substrate ofMmr. In fact, a recent study that used
a computational approach combined with gene expression data
and an interactome network has suggested that the SOS response
is upregulated under isoniazid treatment (33). This may affect
several cellular processes, namely, the regulation of efflux pumps,
and be a trigger for drug resistance. It is also possible that Mmr
could be involved in the transport of a cell wall component(s) and
that overexpression of this efflux pump would occur to compen-
sate for the cell wall damage caused by isoniazid, which targets
InhA, an NADH-dependent enoyl acyl carrier protein reductase
involved in the synthesis of mycolic acids (3, 4).
Concerning the other compounds tested, the MmrKOmutant
showed an increased susceptibility to ethidium bromide, tetra-
phenylphosphonium, safranin O, and CTAB. In the particular
case of ethidium bromide, the MIC was restored to the wild-type
value (2 g/ml) in the complemented strain MmrKO::pCRS5,
whereas the H37Rv strain overexpressing mmr (H37Rv::pCVZ2)
presented an increasedMIC (4g/ml). This strain also showed an
increased MIC for safranin O and acriflavine, although there was
no change for the latter in the knockout mutant. These data con-
firm that the mmr gene cloned in either the integrative plasmid
pCRS5 or the replicative plasmid pCVZ2 is being expressed and
produces a fully functional Mmr protein. To confirm that this
phenotype was in fact due to efflux activity and not to any other
indirect mechanism, MICs were determined in the presence of
efflux inhibitors (Table 3). Most cases of MIC reduction were
obtained with CCCP, followed by verapamil. CCCP drastically
reduced bymore than 30 times theMICs of acriflavine, safraninO,
and CTAB for the mmr-overexpressing strain. Since CCCP is a
proton gradient uncoupler, these results demonstrate the in-
creased dependency of this efflux pump on the proton motive
force, as predicted for efflux pumps of the SMR family of trans-
porters. AnMIC reduction was observed for ethidium bromide in
all strains in the presence of verapamil, and CCCP caused only a
slight reduction (1 dilution) in the strain overexpressing themmr
gene. There was a significant reduction of the MIC of ethidium
bromide (8 times) in the presence of verapamil for the knockout
mutant, which suggests that other efflux pumps that extrude
ethidium bromide may be active in this strain and are affected by
verapamil. Chlorpromazine promoted a slight reduction of the
MIC of tetraphenylphosphonium and safranin O in the knockout
mutant.
Following the results obtained for the MIC determination,
ethidium bromide was selected as a substrate for detecting efflux
activity in M. tuberculosis H37Rv and its Mmr mutants. The
MmrKO mutant showed a 62% maximum increased accumula-
tion of ethidium bromide at 1 g/ml relative to wild-type strain
H37Rv, whereas overexpressed strain H37Rv::pCVZ2 showed a
consistent decreased accumulation of ethidium bromide at all
concentrations tested (Table 4; Fig. 2). These results are in agree-
TABLE 3 Effect of efflux inhibitors on the MICs of potential substrates of Mmr efflux pump
M. tuberculosis strain
MIC (g/ml)d
Ethidium bromide Tetraphenylphosphonium Acriflavine Safranin O CTAB
No
inhibitor CCCP CPZ VP
No
inhibitor CCCP CPZ VP
No
inhibitor CCCP CPZ VP
No
inhibitor CCCP CPZ VP
No
inhibitor CCCP CPZ VP
H37Rv 2 2 2 0.5 12.5 3.1 12.5 12.5 3 1.5 3 3 1 0.5 1 0.5 12.5 3.1 12.5 12.5
MmrKOa 1 1 1 0.13 3.1 3.1 1.5 1.5 3 1.5 3 1.5 0.5 0.5 0.25 0.5 6.25 3.1 6.25 6.25
MmrKO::pCRS5b 2 2 2 1 12.5 3.1 12.5 12.5 3 1.5 3 3 1 0.5 1 0.5 12.5 3.1 12.5 12.5
H37Rv::pCVZ2c 4 2 4 1 12.5 6.2 12.5 12.5 6 0.18 6 6 2 0.06 2 2 12.5 0.4 12.5 12.5
a M. tuberculosisH37Rv withmmr gene inactivated.
b MmrKO complemented with pCRS5.
c M. tuberculosisH37Rv containing pCVZ2.
d CCCP, carbonyl cyanidem-chlorophenylhydrazone; CPZ, chlorpromazine; CTAB, cetyltrimethylammonium bromide; VP, verapamil. Data in bold represent at least a 4-fold
reduction, considered to denote a significant MIC reduction in the presence of an efflux inhibitor.
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ment with theMIC obtained for ethidium bromide for each strain
and further support the possibility that the Mmr efflux activity
contributes directly to the susceptibility of M. tuberculosis to this
compound and that the absence of Mmr decreases the efflux of
quaternary compounds inM. tuberculosis. The effect of efflux in-
hibitors on the accumulation of ethidium bromide was also tested
in all strains using ethidiumbromide at 1/2 theMIC (Fig. 3; Table 5).
In general, the accumulation of ethidium bromide by wild-type,
knockout mutant, and overexpressing strains in the presence of
efflux inhibitors (Fig. 3; Table 5) paralleled that of the same strains
in the absence of efflux inhibitors (Fig. 2; Table 4). The inhibitor
that promoted higher ethidium bromide accumulation for all
strains was verapamil, which is in agreement with theMIC results
described above (compare the results with the MICs of ethidium
bromide in the presence and absence of an inhibitor; Table 3) and
with previous studies (19, 34). Surprisingly, despite not having an
effect on theMIC of ethidiumbromide (Table 3), chlorpromazine
caused an increased accumulation of ethidium bromide in the
wild-type and overexpressing strains (Fig. 3).
This workwas carried out inM. tuberculosis, the natural host of
the Mmr efflux pump, and the results largely support those of the
previous studies performed in the heterologous hostM. smegmatis
that reported Mmr to be an efflux pump associated with suscep-
tibility to a variety of compounds, such as ethidium bromide,
tetraphenylphosphonium, and safranin O (15, 16). Our findings
have been corroborated by the use of ethidium bromide, coupled
with the use of real-time monitoring of its efflux by a fluoro-
metric system, which was a good marker for the study of the
efflux activity of Mmr and may be used to evaluate the activity
of potential efflux inhibitors. In addition, this work has shown
that Mmr has an effect on susceptibility to CTAB, a widely used
disinfectant, demonstrating the role of efflux systems, in par-
ticular, Mmr, in M. tuberculosis tolerance to this class of com-
pounds. In this case, the use of efflux inhibitors would prevent the
development of this tolerance. In conclusion, the study of the Mmr
efflux pumpmay be used as proof of concept for the demonstration
of efflux activity inM. tuberculosis, and the strategy employedmay be
TABLE 4 RFF based on the accumulation of ethidium bromide for each
mutant strain compared to that for wild-type strain H37Rva
Strain
RFF at the following ethidium bromide concn
(g/ml):
0.125 0.25 0.5 1 2
MmrKO 0.07 0.47 0.53 0.62 0.55
MmrKO::pCRS5  0.21 0.16 0.20 0.25 0.11
H37Rv:pCVZ2 0.20 0.20 0.38 0.53 0.58
a The values correspond to the last point of measurement at 60 min, when fluorescence
had reached a steady state. Data correspond to the averages of three independent assays.
FIG 2 Accumulation of ethidium bromide at 1 g/ml by M. tuberculosis
H37Rv,H37RvMmrKO (H37Rvwith themmr gene inactivated), andH37Rv::
pCVZ2 (H37Rv containing pCVZ2).
FIG 3 Effect of efflux inhibitors on the accumulation of ethidium bromide
for M. tuberculosis H37Rv (A), H37Rv MmrKO (B), and H37Rv::pCVZ2
(C). Ethidium bromide and efflux inhibitors were used at 1/2 the MIC to
not compromise cellular viability. CCCP, carbonyl cyanide m-chlorophe-
nylhydrazone; CPZ, chlorpromazine; EPI, efflux pump inhibitor; VP, ve-
rapamil.
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used to characterize other efflux pumps ofM. tuberculosis and other
mycobacteria.
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A B S T R A C T
Tuberculosis is still a major health problem worldwide and one of the main causes of death by a single
infectious agent. Only few drugs are really effective to treat tuberculosis, hence, the emergence of
multiple, extensively, and totally drug resistant bacilli compromises the already difficult antituberculo-
sis treatments. Given the persistent global burden of tuberculosis, it is crucial to understand the
underlying mechanisms required for the pathogenicity of Mycobacterium tuberculosis (Mtb), the causal
agent of tuberculosis, in order to pave the way for developing better drugs and strategies to treat and
prevent tuberculosis.
The exclusive mycobacterial cell wall lipids such as trehalose monomycolate and dimycolate (TMM,
TDM), phthiocerol dimycocerosate (PDIM), sulpholipid-1 (SL-1), diacyl trehalose (DAT), and pentacyl
trehalose (PAT), among others, are known to play an important role in pathogenesis; thus, proteins
responsible for their transport are potential virulence factors. MmpL and MmpS proteins mediate
transport of important cell wall lipids across the mycobacterial membrane. In Mtb, MmpL3, MmpL7 and
MmpL8 transport TMM, PDIM and SL-1 respectively. The translocation of DAT and biosynthesis of PAT is
likely due to MmpL10. MmpL and MmpS proteins are involved in other processes such as drug efflux
(MmpL5 and MmpL7), siderophore export (MmpL4/MmpS4 and MmpL5/MmpS5), and heme uptake
(MmpL3 and MmpL11). Altogether, these proteins can be regarded as new potential targets for
antituberculosis drug development. We will review recent advances in developing inhibitors of MmpL
proteins, in the challenging context of targeting membrane proteins and the future prospects for
potential antituberculosis drug candidates.
 2015 Elsevier Inc. All rights reserved.
Contents lists available at ScienceDirect
Biochemical Pharmacology
jo u rn al h om epag e: ww w.els evier .c o m/lo cat e/b io c hem p har m1. Tuberculosis along history
Mycobacterium tuberculosis (Mtb), the causative agent of
tuberculosis, has been present in the human population since
antiquity. Initially, it was thought that during the domestication of
animals in the Neolithic period, Mycobacterium bovis strains from
infected cattle evolved and acquired the capability of infecting
humans, hence originating human tuberculosis [1]. However, it is
now widely accepted that the ancients Mtb strains were originated
from environmental mycobacteria 70,000 years ago in Africa
[2,3]. The introduction of agriculture, civilization and the increase
in human population density led to the selection of virulent and* Corresponding author at: Grupo de Gene´tica de Micobacterias, Departamento
de Microbiologı´a, Facultad de Medicina, Universidad de Zaragoza, c/Domingo Miral
s/n, 50009-Zaragoza, Spain. Tel.: +34 876 554343.
E-mail address: ainsa@unizar.es (J.A. Aı´nsa).
Please cite this article in press as: Bailo R, et al. Lipid transport in Myc
development. Biochem Pharmacol (2015), http://dx.doi.org/10.1016
http://dx.doi.org/10.1016/j.bcp.2015.05.001
0006-2952/ 2015 Elsevier Inc. All rights reserved.transmissible Mtb strains. These modern Mtb strains spread
throughout the world causing the tuberculosis epidemics that
ravaged mankind for centuries [4].
Nowadays, 9 million people fell ill with tuberculosis and
1.5 million died in 2013 (including 360,000 deaths among HIV-
positive people) according to the most recent report of the World
Health Organization (WHO) [5]. At present, tuberculosis is the
second leading cause of death from an infectious agent worldwide,
after the Human Immunodeficiency Virus (HIV), in spite of the fact
that we have powerful tools in order to face tuberculosis:
vaccination, diagnostics and treatments.
2. Tuberculosis treatment and drug resistance
Drug treatment is the only effective therapy for tuberculosis.
Drugs are classified into three groups (Table 1) based on evidence
of efficacy, potency and experience of use [6].obacterium tuberculosis and its implications in virulence and drug
/j.bcp.2015.05.001
Table 1
Drugs used in the treatment of tuberculosis.
Groups of drugs Drugs
First-line drugs Isoniazid
Rifampicin
Pyrazinamide
Ethambutol
Rifapentine
Rifabutin
Second-line drugs Aminoglycosides
(Streptomycin, Kanamycin, Amikacin)
Polypeptides (Capreomycin, Viomycin)
Fluoroquinolones (Ciprofloxacin,
Levofloxacin, Moxifloxacin, Ofloxacin, Gatifloxacin)
Para-aminosalicylic acid
Cycloserine
Terizidone
Ethionamide
Prothionamide
Thioacetazone
Linezolid
Third-line drugs Clofazimine
Linezolid
Amoxicillin plus clavulanate
Imipenem plus cilastatin
Clarithromycin
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widely used drugs for the treatment of drug-susceptible
tuberculosis.
 Second-line antituberculosis drugs are reserved for treating
bacilli resistant to first-line therapy. A drug may be classed as
second-line instead of first-line for being less effective than the
first-line drugs (e.g. para-aminosalicylic acid), having toxic side-
effects (e.g. cycloserine) or being effective, but unavailable in
many developing countries (e.g. fluoroquinolones).
 Third-line antituberculosis drugs are characterized for being less
effective (e.g. clarithromycin) or because their efficacy has not
been fully proven (e.g. clofazimine).
With appropriate antibiotic treatment, around 90% of HIV-
negative patients with drug-susceptible tuberculosis can be cured
in 6 months using a combination of rifampicin (Rif), isoniazid (Inh),
pyrazinamide (Pza) and ethambutol (Emb) for 2 months, followed
by a four-month continuation phase of Rif and Inh [5]. The main
reason for prescribing this combination of medicines in the
treatment of tuberculosis is because the likelihood of the
emergence of multiple drug resistance bacteria is virtually
impossible [7], apart from the fact that the distinct antituberculosis
drugs have different modes of action: Inh is bactericidal against
replicating bacteria; Emb is bacteriostatic at low doses, but is used
in tuberculosis treatment at higher, bactericidal doses; Rif is
bactericidal and has a sterilizing effect; and Pza is only weakly
bactericidal, but is very effective against bacteria located in acidic
environments, inside macrophages, or in areas of acute inflamma-
tion, where they enter into a non-replicative condition. Thus, the
combination of all these drugs targets all subpopulations of Mtb,
i.e. those actively replicating and those in a non-replicative state.
Monotherapy, irregular drug supply, poor drug quality,
inappropriate prescription, poor adherence to treatment and
unsuitable supervision and support on the part of health personnel,
can contribute to appearance and selection of drug-resistant Mtb
strains that can disseminate and cause drug resistant tuberculosis.
Depending on the drug resistance pattern, three major categories
have been defined:
 Multidrug-resistant (MDR) strains are those resistant to Inh and
Rif. In 2013, the highest levels of MDR tuberculosis were found inPlease cite this article in press as: Bailo R, et al. Lipid transport in Myc
development. Biochem Pharmacol (2015), http://dx.doi.org/10.1016Eastern Europe and central Asia, where in some countries more
than 20% of new tuberculosis cases and more than 50% of those
previously treated for tuberculosis have MDR tuberculosis [5].
 Extensively drug-resistant (XDR) strains are MDR strains (i.e.,
resistant to Inh and Rif) that are also resistant to a quinolone and
one of the second-line injectable drugs (kanamycin, amikacin or
capreomycin). In 2006, the first XDR tuberculosis outbreak was
described in KwaZulu-Natal in South Africa. The mortality rate
among HIV-positive patients, with limited or no access to highly
active antiretroviral therapy was 98%, after a median survival
period from diagnosis of only 16 days [8].
 Totally drug-resistant (TDR) refers to strains that are resistant to
all available tuberculosis drugs, although the number and level of
resistance to each drug has not yet been precisely defined. To
date, only a limited number of TDR tuberculosis cases have been
confirmed in Iran, India, South Africa and Italy [9].
All these are cases of acquired resistance [7]. The mechanisms
by which bacteria in general acquired drug resistance are: barrier
mechanisms (decreased permeability/increased efflux), degrad-
ing/inactivating enzymes, modification of pathways involved in
drug activation/metabolism, and drug target modification (muta-
tions) or target amplification [10]. Mtb in particular is able to
acquire drug resistance by spontaneous mutations in chromosom-
al genes then leading to target modification, target amplification,
reduced ability for activating drugs, or increased capacity for
inactivating drugs (Table 2); no horizontal transfer of resistance
genes has been reported [11].
3. Mycobacterial cell envelope: biochemically complex,
pharmacologically interesting
The mycobacterial envelope is unique, both in molecular
composition and in the architectural arrangement of its consti-
tuents (Fig. 1; adapted from [12,13]). Its complex structure is
composed of a typical phospholipid bilayer plasma membrane, an
outer membrane called mycomembrane, and an outermost layer
known as the capsule. The plasma membrane is composed mainly
of anionic phospholipids in a bilayer arrangement with proteins.
The mycomembrane consists of an asymmetric lipid bilayer made
of long chain (C60-C90) mycolic fatty acids in the inner leaflet, and
free intercalating glycolipids and waxy components on the outer
leaflet. Cryo-electron microscopy images support a folded or
compact configuration of these mycolic chains, which reminiscent
of Gram-negative bacterial cell walls [14–16], and also confirm
that the measured thickness of the outer membrane is consistent
with the size of mycobacterial porins, such as MspA from
M. smegmatis, which may therefore form channels in this bilayer
[14]. The outer and inner membrane form a periplasmic space,
with the presence of a thin layer of peptidoglycan covalently linked
to arabinogalactan and lipoarabinomannan, which in turn are
bound to mycolic acids. Peptidoglycan, arabinogalactan and
mycolic acids form the cell wall skeleton. The capsule is mainly
composed of polysaccharides, proteins and small amounts of
lipids, and it is considered to have a different molecular
composition in pathogenic and non-pathogenic species [17]. The
outermost layer is visible in conventional electron microscopy
preparations only when cultures have been grown in free
detergent medium. It is thought that mycobacterial growth under
laboratory routine culturing conditions (with a detergent as
Tween-80) promotes removing of this layer [13].
The mycobacterial envelope is involved in important roles, such
as defining the shape of the cell and providing mechanical and
osmotic protection. Its unusual high hydrophobicity makes it an
efficient barrier for chemotherapeutic agents. Other important
function is the transport of molecules, including nutrients, ions andobacterium tuberculosis and its implications in virulence and drug
/j.bcp.2015.05.001
Table 2
The commonly used antituberculosis drugs with the genes associated with their respective resistance and major mechanism.
Drug or drug class Mechanism of action Genes associated
with drug
resistance
Gene
number*
Protein function Mechanism of drug
resistance
Rifamycins (rifampicin,
rifabutin, etc.)
Inhibition of RNA synthesis rpoB Rv0667 RNA polymerase ß-subunit Target modification
Isoniazid Inhibition of mycolic acid
biosynthesis and multiple
effects in DNA, lipids,
carbohydrates, and NAD
metabolism
katG Rv1908c Catalase-peroxidase enzyme Decreased drug activation
inhA Rv1484 NADH-dependent enoyl-acyl
carrier protein
Target amplification or
modification
Pyrazinamide Depletion of membrane energy
and other effects
pncA Rv2043c Pyrazinamidase Decreased drug activation
Ethambutol Inhibition of arabinogalactan
synthesis
embCAB Rv3793-5 Arabinosyltransferases Target modification
Streptomycin Inhibition of protein synthesis rpsL Rv0682 12S ribosomal protein Target modification
rrs MTB000019 16S rRNA Target modification
gidB Rv3919c 7-Methylguanosine
methyltransferase
Target modification
Kanamycin/amikacin Inhibition of protein synthesis rrs MTB000019 16S rRNA Target modification
eis Rv2416c Aminoglycoside
acetyltransferase
Increased drug inactivation
Capreomycin Inhibition of protein synthesis rrs MTB000019 16S rRNA Target modification
tlyA Rv1694 rRNA methyltransferase Target modification
Quinolones Inhibition of DNA gyrase gyrA Rv0006 DNA gyrase A Target modification
gyrB Rv0005 DNA gyrase B Target modification
Ethionamide Inhibition of mycolic acid
synthesis
ethA Rv3854c Mono-oxygenase Decreased drug activation
ethR Rv3855 Transcriptional regulatory
repressor protein (TetR family)
Decreased drug activation
inhA Rv1484 NADH-dependent enoyl-acyl
carrier protein
Target amplification and
modification
Para-aminosalicylic
acid
Inhibition of folic acid and iron
metabolism
thyA Rv2764c Thymidylate synthase
ribD Rv2671 Enzyme in riboflavin
biosynthesis
Cycloserine Peptidoglycan biosynthesis alr Rv3423c Alanine racemase
ddl Rv2981c D-Alanine-D-alanine ligase
cycA Rv1704c Bacterial D-serine/L- and D-
alanine/glycine/D-cycloserine
proton symporter
Bedaquiline Inhibition of ATP synthesis atpE Rv1305 ATP synthase Target modification
Linezolid Inhibition of protein synthesis rrl MTB000020 23S rRNA Target modification
rplC Rv0701 50S ribosomal protein L3 Target modification
*Gene numbers are given according to Tuberculist database (http://tuberculist.epfl.ch/).
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been shown to trigger a set of biological effects including
adjuvanticity, toxicity, immune down-modulation, and arrest of
phagosome maturation [18]. For these reasons, antitubercular
drugs acting by inhibiting biosynthesis or assembly of mycobac-
terial cell envelope components are very effective antituberculosis
drugs. This is the case of Inh, one of the two major drugs in
tuberculosis treatment, and ethionamide: both are prodrugs that
need activation by catalase-peroxidase (KatG) and mono-oxyge-
nase (EthA), and their active products inhibit InhA, and enzyme
involved in mycolic acids biosynthesis; similarly, Emb directly
blocks biosynthesis of arabinan and its assembly into the bacterial
arabinogalactan. Since these three drugs (Inh, ethionamide, and
Emb) inhibit biosynthesis of cell wall components that are
exclusive of mycobacteria and a few related genera, these drugs
are extremely specific for mycobacterial pathogens, having little (if
any) activity against other bacterial pathogens.Please cite this article in press as: Bailo R, et al. Lipid transport in Myc
development. Biochem Pharmacol (2015), http://dx.doi.org/10.1016In addition to mycolic acids, there are many other lipids that are
also very important components of the mycobacterial cell wall,
most of them being exclusive for mycobacteria. Among them can
be found trehalose dimycolate (TDM), often referred as cord factor,
trehalose monomycolate (TMM), glucose monomycolate (GMM),
glycerol monomycolate, diacyl trehaloses (DAT), triacyl trehaloses
(TAT), pentacyl trehaloses (PAT), the recently characterized family
of mannosyl-b-1-phosphomycoketides, sulpholipids (SLs), pheno-
lic glycolipids (PGLs) and phthiocerol dimycocerosate (PDIM).
Other major glycolipids are lipomannan (LM), lipoarabinomannan
(LAM) and phosphatidylinositol mannosides (PIMs). The impor-
tance of lipids for mycobacteria must be regarded from a double
point of view: on the one hand, they contribute to the structure of
the mycobacterial cell envelope, and in addition, many lipids have
important roles in pathogenesis. A well-known example of this is
PDIM, which is found only in pathogenic mycobacteria; PDIM is
essential during the early step of infection when bacilli encounterobacterium tuberculosis and its implications in virulence and drug
/j.bcp.2015.05.001
Fig. 1. Cell envelope of Mycobacterium tuberculosis.
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genes encoding enzymes that take part in biosynthesis of PDIM
(such as FadD26, FadD28 enzymes in cooperation with polyketide
synthases) or in PDIM transport (such as DrrC protein, which forms
an ABC transporter along with DrrA and DrrB) showed attenuated
phenotypes in mice [19,20]. Similarly, PIMs and mannose-capped
lipoarabinomannan (Man-LAM) both interfere with phagosome
maturation [21].
In summary, proper localization of lipids in the mycobacterial
cell wall, mostly in the outermost layer, is needed for their role in
pathogenicity, thus making transport of lipids an essential process
in mycobacterial cells. Proteins transporting lipids are therefore
important virulence factors and attractive drug targets.
4. Proteins for lipid transport in M. tuberculosis
Efflux pumps are membrane proteins that transport actively a
wide variety of compounds across bacterial envelope. They have
been classified into five superfamilies: ATP-binding cassette (ABC),
major facilitator super-family (MFS), resistance nodulation divi-
sion (RND), small multidrug resistance (SMR) and multidrug and
toxic-compound extrusion (MATE). While MFS, SMR, RND and
MATE members are secondary transporters, typically energized by
the proton motive force (H+ or Na+), members of the ABC
superfamily use ATP as the energy source and are considered as
primary transporters [22]. Whereas efflux pumps are mostly
known because of the transport of drugs from the cytoplasm, otherPlease cite this article in press as: Bailo R, et al. Lipid transport in Myc
development. Biochem Pharmacol (2015), http://dx.doi.org/10.1016efflux pump substrates are sugars, lipids, proteins, synthetic
compounds, toxic metabolites, host-defence molecules, virulence
factors, etc. Such a heterogeneous substrate profile allows bacterial
efflux pumps to play diverse roles in drug resistance, virulence,
bacterial cell physiology, and detoxification [22], among others.
Mce proteins are ABC transporters implicated in virulence. The
Mce proteins are encoded by the mce1, mce2, mce3 and mce4
operons in the genome of Mtb. The involvement of Mce4 transport
system in cholesterol import and intracellular survival has been
confirmed [23,24], but the role of mce1, mce2 and mce3 operons is
not clearly established, especially in the case of the mce3 operon.
As regards to mce1 operon, it has been suggested that these
proteins may serve as a mycolic acid re-importer [25], and mce2
operon might be related in sulpholipid transport [26]. Due to their
most probable implication in lipid metabolism, the Mce proteins
may modulate pathogenicity through changes in Mtb lipid
pathways.
5. A special case for lipid transport: the MmpL and MmpS
families of proteins
The transport of lipids in Mtb is predominantly via a family of
proteins termed MmpL proteins (Mycobacterial Membrane Protein
Large) belonging to the RND family of membrane proteins. The Mtb
genome possesses 15 different genes encoding for RND proteins
[27], 13 of which belong to MmpL (Table 3) protein family. Mutants
with disruptions in mmpL2, mmpL4, mmpL5, mmpL7, mmpL8,obacterium tuberculosis and its implications in virulence and drug
/j.bcp.2015.05.001
Table 3
MmpL and MmpS proteins of Mycobacterium tuberculosis H37Rv.
Name Rv number Protein length
(amino acids)
MmpL1 Rv0402c 958
MmpL2 Rv0507 968
MmpL3 Rv0206c 944
MmpL4 Rv0450c 967
MmpL5 Rv0676c 964
MmpL6 Rv1557 397
MmpL7 Rv2942 920
MmpL8 Rv3823c 1089
MmpL9 Rv2339 962
MmpL10 Rv1183 1002
MmpL11 Rv0202c 966
MmpL12 Rv1522c 1146
MmpL13a Rv1145 303
MmpL13b Rv1146 470
MmpS1 Rv0403c 142
MmpS2 Rv0506 147
MmpS3 Rv2198c 299
MmpS4 Rv0451c 140
MmpS5 Rv0677c 142
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in mice lungs [20,28–30]. Notably, the first Mtb genome also
revealed that many clusters harbouring polyketide synthase genes
with a known or putative role in lipid biosynthesis also contained
an mmpL gene suggesting that the function of the mmpL gene was
associated with the cognate lipid species produced by the enzymes
encoded by the cluster. The first role for MmpLs in lipid transport
was demonstrated by Cox et al. [31] who isolated an mmpL7
mutant from a signature-tag mutagenesis screen. The mutant was
found to be defective in PDIM transport and found to accumulate
the complex lipid intracellularly [31]. mmpL7 is present in the
same cluster that encodes enzymes responsible for the biosynthe-
sis of the pthiocerol (ppsA-E) and mycocerosic acid (mas) moieties
of PDIM. Subsequently, another MmpL protein, MmpL8 was shown
to be involved in the transport of SLs [29,32]. Interestingly, while
no sulpholipid-1 (SL-1) was detected in the cell envelope of Mtb,
the mmpL8 mutant accumulated an intermediate of SL-1, termed
SL-1278, indicating that some, if not all MmpLs were involved in
transporting intermediates, which were consequently processed
further outside the cell [29,32].
More recently, the functions of other mmpL genes have been
deciphered. MmpL10 was shown to be involved in the translocation
of acylated trehaloses; loss of mmpL10 function led to intracellular
accumulation of DATs [33]. Additionally, PATs were missing from
the cell surface, indicating that the translocation of DATs by MmpL10
was likely required for the subsequent acylation of DAT substrates to
yield extracellular PATs. MmpL proteins are also involved in the
transport of mycolic acid derived lipids. mmpL3, the only essential
mmpL gene in Mtb was shown to be involved in the transport of TMM
[34,35] using a conditional mutant of the mmpL3 homologue of
Mycobacterium smegmatis. Furthermore, mmpL11, located in the
same cluster as mmpL3 was shown to be involved in the export of
monomeromycolyl diacylglycerol (MMDAG) [36].
There is also a growing line of evidence that suggests the
MmpLs are not just transporters, but may be involved in
the formation of membrane-associated scaffolds that facilitate
the coupling of lipid biosynthesis with transport. Four mmpL
containing clusters in Mtb also contain a gene encoding an
MmpS protein (Mycobacterial Membrane Protein Small). In
M. smegmatis, MmpS4 was shown to be required for biosynthesis
and export of a surface exposed glycopeptidolipid [37]. A domain
of MmpL7 was shown to interact PpsE, an enzyme involved in
PDIM biosynthesis [38]. MmpL3 was also shown to co-localisePlease cite this article in press as: Bailo R, et al. Lipid transport in Myc
development. Biochem Pharmacol (2015), http://dx.doi.org/10.1016with meromycolate producing FAS-II complex components at
the septa and poles of the mycobacterial cell [39].
6. Other roles for MmpL and MmpS proteins in M. tuberculosis
Besides lipid transport, MmpL and MmpS proteins are involved
in other bacterial processes, including drug resistance and
siderophore export [40] (MmpL4/MmpS4 and MmpL5/MmpS5),
and heme uptake [41,42] (MmpL3 and MmpL11); the acquisition
of iron is an essential attribute of pathogenic bacteria so as to
establish a successful infection.
6.1. Drug resistance
Early studies suggested that MmpL proteins did not play a
significant role in intrinsic resistance to drugs in Mtb [30];
although this seems to be the general case, a few examples have
been reported recently involving MmpL proteins in resistance to
certain drugs. The MmpL5-MmpS5 proteins were originally
characterised for their contribution to drug resistance in Mtb,
which was mediated by active efflux of econazole and other
substrates from cells [43]. In recent years, these proteins were
linked to cross-resistance between clofazimine (a traditional drug
to treat leprosy, which is also considered as a third-line drug for
use against drug resistant tuberculosis) and bedaquiline (a
recently approved drug for treatment of MDR tuberculosis)
[44,45]. In all cases, drug resistance was mediated by increased
transcription of these two genes, mediated by mutations in a
regulatory protein encoded by rv0678 gene; the latter could
probably regulate as well expression of mmpL4–mmpS4 and
mmpL2–mmpS2 [46].
Evidences about a role for MmpL7 transporter in isoniazid
resistance are still controversial: isoniazid readily increases
transcription of mmpL7 gene in Mtb [47], although overexpression
of mmpL7 gene only resulted in resistance to isoniazid in the
heterologous host M. smegmatis [48].
The link between MmpL3 and drug resistance seems to be
indirect and has not been fully characterised yet. MmpL3 interacts
with Wag31 protein as a part of a large network of interactions
between proteins involved in fatty acid metabolism; as a
consequence of Wag31 knock-down, resistance to lipophilic drugs
was altered [49].
6.2. Iron acquisition
Mtb has developed two strategies for acquiring iron when
infecting the human host, and MmpL proteins play an important
role in both pathways. First, a secreted protein, Rv0203, binds
heme groups (an abundant iron source in mammalian tissues and
proteins) in the outside of the bacteria, and then transfer it to
MmpL3 and MmpL11 proteins that will transport iron-containing
heme groups through the mycobacterial membrane into the
cytoplasm, where MhuD protein will degrade heme group
releasing its iron content [41]. Second strategy consists on
producing and exporting siderophores (mycobactins and carbox-
ymycobactins) that will bind non-heme iron outside the bacterial
cell. MmpS4 and MmpS5 proteins resulted essential for producing
and releasing siderophores, hence indicating a role for MmpL4-
MmpS4 and MmpL5-MmpS5 protein complexes in exporting
siderophores in Mtb [40]. Iron-containing siderophores are
subsequently uptaken by a pathway independent of MmpL4-
MmpS4 and MmpL5-MmpS5, which complete the siderophore
recycling system; in those mutants lacking MmpS4 and MmpS5
proteins, siderophores then accumulate in the cytoplasm resulting
in lethality for the bacteria [50].obacterium tuberculosis and its implications in virulence and drug
/j.bcp.2015.05.001
Table 4
Inhibitors of MmpL3.
Drug Structure References
SQ109 [54]
1,5-diarylpyrrole derivatives (BM212) [55,58]
Adamantyl ureas (AU1235) [34,57,61]
Benzimidazole (C215) [62]
Tetrahydropyrazolo[1,5-a]pyrimidine-
3-carboxamides (THPPs)
[60]
R. Bailo et al. / Biochemical Pharmacology xxx (2015) xxx–xxx6
G Model
BCP-12241; No. of Pages 9
Please cite this article in press as: Bailo R, et al. Lipid transport in Mycobacterium tuberculosis and its implications in virulence and drug
development. Biochem Pharmacol (2015), http://dx.doi.org/10.1016/j.bcp.2015.05.001
Table 4 (Continued )
Drug Structure References
N-benzyl-60 ,70-dihydrospiro
[piperidine-4,40-thieno[3,2-c]pyrans
[60]
Indolecarboxamides [56,59]
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MmpL proteins have been investigated for their contribution
to virulence, drug resistance, and other processes in Mtb for
more than a decade, but it was just in the last three years when
MmpL3 (that had been predicted to be the only essential protein
of this family [30]) emerged as a drug target. From 2012, several
families of structurally different chemical entities have been
shown to inhibit MmpL3 (Table 4) opening a new field in the
inhibition of mycolic acids transport [34,51–62]. Notably,
compound SQ109, which was identified a decade ago in a
combinatorial chemistry-based search for ethambutol analo-
gues, currently on phase III of clinical trials, was revealed as an
inhibitor of MmpL3 [54].
Discovering a brand new drug target in Mtb along with 7 new
families of potential inhibitory compounds in such a short period
of time seemed like a success in antituberculosis drug discovery
never before seen. Further investigation into their mechanism of
action demonstrated that most of these compounds are also
targeting several enzymes in the menaquinone biosynthesis
pathway and electron transport chain; as a consequence, respira-
tion and ATP synthesis were inhibited and the transmembrane
electrochemical proton gradient (the energy source in many
transport processes) were abolished [63,64]. Then, since multiple
protein targets can be affected simultaneously, the probability of
selection of resistant mutants remains very low for most of these
compounds. Also, given that the electrochemical gradient, a
general process in many cells, is targeted, compounds in this
group such as SQ109, BM212 [55,58] and the THPPs [60] have
shown to be active against other bacterial and fungal pathogens
lacking mycolic acids and MmpL3-related targets. In any case, the
activity of these compounds against drug resistant and MDR
isolates of Mtb and their synergy with current antituberculosis
therapy (notably in the case of SQ109) makes conceivable the
possibility to shorten current antituberculosis treatment, one of
the key points that will be essential in the near future to control
this terrible disease.Please cite this article in press as: Bailo R, et al. Lipid transport in Myc
development. Biochem Pharmacol (2015), http://dx.doi.org/10.10168. Future directions: the impact of MmpL proteins and lipid
transport in antituberculosis drug discovery
For decades, the role of transport proteins in drug resistance in
Mtb was considered to be marginal. While most of resistant strains,
isolated from clinical specimens or selected under laboratory
conditions, carried mutations in genes encoding target proteins or
activating enzymes, concerning efflux pumps the situation was far
distant to that in Gram-negative bacteria, where efflux-mediated
drug resistance is prominent in many pathogens [65].
Being enthusiastic about the role of transport proteins in drug
resistance, we suggested that efflux pumps could have a role in
transporting new drugs in development, and hence they should be
taken into account in antituberculosis drug discovery programmes
[66]. Recently, several publications have confirmed this hypothe-
sis, and transport proteins were genetically related with resistance
to peptidoglycan synthesis inhibitors [67] and several other
families of new compounds with antituberculosis activity
[68,69]. Notably, among a series of spectinomycin derivatives,
the most active molecules were those that escaped transport by
the Rv1258c efflux pump [70]. Similarly, this has been the case for
the MmpL5 protein since it has been demonstrated to transport
bedaquiline [44,45]. Altogether, it becomes clear that efflux
transporters must be taken into consideration in any tuberculosis
drug discovery programs in order to estimate the likelihood of the
new molecules for being transported out of bacterial cells.
One of the most successful approaches in antimicrobial therapy
has been the combination of beta-lactam antibiotics with
inhibitors of beta-lactamases, and this has inspired a similar
strategy for drug transport proteins [66,71]. For years, this
approached seemed unrealistic, given the toxicity of most efflux
inhibitors, which remained useful only under laboratory condi-
tions to demonstrate efflux mechanism. However, discovery of
several MmpL3 inhibitors on recent years has brought the
attention back to this field. Being a transport protein of the RND
superfamily, MmpL3 is however rather distinct from conventional
efflux pumps of the same family such as AcrAB-TolC from E. coli, inobacterium tuberculosis and its implications in virulence and drug
/j.bcp.2015.05.001
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AcrAB-TolC has a clear role in detoxification by transporting out
antibiotics and other noxious products, MmpL3 has a major role as
both a trehalose monomycolate (TMM) transporter (hence
contributing to the assembly of mycobacterial cell envelope)
and a heme importer [34,35,42]. It is tempting to believe that
inhibiting a protein involved in two such different and important
pathways is like having found the Achilles’ heel of Mtb. In addition,
since several of these MmpL3 inhibitors act by dissipating the
proton gradient, which is the energy source used by MmpL3 itself
and many other transport proteins [63,64], it is expected that lipid
transport in general (not only TMM transport) would be greatly
affected, given the implication of other MmpL proteins in the
transport of other essential lipids (PDIM in the case of MmpL7,
sulpholipid-1 in the case of MmpL8, acylated trehaloses in the case
of MmpL10, and monomeromycolyl diacylglycerol in the case of
MmpL11).
In summary, MmpL proteins have emerged also as attractive
drug targets in Mtb, given their pivotal role in lipid transport (and
other essential processes) in this pathogen. Including specifically
MmpL proteins in drug discovery programmes could be challeng-
ing, given the intrinsic difficulty to work with membrane proteins,
but this should be overcome by the expectations of finding a new
effective drug candidate against tuberculosis.
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